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Cognitive dysfunction following breast cancer treatment is a serious and 
pervasive problem. The underlying mechanisms of cancer related cognitive impairments 
remain unclear, but there is consensus within the scientific community that the causes are 
multifactorial. This non-experimental, cross-sectional study is an analysis of data from 75 
breast cancer survivors six months to 10 years post chemotherapy. The purpose of this 
study was to identify modifiable psychosocial and behavioral factors that may contribute 
to cognitive function both directly and indirectly through inflammatory mediators. 
Non-linear regression models were used to determine whether stress, perceived 
social isolation, physical activity, sleep quality, and inflammation are significant 
predictors of cognitive function. Hierarchical multiple regression was used to determine 
the unique variance of cognitive function (perceived and performance) explained by the 
predictor variables. Non-parametric regression was used to illustrate the complex 
relationships between the psychosocial and behavioral factors and cytokines, and 
between the cytokines and cognitive outcomes. Mediation analyses were used to gain a 
better understanding of how the psychosocial variables influence perceived cognitive 
function. 
 ix 
The findings from this study suggest that perceived stress and loneliness 
contribute to perceived cognitive functioning in breast cancer survivors but that elevated 
IL-6 and TNF-α do not mediate these effects. Non-parametric regression graphing 
illustrated that the cytokines were related to the predictor variables and that cognitive 
outcomes were related to the cytokines but that the relationships varied in direction and 
magnitude across levels. 
This study provides new knowledge on inflammation and cognitive function six 
months to 10 years after breast cancer chemotherapy using a biobehavioral model to 
simultaneously evaluate modifiable psychosocial and behavioral factors that contribute to 
cognitive function in breast cancer survivors.  Findings from this study provide initial 
evidence for needed future prospective and translational studies to improve cognitive 
function in breast cancer survivors. 
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Chapter 1:  Introduction 
Improvements in cancer screening, diagnoses, and treatment have resulted in a 
growing cancer survivorship cohort, especially breast cancer survivors (BCS).  
Approximately 22% of the estimated 13 million cancer survivors in the United States are 
BCS (ACS, 2013). Cancer is now considered a chronic condition (Meyers, 2013) that 
includes long-term mental and physical effects after diagnoses and treatment (IOM, 
2009).  One of the most distressing (Boykoff, Moieni, & Subramanian, 2009), feared 
(Ganz et al., 2013) and prevalent (Janelsins, Kesler, Ahles, & Morrow, 2014) long-term 
effects of treatment that BCS face are problems with cognitive function (deficits in the 
cognitive domains of memory, attention, processing speed, and executive functioning) 
(Janelsins et al., 2014; Wefel & Schagen, 2012). 
Longitudinal studies utilizing neuropsychological (NP) assessment of cognitive 
function indicate that up to 30% of cancer patients experience problems with cognitive 
function prior to treatment; 75% experience problems during primary treatment; and up 
to 35% experience cognitive problems for months to years after treatment ends (Janelsins 
et al., 2014). One study found that 30-40% of survivors may experience worsening of 
cognitive function over time (Wefel, Saleeba, Buzdar, & Meyers, 2010).  
BACKGROUND AND SIGNIFICANCE 
Problems with cognitive function in survivors can impede daily functioning and 
quality of life (Duijits et al., 2014) and have a profound negative impact on social 
functioning, occupational performance, and overall well being (Nelson & Suls, 2013). 
For example, decreased work productivity and social role performance have been 
reported in survivors with cognitive problems as opposed to those without them (Reid-
Arndt, 2009; Wefel, Lenzi, Theriault, & Buzdar, 2004). Unfortunately, there are limited 
 2 
treatment options and no clinical guidelines for the amelioration of problems with 
cognitive function in cancer survivors.  
The mechanisms underlying problems with cognitive function in BCS remain 
unclear, but direct and indirect neurotoxic effects of chemotherapy are the leading 
candidates (Janelsins et al., 2011; Saykin & Ahles, 2007; Vardy, 2009).  Recent research 
findings indicate that elevated inflammation (estimated by pro-inflammatory markers) 
may mediate the problems with cognitive function both during and after chemotherapy 
(Cheng et al., 2014; Ganz et al., 2013; Janelsins et al., 2012; Kesler et al., 2013; 
Pomykala et al., 2013).  
Several individual and treatment related risk factors for problems with cognitive 
function have been identified in BCS.  Those with the most supporting evidence include 
individual factors— older age (Ahles, Root, & Ryan, 2012; Janelsins et al., 2014; 
Mandelblatt et al., 2013; Ono et al., 2015; Wefel & Schagen, 2012) and lower cognitive 
reserve (estimated by educational attainment, IQ; Kesler et al., 2013; Wefel, Witgert, 
Meyers, 2008). Additionally, breast cancer treatment factors have been identified as risk 
factors for problems with cognitive functioning such as certain types of chemotherapy. 
Treatment with anthracycline- based chemotherapy has shown more neural damage than 
5-FU chemotherapy in vitro (Tsvetkov, 2016), and worse cognitive performance (verbal 
learning) in BCS than those treated with non-anthracycline based chemotherapy (Kesler 
& Blaney, 2016). Some research suggests that treatment with selective estrogen receptor 
modulators (i.e. tamoxifen) is associated with poorer cognitive function but more 
research is needed (Janelsins et al., 2012; Jim et al., 2012; Schilder et al., 2009).  
Importantly, these individual and treatment related factors (age, education, treatment with 
anthracycline or tamoxifen) are largely not modifiable or unavoidable when faced with a 
breast cancer diagnosis. Researchers have also consistently found relationships between 
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emotional distress (i.e. depression and anxiety; Asher, 2011; Poppelreuter et al., 2004; 
Pullens, De Vries, & Roukema, 2010), fatigue (Bower & Lamkin, 2013; Cheung, Lim, 
Ho, & Chan, 2013; Hodgson, Hutchinson, Wilson, & Nettelbeck, 2013; Hutchinson, 
Hosking, Kichenadasse, Mattiske, & Wilson, 2012), and problems with cognitive 
function in BCS. Preliminary data also suggests connections between cognitive 
functioning and hours of sleep (Hartman et al., 2015) and physical activity (Hartman et 
al., 2015). 
Even though evidence supports relationships between the aforementioned 
individual, treatment-related, emotional factors (depression, anxiety, fatigue) and cancer-
related cognitive impairments (CRCI), these factors do not completely explain why a 
subgroup of BCS who undergo chemotherapy experience persistent problems with 
cognitive function after treatment ends. Therefore, other factors must be contributing to 
the manifestation and vulnerability to cognitive impairments and/or decline.  
It is possible that factors other than individual demographic and treatment-related 
factors may contribute to cognitive function either directly or indirectly, through 
inflammatory mediators. For instance, stress (Aggarwal et al., 2014; Carlson, Speca, 
Faris, & Patel, 2007), physical activity (Beavers, Brinkley, & Nicklas, 2010; Bherer, 
2013), social isolation (Cacioppo & Hawkley, 2009; Yang, McClintock, Kozloski, & Li, 
2013), and sleep quality (Clevenger et al., 2012; Miller et al., 2009; Sprod et al., 2010) 
have been associated with inflammation and cognitive function in similar populations but 
have not been empirically evaluated in BCS. 
CONCEPTUAL FRAMEWORK  
For this study, Kang, Rice, Park, Turner-Henson, & Downs’ (2010) integrated 
biobehavioral model provided a framework for exploring the impact of modifiable factors 
on inflammation and cognitive function in BCS. This model posits six domains, factors 
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across and within which interact to explain biobehavioral interactions and health 
outcomes. The six domains include individual, psychosocial, behavioral, environmental, 
biological, and health and health-related outcomes. Most often, factors across and within 
the first four domains, individually or in combination, influence biological responses, 
which, in turn, influence health outcomes. However, under specific context or inquiry, 
biological factors may also be conceptualized as a moderator along with other factors to 
influence health outcomes. This model has integrated the strengths of three theoretical 
models— Stress and Coping Model (Lazarus & Folkman, 1984), Physiological Model of 
Stress (Selye, 1974), and Allostatic Load Model (McEwen, 1998, 2003), all of which 
have been extensively studied but individually have weaknesses when applied to 
biobehavioral research. The model iteration proposed by Kang et al. (2010) offers 
conceptual and propositional flexibility, and has been adapted for this dissertation study 
into the framework depicted in Figure 1.1.  
The conceptual model for this study includes individual factors (age, cognitive 
reserve [estimated by education], BMI, history of anthracycline-based chemotherapy, 
tamoxifen use,) as potential covariates, which have been selected for their relevance to 
inflammation and cognitive function. The study model incorporates modifiable 
psychosocial factors (stress, social isolation, emotional distress), and modifiable 
behavioral factors (physical activity, sleep quality, fatigue) that are known to influence 
both inflammation and cognitive function in the general populations but have not yet 
been evaluated in BCS experiencing cognitive changes. Next, the model includes a 
biological factor, inflammation, which is a mediator by which the individual, 
psychosocial, and behavioral factors impact cognitive function, the health outcome. The 
psychosocial, behavioral, and biological factors are all independent predictors of the 
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Figure 1.1. Conceptual model for the study adapted from Kang et al.’s (2010) Expanded Biobehavioral Interaction Model. Variables of 






















health outcome; however, the model assumes that these factors can occur simultaneously 
and conceptualizes that the predictor variables (individual, psychosocial, and behavioral) 
can be interrelated. This model provides a framework for exploring the impact of factors 
other than individual factors on inflammation and cognitive function in BCS following 
chemotherapy and will be adapted and used in this study. 
 PURPOSE OF THE STUDY  
The purpose of this study was to identify modifiable psychosocial and behavioral 
factors that may contribute to cognitive function both directly and indirectly through 
biological factors (inflammatory markers) in 80 BCS (ages 21 to 65) six months to ten 
years after chemotherapy. The specific aims and hypotheses are: 
HYPOTHESES 
The specific hypotheses of the research aims were as follows: 
Aim 1: To assess the impact of psychosocial (stress, social isolation) and behavioral 
(physical activity, sleep quality) factors on inflammatory markers (IL-6, TNF-α). 
Hypothesis 1.1: Higher levels of stress and social isolation will predict higher 
levels of IL-6 and TNF-α. 
Hypothesis 1.2: Higher levels of physical activity and sleep quality will predict 
lower levels of IL-6 and TNF-α. 
Aim 2: To assess the impact of inflammatory markers on cognitive function (memory, 
attention, processing speed, executive function, perceived cognitive function). 
Hypothesis 2.1: Higher levels of IL-6 and TNF-α will predict lower levels of 
cognitive function. 
Aim 3 (exploratory): To explore direct and indirect effects (through inflammatory 
mediators IL-6 and TNF-α) of psychosocial and behavioral factors on cognitive function.
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CONCEPTUAL AND OPERATIONAL DEFINITIONS 
Individual Factors 
Age 
Theoretical Definition: Age is the length of time a person has been alive on the 
earth. 
Operational Definition: Age was measured using participants’ date of birth as a 
self-report question on the Demographic and Treatment Form. 
Education 
Theoretical Definition: Education is the process of learning under the guidance of 
educators (Wikipedia, 2016). 
Operational Definition: Education was operationalized as number of years spent 
in formal education and highest degree earned as a self-report question on the 
Demographic and Treatment Form. 
BMI 
Theoretical Definition: Body mass index (BMI) is a measure of body fat in adults 
(Harvard Public Health, 2015) 
Operational Definition: BMI is body fat calculated by a persons’ height and 
weight— normal weight is 18.5 to 24.9 kg/m2; 25.0 to 29.9 kg/m2 is overweight (CDC, 
2012). BMI was based on weight in kilograms and height in cm. Height was measured to 
the nearest 0.5 cm with participants’ back to the wall, without shoes, looking straight 
ahead. Participants’ were weighed with a standing lever scale to the nearest 100 gram, 
wearing no shoes and light clothing.  
Tamoxifen use 
Theoretical Definition: Tamoxifen is a selective endocrine receptor modulator— 
an oral medication used for treatment of hormone receptor (positive) breast cancer for 
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women who are premenopausal (Burstein et al., 2014). Tamoxifen use has been identified 
as a risk factor for developing cognitive dysfunction following breast cancer (Janelsins et 
al., 2012; Jim et al., 2012; Schilder et al., 2009). 
Operational Definition: Self-report of Tamoxifen use on the Demographic and 
Treatment Form was operationalized by asking whether participants are currently taking 
or have ever taken tamoxifen. 
History of Anthracycline Chemotherapy 
Theoretical Definition: Anthracycline is an anthracycline topoisomerase inhibitor 
medication that is given intravenously and is approved for the use of adjuvant therapy for 
breast cancer that has spread to the lymph nodes after surgery (“Anthracycline 
Hydrochloride”, 2014). Anthracycline has been identified as a risk factor for developing 
cognitive dysfunction following breast cancer (Andreano, Waisman, Donley, & Cahill, 
2012; Minisini et al., 2004; Schagen, Boogerd, Muller, Dam, & Mellenbergh, 2006; 
Wefel, Witgert, & Meyers, 2008). 
Operational Definition: Self-report of anthracycline chemotherapy use on the 
Demographic and Treatment Form was operationalized by asking whether participants 
are currently taking or have ever being treated with anthracycline chemotherapy. 
Psychosocial Factors 
Psychological Stress 
Theoretical Definition: Lazarus & Folkman (1984) describe psychological stress 
as “a relationship between the person and the environment that is appraised by the person 
as taxing or exceeding his or her resources and endangering his or her well-being” (p. 
21).  
Operational Definition: Stress was operationalized as perceived psychological 
stress and measured using the Perceived Stress Scale, a 10-item scale measuring the 
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degree that life circumstances are appraised as having been stressful in the previous 4 
weeks (Golden-Kreutz, Browne, Frierson, & Andersen, 2004).  
Perceived Social Isolation 
Theoretical Definition: Conceptually, social isolation is comprised of objective 
social isolation (in regards to a persons’ social network) and perceived social isolation 
(often referred to as loneliness). This study is focused on perceived social isolation (or 
loneliness) defined as “subjectively experienced, aversive emotional state resulting from 
the perception of unfulfilled personal and social needs” (Boss, Kang, & Branson, 2015).  
Perceived social isolation, is more closely related to quality rather than quantity of social 
interactions, (Cacioppo & Hawkley, 2009).    
Operational Definition: Perceived social isolation was operationalized as 
loneliness and measured using the UCLA Loneliness Scale- Revised (Russel, 1996). 
Emotional Distress  
Theoretical Definition: The emotional state of an individual in response to a 
stressor that is harmful and manifests often as changes in mood, specifically, symptoms 
of anxiety or depression (Ridner, 2004) 
Operational Definition: Emotional distress was operationalized as perceived 
feelings of depression and anxiety and measured using the PROMIS emotional distress 
scales (PROMIS Item Bank v1.0 – Emotional Distress – Depression–Short Form 8a; 
PROMIS Item Bank v1.0 – Emotional Distress – Anxiety – Short Form 8a). 
Fatigue 
Theoretical Definition: “A subjective sensation of generalized tiredness and 
exhaustion”  (Ream & Richardson, 1996, p. 522). Furthermore, fatigue is a whole body 
experience, and typically a negative experience. 
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Operational Definition: Fatigue was operationalized as perceived feelings of 
tiredness and measured using the PROMIS fatigue scale (PROMIS Item Bank v1.0 – 
Fatigue – Short Form 8a). 
Behavioral Factors 
Physical Activity 
Theoretical Definition: Physical activity is conceptually “any bodily movement 
produced by skeletal muscles that results in energy expenditure”(Caspersen, Powell, & 
Christenson, 1985 p. 128). 
Operational Definition: Physical activity was operationalized by measuring self-
reported recall of the frequency of various forms of physical activity (job related, 
transportation, household, recreation /leisure time, time spent sitting/sedentary time) in 
the last 7 days using the International Physical Activity Questionnaire (IPAQ) long 
version (Craig et al., 2003). 
Sleep Quality 
Theoretical Definition: Sleep quality has been conceptually defined as perception 
of sleep, actual number of hours spent sleeping, time spent trying to fall asleep. Sleep 
quality and daytime sleepiness can have a substantial impact on daytime functioning, 
including cognitive functioning (Chiu & Chao, 2010).  
Operational Definition:  Operational definition of sleep quality for this study is 
subjective reports of sleep quality, sleep latency, sleep duration, sleep efficiency, sleep 
disturbance, use of sleep medication, and daytime dysfunction and was measured with the 
Pittsburgh Sleep Quality Index (PSQI; Buysse, Reynolds, Monk, Berman, & Kupfer, 
1989). Additionally, the operational definition includes daytime sleepiness and was 
measured using the Epworth Daytime Sleepiness Scale (Johns, 1991). 
  
 




Theoretical Definition: Tumor necrosis factor alpha (TNF- α) is a cytokine 
produced by many cell types in the body including macrophages and is recognized as a 
defense factor that affects malignant and normal cells and is part of inflammatory 
cascades (Yamazaki, 1994). 
Operational Definition: TNF-α was assessed from serum using a quantitative 
sandwich enzyme immunoassay technique according to the manufacturer’s protocols 
(EMD Millipore; Darmstadt, Germany). 
IL-6 
Theoretical Definition. Interleukin-6 (IL-6) is a multifunctional cytokine that 
plays an important role in immune response, inflammation, and hematopoiesis (Chen, 
2012). 
Operational Definition. IL-6 was assessed from serum using a quantitative 
sandwich enzyme immunoassay technique according to the manufacturer’s protocols 
(EMD Millipore; Darmstadt, Germany). 
Cognitive Function 
Theoretical Definition: Broadly speaking, cognition refers to the process of 
knowing that arises from awareness, perception, and reasoning (Gazzaniga, Ivry, & 
Mangun, 2014). Perceived cognitive function, or meta cognition, is defined as one’s 
knowledge about knowing, or thinking about thinking (Hussain, 2015).  Cognitive 
performance refers to how an individual behaves or “performs” under the conditions of a 
NP test administered by a trained professional (Hodgeson et al. 2012). 
Operational Definition (s): Perceived cognitive function was operationalized as a 
person’s perceptions of their cognitive impairments, the influence or impairments on 
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daily life, if others notice their cognitive changes, and how they perceive their cognitive 
abilities.  Perceived cognitive function was measured using the Functional Assessment of 
Cancer Therapy-Cognitive Function Instrument version 3 (FACT-Cog; Wagner, Sweet, 
Butt, Lai, & Cella, 2009). Objective cognitive performance was operationalized as 
performance of cognitive tasks attention, verbal memory, processing speed, cognitive 
flexibility, executive function and measured using validated NP measures: the HVLT-R 
(a measure of verbal memory; Benedict, Schretlen, Groninger, & Brandt, 1998), the Trail 
Making Test (a measure of processing speed, executive function, attention, and cognitive 
flexibility; Tombaugh, 2004), and the Controlled Oral Word Association Test (a measure 
of verbal fluency and word finding; Wefel, Vardy, Ahles, & Schagen, 2011).   
ASSUMPTIONS 
The assumptions of the present study include: 
1. Participants provided truthful and accurate answers to questions regarding 
breast cancer history and self-report measures. 
2. The phenomenon “cognitive function” is comprised of both objective 
cognitive performance and perceived cognitive function. 
3. Linear relationships exist between the study variables. 
LIMITATIONS 
Potential limitations of the current study include: 
1. The design is cross sectional; therefore, causality cannot be assumed. 
2. Results from the study cannot be generalized beyond breast cancer survivors 
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3. Participants in this study may not reflect other breast cancer survivors who 
may not be willing or able to participate in this study or live geographical 
areas outside of Central Texas. 
4. Self-report measures can be influenced by response bias. 
5. NP evaluation may not be sensitive enough to capture survivors’ problems 
with cognitive function. 
6. Biomarkers chosen for analysis here may not adequately capture the 
inflammatory response related to cognitive functioning 
SUMMARY 
This chapter discussed the background and significance of problems with 
cognitive function following breast cancer chemotherapy.  The primary purpose of this 
study was to identify modifiable psychosocial and behavioral factors that may contribute 
to cognitive function both directly and indirectly through biological factors 
(inflammatory markers) in 80 BCS (ages 21 to 65) six months to 10 years after 
chemotherapy.  A biobehavioral framework proposed by Kang et al. (2010) guided this 
study to simultaneously evaluate the direct and indirect effects (through biological 
mediators) of individual, psychosocial, behavioral factors on cognitive function in breast 
cancer survivors. Findings from this study advance the science in the direction of 
theoretically based translational research—building on previous research that has 
identified factors that increase survivors’ vulnerability to problems with cognitive 
function, and identifying modifiable factors that may also contribute to inflammation and 
cognitive function in BCS. This study provides foundational evidence for future 
prospective research studies and targets for behavioral interventions. 
The study is significant because it (1) fills a gap in the literature by providing 
knowledge on inflammation and cognitive function 6 months to ten years after breast 
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cancer chemotherapy; (2) using a biobehavioral model to simultaneously evaluate 
modifiable psychosocial and behavioral factors that may be contributing to inflammation 
and cognitive function in BCS; and (3) provides initial evidence for needed future 
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Chapter 2:  Review of the Literature 
This chapter presents a review of the literature relevant to the topic of modifiable 
factors that may contribute to cognitive function following breast cancer chemotherapy.  
The chapter begins with an overview of breast cancer and the late effects of breast cancer 
treatment.  Next, the cognitive changes associated with breast cancer treatment are 
discussed including the prevalence, effects on daily functioning, along with identified 
risk factors and likely contributing factors.  Possible etiological mechanisms of cognitive 
changes after breast cancer treatment are presented with an emphasis on recent research 
suggesting the role of inflammation.  The chapter continues with several systematic 
review of modifiable behavioral and psychosocial factors that may contribute to both 
inflammation and cognitive function in breast cancer survivors (BCS)— the topic of this 
study. Systematic reviews were conducted to fully understand the relationships between 
the variables of interest (stress, social isolation, physical activity, and sleep quality) and 
both inflammation and cognitive function, especially what is known in oncology 
populations.   
BREAST CANCER OVERVIEW 
Breast cancer accounts for 29% of newly diagnosed cancers in the United States.  
Seventy-nine percent of new breast cancer cases occur in women 50 years of age or older. 
Women in the U.S. have a 1 in 8 lifetime risk of being diagnosed with breast cancer. The 
incidence of breast cancer diagnoses is highest in non-Hispanic whites; however, African 
American women have the highest mortality rates at all ages (American Cancer Society, 
2013).   
Breast cancer originates in breast tissue and is characterized as either in situ 
(originating in the cells lining the breast ducts), or invasive, (cancer cells have migrated 
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out of the ductal walls into the breast tissue, also known as infiltrating).  The majority of 
breast cancer diagnoses are invasive breast cancer, and in 2013 there were an estimated 
232,340 new cases of invasive breast cancer in the U.S. Two staging systems exist for 
cancer— the TNM (tumor, nodes, metastasis) classification and the Surveillance, 
Epidemiology and End Results (SEER) summary staging system.  The SEER staging 
system is a simplified system and used for cancer registry reporting. According to the 
SEER system, local stage refers to those tumors contained to the breast (corresponding to 
stage 1 or II in the TNM system); regional stage refers to tumors that have spread to 
surrounding tissue including lymph nodes (corresponding to stage II or III depending on 
the size); and distant stage refers to tumors that have spread to distant organs or bones 
(corresponding with stages IIIc and IV; American Cancer Society, 2013).  
Breast cancer screening and prevention includes self-breast exam, mammography, 
clinical breast examination, and magnetic resonance imaging. Clinical breast 
examinations are recommended for average-risk women in their 20’s and 30’s every three 
years. The American Cancer Society recommends that 1) women ages 40 to 44 should 
have a choice to receive an annual mammography; 2) all women should receive an annual 
mammography screening and clinical breast examinations from ages 45 to 54; and 3) 
women 55 and older should switch to a mammography every other year (American 
Cancer Society, 2015). Early detection of breast cancer with mammography reduces the 
risk of breast cancer death by one-third and leads to increased treatment options.  Women 
are utilizing breast cancer screening tools now more than ever before. In 2010, a national 
survey was conducted and it was reported that 67% of women 40 years of age or older 
had a mammogram in the previous two years (an increase from 29% in 1987; American 
Cancer Society, 2013).  
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Breast cancer treatment depends on stage and biological characteristics of the 
cancer and includes surgery, radiation therapy, and systematic therapy (chemotherapy, 
hormone therapy, and targeted therapy). Systemic therapy is also referred to as adjuvant 
treatment.  Most women will receive surgery combined with another treatment modality 
or modalities. Advancements in breast cancer treatments have greatly decreased mortality 
rates and a breast cancer survivor cohort is growing. In 2012, more than 2.9 million U.S. 
women had a history of breast cancer. For local disease the five year survival rate is 99%, 
for regional disease it is 84%, and for distant stage disease 24% (American Cancer 
Society, 2013).  These statistics highlight the importance of understanding and meeting 
the unique needs of cancer survivors. 
SUMMARY 
Breast cancer is the most common cancer, affecting women in the United States.  
Improvements in cancer screening, diagnosis, and treatment are contributing to an 
increasing number of cancer survivors with their own unique health needs. 
LATE AND LONG TERM EFFECTS OF BREAST CANCER TREATMENT 
The advances in breast cancer treatments are not without unintended 
consequences that include long-term and/or late effects of treatment. “Long-term effects” 
of treatment refer to adverse symptoms that appear during treatment and persist months 
or years after treatment stops. “Late effects” of treatment refer to symptoms that appear 
secondary to cancer treatments 12 months or more after curative treatment ends (Crist, 
2013).  Most BCS will ultimately face physical, psychological, and practical 
complications for months to years after treatment ends (Hewitt, Greenfield& Stovall, 
2005) including psychosocial distress, lymphedema, estrogen deprivation, insomnia, 
fatigue, and cognitive dysfunction (Pinto & de Azambuja, 2011). An estimated 75% of 
cancer survivors experience physical and psychosocial late effects of treatment (Ganz, 
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2005) that can negatively impact daily functioning and social role performance (the 
ability to act in socially defined roles and complete the tasks appropriate within one’s 
sociocultural and physical environment; Verbrugge & Jette, 1994), such as returning to 
work or sustaining employment (Crist, 2013; Hewitt et al., 2005, Ness et al. 2013).  
COGNITIVE FUNCTION FOLLOWING BREAST CANCER  
One of cancer’s most distressing (Boykoff et al., 2009), feared (Ganz et al., 2013), 
and prevalent (Janelsins et al., 2014) long-term/late effect of treatment is cognitive 
dysfunction. Most often cognitive dysfunction occurs in the domains of memory, 
attention, processing speed, and executive function (Janelsins et al., 2014; Wefel & 
Schagen, 2012). Collectively, dysfunction in these domains is referred to as cancer-
related cognitive impairments (CRCI). Twenty years of research (primarily in breast 
cancer patients) has consistently confirmed relationships between CRCI and adjuvant 
cancer treatment, namely chemotherapy (Hodgson, Hutchinson, Wilson, & Nettelbeck, 
2013; Jim et al., 2012; Saykin et al., 2013).  
The definitions of “cognitive impairment” and “cognitive decline” are variable 
across studies that utilize NP assessment.  Cognitive impairment is typically defined as 
two standard deviations below a healthy control or published norm. Cognitive decline 
refers to a one to two standard deviation change from pre-treatment to post-treatment 
(Ono et al., 2015) in prospective studies.  It should be noted that, “There is no widely 
accepted statistical convention or cut-off in determining clinically significant declines or 
impairments in cognitive functioning.” (Ono et al., 2015, p. 2). 
Estimates of the prevalence of CRCI vary; however, most recent longitudinal 
research studies utilizing NP assessments indicate that up to 30%-40% of patients 
experience CRCI prior to starting adjuvant treatment; 75% experience CRCI during 
adjuvant treatment; and 35%-60% experience CRCI for months to years following the 
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end of treatment (Janelsins et al., 2014; Wefel, Kesler, Noll, & Schagen, 2015). Long-
term CRCI has been reported in BCS seven to nine years after end of treatment (Amidi et 
al., 2015) and in some cases up to 20 years later (Koppelmans et al., 2012). When self-
report measures are used to evaluate cognitive function in survivors, prevalence rates are 
much higher— up to 90% (Pullens, De Vries, Roukema, 2010). Self-reported cognitive 
dysfunction is more strongly correlated with fatigue and affective symptoms such as 
anxiety, depression, and distress than cognitive performance measures (Hutchinson, 
Hosking, Kichenadasse, Mattiske, & Wilson, 2012; Pullens et al., 2010; Wefel et al., 
2015).   
BCS’s neurocognitive test performance usually fall into the range “mild cognitive 
impairment”; although, survivors often report significant impact on functioning 
(Hutchinson et al., 2012; Wefel et al., 2015). The evidence surrounding associations 
between subjective measures and measures of cognitive performance is inconclusive, 
suggesting that self-report and objective measures capture different aspects of CRCI and 
both should be utilized in research to capture the phenomenon of CRCI (Ganz et al., 
2013; Pullens et al., 2010).  
CRCI usually presents within six months of initiating chemotherapy, with full or 
partial recovery one year after chemotherapy ends (Kesler et al., 2013). The pattern of 
CRCI is unique to the individual and can vary in terms of the domains affected, severity 
of dysfunction, and duration of cognitive changes (Janelsins et al., 2014). The “severity” 
of this problem has been estimated statistically with effect sizes that range from 0.3 to 0.5 
when calculated using standardized mean differences of the means and standard 
deviations reported for each NP test result (O’Farrell, MacKenzie, & Collins, 2012).  
A recent review article by Ono and colleagues (2015) reported that, in general, 
patients exposed to chemotherapy performed worse than controls on general cognitive 
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tasks in cross sectional studies using a random effects model (d=-0.14, 95% CI from -
0.14 to -0.11). In prospective studies, chemotherapy patients showed improved overall 
cognitive functioning from their pre-chemotherapy to post chemotherapy assessments 
(d=0.11 95% CI from 0.09 to 0.14). However, when weighted grand mean scores for the 
eight individual cognitive domains were calculated (attention, executive function, 
language, long-term memory, short-term memory, motor function, processing speed, and 
visuospatial function), larger effect sizes were found in both cross sectional and 
longitudinal studies (weighted mean effect sizes using random effects models ranged 
from d=-0.04 to -0.25).  The largest effect sizes were found in processing speed, 
executive function, and attention using random effects models (d= -0.25 and -0.19, -0.16, 
p<.05) indicating that chemotherapy patients experienced impairments in these domains 
compared to controls in cross sectional studies.  Effect sizes ranged from d= -0.29 to d= 
0.41 across cognitive domains in longitudinal studies using random effects models.  The 
only significant effect was found for long-term memory (d=0.41) indicating that 
chemotherapy patients improved in long-term memory when reassessed after treatment. 
These differences in magnitude between general cognitive impairments and specific 
cognitive domains suggest that chemotherapy related cognitive changes are likely 
specific rather than generalized (Ono et al., 2015, p. 8).  
Structural and functional neuroimaging techniques have been used to investigate 
the neural substrates of CRCI. Researchers consistently report subtle and diffuse brain 
changes in survivors exposed to chemotherapy compared to healthy controls or cancer 
survivors not exposed to chemotherapy.  These diffuse brain changes include decreased 
grey matter volume and white matter atrophy (Ahles, Root & Ryan, 2012, deRuiter & 
Schagen, 2013; Kesler, 2014; McDonald, Conroy, Ahles, West, & Saykin, 2012).  
Decreased grey matter volume appears to be most pronounced in the prefrontal and 
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temporal lobes (Janelsins et al., 2014). Diffusion tensor imaging has showed decreased 
white matter integrity from 12 months to 20 years post treatment in survivors compared 
to healthy controls and in some cases compared to non-chemotherapy treated survivors 
(Deprez, Billiet, Sunaert, & Leemans, 2013). A recent study by Kesler et al. (2016) 
reported that BCSs treated with anthracycline-based chemotherapies demonstrated less 
efficient brain connectivity than those treated with non-anthracycline based 
chemotherapies using resting state fMRI imaging techniques. Other types of imaging 
methods including functional magnetic resonance imaging (fMRI), spectroscopy, and 
positron emission tomography (PET) have shown altered neurochemistry, activation 
patterns, and brain metabolism in survivors compared to healthy controls (McDonald & 
Saykin, 2013; Saykin et al., 2013; Janelsins et al., 2014, Conroy et al., 2013). 
Importantly, even subtle impairments, indicated by small statistical effect sizes 
can have profound effects on daily life (Wefel et al., 2015). CRCI is a major concern 
because this set of problems can interfere with medication adherence, negatively affect 
quality of life, impair productivity, and reduce abilities to return to work  (Janelsins et al., 
2014). Our previous study noted BCS descriptions of psychological distress, 
embarrassment, and guilt associated with CRCI (Becker, Henneghan & Mikan, 2015). 
For these reasons, efforts have been made to evaluate and test interventions including 
medications, cognitive behavioral therapies, cognitive training, and physical activity to 
ameliorate symptoms associated with CRCI, and results have been mixed (Craig, Monk, 
Farley, & Chase, 2014; Janelsins et al., 2014; Wefel et al., 2015).  Improvements in 
objective measures of cognitive function and perceived cognitive function have been 
reported in studies of several behavioral interventions (Alvarez, Meyer, Granoff, & 
Lundy, 2013; Becker et al., 2015; Cherrier et al., 2013; Ercoli et al., 2013; Ferguson et 
al., 2012; Oh et al., 2012). Three studies have utilized computerized cognitive training 
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and reported significant improvements in executive function, verbal fluency, processing 
speed (Kesler et al., 2013), and verbal memory (Von ah et al., 2012) along with self-
report measures of cognition (Kesler et al., 2013; Von ah et al., 2012). Most of the studies 
evaluating pharmaceutical interventions including donepezil, modafinil, and epoetin have 
not found significant improvements in cognitive function (Craig et al., 2014), with the 
exception of two studies of modafinil that reported improved memory, attention (Kohli et 
al., 2009), and psychomotor speed (Lundorff, Jonsson, & Sjogren, 2009).  Several studies 
have evaluated the effect of physical activity interventions, albeit non-aerobic physical 
activity, on cognitive function in BCS and reported improvements in self-reported 
cognitive function, quality of life, and psychological symptoms (Alvarez et al., 2013; 
Janelsins et al., 2012; Oh et al., 2012; Reid-Arndt & Cox, 2012).  
SUMMARY 
Taken together, approximately one third of BCS who undergo chemotherapy as 
part of their treatment will experience long term or late cognitive changes that are 
distressing and can negatively affect daily functioning and quality of life. Imaging studies 
have consistently elucidated structural and functional brain changes in BCS treated with 
chemotherapy compared to those not treated with chemotherapy and to controls. Efforts 
have been made to improve cognitive functioning in BCS with modest results, likely 
because the exact etiology of this phenomenon is not completely understood and the 
cause of CRCI is likely multifactorial. A better understanding of the mechanism of CRCI 
will aid in finding effective treatments for this problem. 
PROPOSED MECHANISMS FOR CRCI 
Several mechanisms have been proposed in the literature to explain the 
manifestation of CRCI.  These include direct effects of chemotherapy on the central 
nervous system; indirect effects of chemotherapy on the central nervous system; 
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processes related to the cancer pathology, and processes related to hormone imbalances 
(stress-related hormones and estrogen) (Craig et al., 2014; Wefel et al., 2015). 
Direct Effects 
 Chemotherapy targets rapidly dividing cells in the body; therefore, it can affect 
healthy cells and lead to many unwanted side effects. Several chemotherapies have been 
shown to cause damage to the central nervous system; in fact, it has been demonstrated 
that some are more toxic to brain cells than to cancer cells (Dietrich, Han, Yang, Y., 
Mayer-Pröschel, & Noble, 2006; Wefel et al., 2015).  In animal models, the direct effects 
of chemotherapies on the central nervous system appear clear (Seigers, & Fardell, 2011) 
and include hippocampal toxicity (Dietrich et al., 2015), white matter degradation, and 
neuroinflammation (Seigers, & Fardell, 2011).  It is unknown how these animal models 
translate to the human brain (Dietrich, Prust, & Kaiser, 2015). Clinical data support 
animal models and also suggests structural and functional brain changes associated with 
chemotherapy treatment including hippocampal volume reduction and altered patterns of 
neural activation (Dietrich et al., 2015); however, more clinical research is needed to 
yield conclusive findings (Craig et al., 2014).  
Indirect Effects 
Another proposed mechanism of CRCI is the indirect effects of chemotherapy on 
processes in the body such as inducing pro-inflammatory cascades.  These cascades can 
lead to prolonged cytokine activation and subsequent production of reactive oxygen 
species (ROS). ROS have adverse effects on the brain via inflammatory mechanisms that 
will be discussed in detail in the following section titled “Inflammation and CRCI in 
BCS”. Chemotherapy toxicity can result in an imbalanced oxidative stress load from the 
production of ROS, that leads to DNA mutations and further ROS production (a vicious 
cycle), that results in high oxidative stress, damaged neurons, and cognitive impairments 
  
 
           
 24 
(Craig et al., 2014; Seigers & Fardell, 2011; Wefel et al., 2015). Oxidative damage has 
already been associated with other neurodegenerative diseases such as Alzheimer’s, 
Parkinson’s disease, and mild cognitive impairment (Walker, Drew, Antoon, Kalueff, & 
Beckman, 2012). Moreover, high levels of oxidative stress and DNA damage may be 
even more detrimental to cancer patients and survivors who likely already have decreased 
DNA repair abilities (Walker et al., 2012). 
Cancer-related Mechanisms 
Changes in cognitive function prior to initiation of chemotherapy led scientists to 
theorize that physiological processes due to the cancer itself could lead to CRCI. For 
instance, the body has inflammatory responses to cancer that can trigger neurotoxic pro-
inflammatory cascades (Wefel et al., 2015). Additionally, relationships between greater 
disease severity and more cognitive problems have been reported (Ahles, et al., 2008; 
Kesler, Kent, & O’Hara, 2011). It has been demonstrated that some tumors interfere with 
protective immune responses to cancer that can lead to higher levels of inflammation that 
are sustained over time (Seruga, Zhang, Bernstein, & Tannock, 2008; Whiteside, 2006).  
Hormonal Changes 
Cancer patients and survivors are subject to high levels of psychological stress 
that can interfere with hypothalamic-pituitary-adrenal (HPA) axis function and result in 
irregular levels of circulating glucocorticoids. It is documented that glucocorticoids can 
trigger damage to areas of the brain (Seigers & Fardell, 2011). High levels of stress can 
also over tax the HPA axis and result in sub optimal levels of glucocorticoids resulting in 
dysregulation of cytokines in the body that can lead to cognitive dysfunction (Kesler et 
al., 2013). Similarly, sex hormones have been linked to cognitive functioning. Estrogen is 
thought to be neuro-protective— playing a role in both neurotransmitter production and 
relieving oxidative stress (Walker et al., 2012). There are estrogen receptors in the 
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brain—in the hippocampus, cerebral cortex, and frontal lobe.  In animal models, low 
estrogen can result in cognitive impairments (Craig et al., 2014); however, the action of 
estrogen in the human brain appears to be more complex and is not completely 
understood (Walker et al., 2012).   
Inflammation and CRCI in BCS 
A leading candidate mechanism of CRCI is the indirect neurotoxic effect of 
chemotherapy resulting in inflammation that leads to cognitive impairments (Saykin & 
Ahles, 2007; Janelsins et al., 2011; Vardy, 2009).  Both cancer and cancer treatment have 
been shown to elevate peripheral pro-inflammatory markers, including cytokines, in 
women with breast cancer (Seruga et al., 2008; Kesler et al., 2013). A summary of the 
research supporting the connection between inflammation and CRCI in oncology 
populations can be found in Table 2.1. Cytokines are “polypeptides produced principally 
inflammation and immune responses” (Walker et al., 2012, p. 142). In the brain, 
cytokines have also been shown to play a role in neural repair and modulate 
neurotransmission (Walker et al., 2012). A growing body of animal and human research 
indicates that high levels of circulating pro-inflammatory markers can access the brain 
and cause neurotoxic damage, resulting in a sequelae of behavioral symptoms including 
depression, sleep disturbance, fatigue, and cognitive dysfunction (Ahles et al., 2014; 
Cheung et al., 2014; Miller, Ancoli-Israel, Bower, Capuron, & Irwin, 2008; Pomykala et 
al., 2013; Saykin et al., 2013; Seruga et al., 2008). Prolonged exposure to inflammatory 
cytokines can have degenerative effects on the human body including neurodegeneration.  
Inflammatory cytokines have been investigated in relation to Alzheimer’s disease and 
mild cognitive impairment, and literature supports links between low-grade systemic 
inflammation and cognitive impairments in adults (Nascimento et al., 2014). 
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Table 2.1  
Inflammation and CRCI in Oncology populations 
First 
Author, 
Year Objective Sample Design 
Inflammatory 










function in BCS  









Controls (n= 20) 
Experimental  
T1 (anytime during 
Lupron treatment) 










memory- Story A 
[emotionally 
charged story] and 
Story B [weather 
report)] 
Controls (T2) recall for story A was 
significantly positively correlated with 
salivary cortisol levels (r=.54, p<.05, 
df=9),  
 
No significant correlations between 
cortisol and recall in the breast cancer at 





To evaluate the 

















T1 (before chemo 
initiation) 
T2 (6 weeks after 
T1) 



















Cog version 3) 
IL-1β was associated with 0.78 decrease in 
response performance (p=.023) 
 
Higher concentration of IL-4 was 
associated with better response speed 
performance (p= .022) 
 
Higher concentrations of IL-1β and IL-6 
were associated with more perceived 
cognitive disturbances (p=.018; p =.001) 
 
Every unit increase of IL-4 was associated 











10 years after 
chemo (n=24) 












No significant relationships between 
oxidative damage and perceived cognitive 
impairments (MASQ, FACT-Cog) 
 
Increased oxidative damage was related to 
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lower gray matter density (r= -.5, p=.011) 




whether or not 





in women with 









Early Stage BCS 
(n=49)  
Age 49.9 (8.5) 






T1: 0-3 months 
post primary 
treatment 
T2: 6 months later 




Memory (SMQ) At T1 significant negative correlation 
between sTNF-RII and SMQ (r=-.21, 
p=.05) controlling for age, BMI, radiation 
and depression 
 
Significant negative correlation between 
change in SMQ and change in sTNF-RII 





levels of IL-6, IL-
8, and MCP-1 in 
patients receiving 
doxorubicin-
based chemo with 
levels in those 
receiving a 
combination of 






chemo: Group 1 















T1: 1st 0-2 cycles 
of chemo 
T4: after 2 more 
















In the AC/CAF group: 
Changes in MCP-1 from T1 to T2 
significantly correlated with difficulty 
concentrating (r = -.498, p <.05) and 
forgetfulness (r=-.466, p<.05)  
Both IL-8 and IL-6 were positively 
correlated with all the items (p=NS) 
In the CMF group: 
IL-6 was negatively correlated with all 5 
items (p=NS) 
IL-8 was positively correlated with all 
but difficulty thinking (p=NS) 
MCP was positively correlated with all 
items except heavy headed (p=NS) 
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Mean age 54.6 
(6.5)  











TNFα on the HVLT-R was reported in the 
chemo treated breast cancer survivors (β= 
-2.46, p =.006) 















early stage breast 
cancer patients 
BCS (n= 33) 
Stage 0-IIIA 
(59% Stage 2) 









T2: 6 months later 




soluble TNF  








At baseline-significant positive correlation 
between total severity scores for PAOFI 
memory subscale and IL-6 levels (p= 
.0287, n=32) 
Note. Outcomes: SR, Self-rated; NP, neuropsychological test performance Self-Report Measures.  AFI, Attentional Function Index; BAI, Beck Anxiety Inventory; 
BRIEF, Behavioral Rating Inventory of Executive Function; CSC-W59, Cognitive Symptom Checklist Work-59; FACT-COG, Functional Assessment of Cancer 
Treatment Cognition; EORTC-CFS, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0; FEDA, 
Questionnaire of Experienced Deficits of Attention; GHQ-12, General Health Questionnaire- 12; GSDS, General Sleep Disturbance Scale; GLT-EQ, Godin Leisure 
Time- Exercise Questionnaire; HADS, Hospital Anxiety Depression Scale; PSQI, Pittsburgh Sleep Quality Index; MASQ, Multiple Ability Self-Report 
Questionnaire; MMQ, Memory Questionnaire Ability Scale; PANAS, Positive and Negative Affect Schedule; PAOFI, Patient's Complaints of Own Functioning 
Inventory; SMQ, Squire Memory Questionnaire; TEA, Test of Everyday Attention Neuropsychological Tests. COWAT; Controlled Oral Word Association Test; 
HVLT-R, Hopkins Verbal Learning Test Revised; RCFT; Rey Complex Figure Test; WAIS-IV, Wechsler Adult Intelligence Scale 4th edition; WCST, Wisconsin 
Card Sorting Test; WMS III, Wechsler Memory Scale III. 
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Elevated levels of IL-6 and TNF-α have been found in mild cognitively impaired 
elderly compared to non-impaired controls (Nascinmento et al., 2014). TNF-α has been 
associated with demyelination in the brain and high levels of TNF-α are consistently 
associated with breast cancer. High levels of IL-6 have been associated with several 
chemotherapy agents and IL-6 has also been associated with poor executive functioning 
(Walker et al., 2012). Furthermore, stress elicited by cancer and cancer treatment 
(including chemotherapy) can disrupt the HPA axis regulation of high levels of 
circulating cytokines (Kesler et al., 2013) and treatments that stimulate cytokine 
production have been associated with cognitive deficits (Vardy, Wefel, Ahles, Tannock, 
& Schagen, 2008). Taken together, the evidence suggests that cytokines may mediate 
cognitive impairments both during and after chemotherapy (Cheung et al., 2014; Ganz et 
al., 2013; Kesler et al., 2013; Janelsins, Mustian, et al., 2012; Pomykala et al., 2013).  
Subsequently, investigators have begun to evaluate the role of inflammation in survivors’ 
cognitive function.  
Much of the research related to inflammation and cognition in BCS has evaluated 
pro-inflammatory biomarkers, including interleukins (IL), interferons (IFN), tumor 
necrosis factor (TNF), and soluble TNF receptors (sTNF-R; Cheung, 2013). Ganz et al. 
(2013) reported that the longitudinal decline in sTNF-RII levels was significantly 
correlated with fewer self-reported memory complaints in BCS who received 
chemotherapy (n=49: r=-.34, p=.04). Kesler et al. (2013) found a significant interaction 
between TNF-α and IL-6 and verbal memory performance in BCS (n=42) 4.8 ± 3.4 years 
post-chemotherapy suggesting that IL-6 may modulate the effects of TNF-α on verbal 
memory and the hippocampus following breast cancer and chemotherapy (beta=-2.46, 
p=.006). Janelsins et al. (2012) found a significant inverse relationship between monocyte 
chemoattractant protein-1 (MCP-1) and forgetfulness (r=-.47, p=.019) and a positive 
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correlation approaching significance between higher levels of IL-6 and greater difficulty 
concentrating (r=.38, p=.059) in breast cancer patients who received anthracycline-based 
chemotherapy. Finally, another study reported that higher levels of IL-1β predicted 
slower processing speed (p=.008), higher TNF-α predicted memory decline (p=.003), and 
both higher IL-4 (p=.025) and IL-8 predicted worsening attention (p=.021) in 81 breast 
cancer patients (Cheung et al., 2014). Only one of the aforementioned studies (Vardy, 
2009); however, evaluated these relationships one or more years after chemotherapy.  
Associations between inflammatory factors and neural correlates of CRCI have 
also been explored.  Kesler et al. (2013) found that higher levels of both TNF-α and IL-6 
were significant predictors of lower hippocampal volume (using MRI) in 20 BCS who 
received chemotherapy.  Pomykala et al. (2013) reported consistent correlations between 
less left medial frontal and right anterior temporal cortical metabolism and higher levels 
of inflammatory markers (IL-1ra, sTNF-RII, CRP, IL-6) in BCS who received 
chemotherapy 18 months earlier (n=23) suggesting neural inefficiencies. 
SUMMARY 
Taken together, several mechanisms have been proposed to explain the 
manifestation and persistence of CRCI in BCS and research suggests a link between 
inflammation and cognitive changes experienced by BCS.  Recent research has 
demonstrated relationships between higher TNF-α, higher IL-6, interactions between 
these two cytokines, and worse cognitive functioning and cognitive performance.  
CONTRIBUTING FACTORS TO COGNITIVE FUNCTION IN BREAST CANCER SURVIVORS 
Individual Factors and Cognitive Function 
It is well documented that there are several predisposing or precipitating 
demographic, treatment, and emotional factors that contribute to CRCI in BCS. 
Demographic factors like older age (Ahles et al., 2012; Janelsins et al., 2014; Mandelblatt 
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et al., 2013; Ono et al., 2015; Wefel & Schagen, 2012), lower cognitive reserve (as 
estimated by either educational attainment or IQ; Ahles et al., 2010; Janelsins et al., 
2012), and pre treatment menopausal status (Conroy et al., 2013) have at times been 
found to be risk factors for developing CRCI. At other times researchers failed to find 
such correlations (Ahles et al., 2010; Janelsins et al., 2014).  
Certain genetic factors have been proposed as risk factors for CRCI (Ahles, et al., 
2012). APOE is a glycoprotein responsible for the uptake, transport, and distribution of 
lipids and has been shown to play a role in neural repair and plasticity (Walker et al., 
2012, p.142). In 2003, Ahles et al. established an association between apoliprotein E 
(APOE) E4 allelle and lower cognitive performance on memory and spatial ability tasks 
along with a trend towards lower performance on an executive function task. More 
recently, Lengacher et al. (2015) reported findings that support this association. Two 
studies have established associations between single nucleotide polymorphisms (SNPs) 
and CRCI, specifically with the SNPs: catecholo-methyltransferase (COMT; Small et al., 
2011), ankyrin repeat and kinase domain containing 1 (ANKK1; Lengacher et al., 2015), 
methylenetetrahydrofolate reductase (MTHFR; Lengacher et al., 2015), and solute carrier 
family 6 member 4 (SLC6A4; Lengacher et al., 2015).  In these studies, survivors who 
were carriers of the aforementioned SNPs performed worse than healthy controls on tests 
of attention, verbal fluency, and motor speed (Small et al., 2011), and had worse 
perceived cognitive function (Lengacher et al., 2015). 
Cancer treatment factors including less time since chemotherapy, higher dose of 
chemotherapy, and greater number of chemotherapies and/or treatment modalities have 
also been associated with vulnerability to CRCI.  Evidence suggests a dose response 
relationship between chemotherapy and CRCI. Higher doses of chemotherapy (more 
cycles, longer duration) have been associated with greater cognitive impairments, 
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decline, and structural and electrophysiological changes in breast cancer patients 
(O’Fardell et al., 2013).  Additionally, certain types of chemotherapies (anthracycline-
based and methotrexate) have been associated with higher risk of CRCI (Janelsins et al., 
2012; Kesler & Blaney, 2016); however, methotrexate is not commonly used to treat 
breast cancer anymore. Studies with the majority of participants with a history of 
anthracycline chemotherapy (e.g. anthracycline) show worse cognitive performance than 
controls (McDonald, 2012; Kesler, 2011; Lepage, 2014). Neuroimaging studies 
comparing anthracycline chemotherapies to non-anthracycline show altered morphology 
and activation patterns in those with anthracycline chemotherapies (Koppelmans, 2013). 
Only one study to the author’s knowledge has directly compared anthracycline-based 
chemotherapies to non- anthracycline chemotherapies in a clinical population on 
cognitive measures (kesler and blayney, 2016). Kesler & Blayney (2016) reported 
significantly lower verbal memory (both immediate and delayed) in those treated with 
anthracycline-based chemotherapy than those treated with non-anthracycline 
chemotherapy, but similar levels of perceived cognitive dysfunction in both groups. 
Janelsins et al. (2012) found differences in cytokine expressions when comparing 
anthracycline-based chemotherapy to non-anthracycline based chemotherapy in breast 
cancer patients. Hormonal treatments are another treatment factor linked to CRCI 
(O’Fardell et al., 2013). Tamoxifen (a selective estrogen receptor modulator) decreases 
the effects of estrogen in the bone and endometrium (Walker et al., 2012) and has been 
associated with greater cognitive impairments such as verbal memory deficits in BCS 
taking tamoxifen compared to BCS not taking this medication (Walker et al., 2012). 
It is widely accepted that anxiety, depression, and fatigue contribute to cognitive 
function.  For many years, the cognitive changes reported by breast cancer patients were 
attributed to psychological or emotional distress and treated with anti-depressants. 
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Anxiety, depression, and fatigue correlate with perceived cognitive dysfunction stronger 
than performance measures, and in some cases these factors do not correlate at all with 
cognitive performance (O’Fardell et al., 2013). Even though the relationships between 
CRCI and anxiety, depression (Asher, 2011; Poppelreuter et al., 2004; Pullens et al., 
2010) and fatigue (Bower & Lamkin, 2013; Cheung, Lim, Ho, & Chan, 2013; Hodgson et 
al., 2013; Hutchinson et al., 2012) are clear, these factors do not completely explain why 
one third of survivors who undergo chemotherapy experience ongoing problems with 
cognitive function more than one year after treatment ends. Therefore, other factors must 
contribute to the manifestation of cognitive impairments and/or decline in BCS. 
Of the demographic, treatment, and emotional factors discussed above, the 
following are being measured in this study for their potential use as covariates because 
they have been consistently reported in the literature as risk factors for either cognitive 
function or inflammation— age, education, BMI, tamoxifen use, history of anthracycline-
based chemotherapy, emotional distress, and fatigue.  
MODIFIABLE FACTORS  
With the exception of the emotional and fatigue related factors (which are not the 
focus of this study), the demographic and treatment related risk factors for CRCI 
discussed in the previous section are largely not modifiable or unavoidable when faced 
with breast cancer. It is possible that other factors that are modifiable may contribute to 
cognitive function either directly or indirectly, through inflammatory mediators. For 
instance, stress (Aggarwal et al., 2014; Carlson, Speca, Faris, & Patel, 2007, Lupien 2005 
& 2009), physical activity (Beavers, Brinkley, & Nicklas, 2010, Bherer, Erickson, & Liu-
Ambrose, 2013), social isolation (Cacioppo & Hawkley, 2009; Yang, McClintock, 
Kozloski, 2013), and sleep (Clevenger et al., 2012; Miller et al., 2009; Sprod et al., 2010) 
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have been associated with inflammation and cognitive function in similar populations but 
have not been simultaneously evaluated in BCS. 
These modifiable factors (stress, perceived social isolation, physical activity, and 
sleep quality) may be particularly relevant to BCS because survivors experience one and 
a half times more stress than the general population (Parelkar, Thompson, Kaw, Miner, & 
Stein, 2013). Additionally, BCS experience a unique type of loneliness following the 
completion of treatment termed “survivor loneliness” that encompasses a sense of 
loneliness in the face of mortality and invalidated, ongoing symptom burden (Rosedale, 
2009). Up to 87% of cancer patients experience sleep problems that persist long after 
treatment ends (Palesh et al., 2012), and breast cancer patients experience insomnia more 
frequently than persons with other types of cancer (Caplette-Gingras, Savard, Savard, & 
Ivers, 2013). And finally, only 37% of BCS (n=2,885) are meeting physical activity 
guidelines (Blanchard et al., 2008), and associations between physical activity and 
cognitive health have been reported in older breast and colorectal cancer survivors 
(Fitzpatrick, Edgar, & Holcroft, 2012).   
MODIFIABLE FACTORS AND INFLAMMATION 
Several unavoidable factors increase the likelihood of activated inflammatory 
pathways in BCS during treatment, including cancer pathology, surgery, chemotherapy, 
and radiation (Cheung et al., 2013). After treatment ends, it is possible that other 
psychosocial or behavioral factors may increase the likelihood of ongoing inflammation 
as well as problems with cognitive function in BCS. Robust relationships have been 
reported between several modifiable factors and inflammatory markers in the general 
population, including aging adults. Systematic reviews were conducted on the 
relationships between the variables of interest (stress, social isolation, physical activity, 
and sleep quality) and both inflammation and cognitive function with a focus on what is 
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known in oncology populations.  The details of each of these reviews including the 
search criteria and key words are described in the individual sections below. 
Psychosocial Factors and Inflammation 
Perceived Stress and Inflammation 
It is widely accepted that stress has direct effects on several regulatory systems in 
the body including the HPA axis and sympathetic nervous system, both of which 
modulate immune processes such as inflammation (Yang et al., 2013). In the general 
population, chronic psychological stressors have measurable effects on inflammatory 
processes and inflammation is now recognized as a biomarker for stressors such as job 
stress, low socioeconomic status, caregiver stress, and loneliness (Nakata et al., 2012; 
Hänsel, Hong, Cámara, & von Känel, 2010; Miller et al., 2008).  The most common and 
consistently detected inflammatory markers that are linked to psychological stressors are 
cytokines—specifically IL-6, TNF-α and IFN-gamma (Hansel et al., 2010).  
In otherwise healthy adults, positive relationships between psychological stress, 
IL-6, and C-reactive protein (CRP) have been reported (Ranjit et al., 2007). Glei et al. 
(2013) reported that higher perceived stress was predictive of greater inflammatory 
dysregulation among women from the U.S but not men suggesting gender differences in 
immune responses to stress. In one study of older adults, inventories of stressful events in 
the last 24 hours were positively related to IL-6 (β =.05, t(109)=2.06, p =.04) and CRP 
levels (β = .9, t(129) = 2.14, p =.04) (Gouin, Glaser, Malarkey, Beversdolf, & Kiecolt-
Glaser, 2012); but no significant relationships were reported between inventory of 
stressful events and TNF-α in another study (Luz et al., 2003). Similarly, in a longitudinal 
study of adults caring for spouses with Alzheimer’s disease (N=118), the stress of longer 
time spent caregiving was associated with elevated CRP levels (p = 0.04) and caregivers 
showed greater TNF-α levels than controls (n=51; p = .048; von Kanel et al., 2012). In a 
  
 
           
 36 
study of healthy young adults exposed to a laboratory stressor, significant increases in 
inflammatory markers— sTNF αRII and IL-6— were reported (Slavich, Way, 
Eisenberger, & Taylor, 2010); but, no relationship between IL-6 and acute laboratory 
stress was found in another study (Aschbacher et al., 2012). 
In persons with MS, moderate positive relationships between perceived stress and 
IL-6 (r=.428, p<.01) and IL-10 (r=.441, p<.01) have been reported (Sorenson, Janusek, & 
Mathews, 2013). In persons with rheumatoid arthritis, higher chronic interpersonal stress 
was associated with greater stimulated IL-6 production (p<.05); however, chronic stress 
ratings were not related to plasma levels of IL-6 or CRP (p’s > .05; Davis et al., 2008).  
A literature review of primary research studies evaluating perceived stress and 
inflammation in breast cancer patients was conducted in Pubmed from 2005 to 2015.  
First, a search of these variables was conducted using the key words: perceived stress, 
psychological stress, inflammat*, proinflammat*, cytokines, IL-6, TNF-α, 
psychoneuroimmunology, and breast cancer.  Studies that included data on relationships 
between perceived stress factors and inflammation in the identified populations were 
included. Animal and in vitro studies, studies evaluating risk for developing breast 
cancer, and pharmaceutical clinical trials were excluded. The search was expanded to all 
oncology populations for a more comprehensive understanding of the relationships 
among people who experience a cancer diagnosis (expanded key words: oncology, 
cancer). The findings of this review are reported in Table 2.2.  
Seven studies were identified in the literature.  Six of these studies included BCS 
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Table 2.2   
Stress, Perceived Social Isolation, and Inflammation in Oncology Populations 
First 
Author, 













life events, and 
increased levels 
of inflammatory 









T1: 6 weeks post-
diagnosis 
T2: 12 weeks  post-
diagnosis 





cancer patients (56 
head and neck 
cancer, mean age 63 
(13) and 34 
colorectal cancer, 
mean age 70 (10.1)) 
Stressful life 
events in the 











TNF- α, IL6, 
IFNg 
CRP) 
Childhood trauma predicted 
higher levels of CRP levels at 
baseline and TNF- α levels at 
one week post-surgery in 
CRC patients (n=18, 
B(CI)=0.09 (0.01 to 0.17) 
p=0.033, n=18, B(CI)=0.03 
(0.01 to 0.05)  p =0.007 
respectively) 
 
There was no evidence of a 
relationship between 
childhood trauma and 
increased inflammation in 







responses to a 










(Trier Social Stress 
Task)  
BCSs stages 0-II 
(N=25; 10 fatigued 








speech to a 
panel) 
 
IL-1, TNF- α, IL-
6 (ELISA) 
Glucocorticoids 
From pre stress to post stress- 
significant effect of time for 
IL-1 β  (F (1, 20)= 10.9, p= 
.004) and for IL-6 (F (1, 20)= 
8.1, p= .01) and TNF- α (F 
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Table 2.2 (continued) 
 
showed a significant increase 
in salivary cortisol 















quality of life, 
symptoms of 







post-intervention, 6  
& 12 months later 
Breast (n=49) and 
prostate survivors 






(IFN-c?), TNF- α, 




Significant relationships were 
reported between high 
perceived stress scores and 
TNF-α (r =0.39, p <0.05) and 














Cross sectional BCSs  (Stages 0 to 
IIIA) completed 
primary cancer 
treatment 1 year 
earlier (n = 152) 
Three types of 
childhood 
adversity-abuse, 







α, CRP: (ELISA) 
Combined measure of 
childhood adversity predicted 
elevations in plasma levels of 
IL-6 (β  = 0.009, p = .027, η2 
= 0.027, after controlling for 
age, BMI, ethnicity, alcohol 
use, and cancer treatment 





















mRNA;  NF-kB 
DNA binding;  
sTNFR2;  IL-1ra;  
IL-6; CRP (blood 
PSS scores correlated with 
CRP (r= .81, p =0.015), IL-6 
(r=.71, p<.05) at time 1; and 
with CRP (r= .81, p <0.05), 
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a result of whole 
breast 
radiotherapy 
T2: Week 6 of 
radiation treatment 





taken prior to 
radiation 
initiation) 
IL-1ra (r=.78, p<.05) for 
those with childhood trauma 
but not in those without 
 
No significant correlations 
between symptoms and 
sTNFR2 or NF-kB DNA 
binding at baseline were 

















surveys and focus 
groups 
Women with BRCA 
1or 2 mutations, 










Among those whose mothers 
were deceased, there is a 
correlative trend between 
post-focus group stress, 
anxiety (r = 0.40, p = 0.13), 
and salivary cortisol (r = 
















T2: day of biopsy 
T3: 1 month after 
biopsy 
T4: 4 months after 
biopsy 












IL-4, IL-6, and IL-10 
production were increased 
before and after the 
procedure (stressful 
experience) compared to the 





















Loneliness unrelated to changes 
in stimulated TNF-α production 
from before to after stress, b  = 
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Table 2.2 (continued) 






before stress T2: 
45 after stress and 
T3: 2 hr after 
stress 
cancer treatment (N 
= 144) mean age 
51.44 (9.17) 
luminescence) 0.14, F (1, 129) = 2.33, p  = 
.130 
 
Lonelier participants exhibited 
greater synthesis of IL-6 and 
IL-1β than participants who 
were less lonely—IL-6: b  = 
0.53, F (1, 129) = 4.48, p  = 
.036; IL-1β : b  = 0.42, F (1, 








to TNF- α 
responses 
Prospective: 
T1 at time of 
diagnosis 
T2 after surgery 




patients stage I or II 
(N=44) 













TNF-α (ELISA) Decreases in social engagement 
explained significantly more 
variance in TNF-α levels at the 
12 month follow up above and 
beyond baseline TNF-α levels 
and cancer stage alone (r2 
change=0.094, p<0.05) 
 
Decreases in both social 
engagement and partner 
satisfaction explained 
significantly more variance in 
TNF-α levels at the 12 month 
follow up above and beyond 
baseline TNF-α levels and 


























CRP and IL-6 
(blood) 
Moderate negative correlation 
between social 
support/attachment and CRP 
levels (r = -.55, 
p = .03) in the survivor group 
 
Moderate relationship between 
social support with IL-6 levels 
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(r = -.37, p = .18) in the 












and loneliness  
 
Cross sectional Colorectal cancer 













Implicit loneliness predicted 
VEGF levels (OR 5.16, 95% CI 
1.05–25.35, p=04) 
 
No significant correlation 
between explicit or implicit 
scores of loneliness (p = .27) 
and IL-6 
 





















Those who were more socially 
isolated or had a SNI score of 3 
or less exhibited increasingly 
elevated inflammation burdens 
adjusting for age and sex 
(b=.13-.24, p<.05) 
 
Higher SNI scores associated 
with lower values of logged 
CRP (p  = .028) and fibrinogen 
(p  = .038) and higher values of 
serum albumin 
Note. BCS, BCSs; fMRI, functional magnetic resonance imaging 
Bio Markers: CRP, c-reactive protein; ELISA, enzyme-linked immunosorbent assay, HbA1c, hemoglobin A1c; IL, interleukin; IFN, interferon; 
IGF-1, Insulin Growth Like Factor- 1; NF, nuclear factor; sTNF-αRII, soluble TNF-α Receptor II; VEGF, vascular endothelial growth factor 
Self Report Scales: PSS, Perceived Stress Scale; PANAS, Positive an Negative Affect Scale; POMS, Profile of Moods Scale; SOSI, Symptoms of 
Stress Inventory; SNI, Social Network Index; UCLA-R, UCLA Loneliness Scale Revived; TSST, Trier Social Stress Test 
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Among these studies, relationships between perceived stress (Carlson et al., 2007; 
Wenzel et al., 2012; Witek-Janusek, Gabram, & Mathews, 2007), laboratory induced 
stress (Bower et al., 2007), history of childhood adversity (Archer, Hutchison, Dorudi, 
Stansfeld, & Korszun, 2012; Croswell, Bower, & Ganz, 2014; Han et al., 2015), and 
inflammatory factors were explored.  For example, in a study of breast and prostate 
cancer patients, significant moderate relationships were reported between high perceived 
stress scores and TNF-α (r=.39, p<.05) and IL-4 (r-.37, p<.05; Carlson et al., 2007).  
Summary 
In summary, moderate positive relationships between perceived psychological 
stress and increases in circulating inflammatory biomarkers in the general population, 
(including older adults) and populations that have comorbidities are supported. In the 
oncology literature, most of the research on these relationships has been conducted in 
women either undergoing breast cancer treatment (Han et al., 2015; Wenzel et al., 
2012;Witek-Janusek et al., 2007) or in survivorship (Bower et al., 2007; Carlson et al., 
2007; Crosswell et al., 2014). There was heterogeneity in inflammatory markers used 
across these studies, however, TNF-α and IL-6 were utilized in five out of seven studies, 
and CRP in three of the seven. Of those studies that focused on BCS, only one study 
evaluated relationships between perceived stress and cytokines (Han et al., 2015).  The 
authors reported strong positive relationships between perceived stress scores and CRP 
(r=.81, p=.015), IL-6 (r=.71, p<.05), and IL-Ra (r=.78, p<.05) in those BCS with a 
history childhood trauma but not in those without (N=20) (Han et al., 2015).  The other 
two studies evaluated the inflammatory effects of an acute laboratory stressor (Bower et 
al., 2007) and how childhood adversities impacted plasma levels of cytokines (Crosswell 
et al., 2014).  Due to publication bias, it is possible that studies that did not find 
relationships between these factors have not been published and therefore were not 
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reviewed in this proposal. This review highlights gaps in the literature regarding 
knowledge on the relationships between the construct of perceived stress and reliable, 
sensitive measures of inflammation such as IL-6 and TNF-α among BCS greater than one 
year after primary treatment ends. 
Perceived Social Isolation and Inflammation  
It is estimated that 15-30% of the adult population suffers from chronic perceived 
social isolation, or loneliness (Hawkley & Cacioppo, 2010).  Loneliness has been 
described as perceived social isolation (Cacioppo & Hawkley, 2009; Hansel et al., 2010); 
however, this definition is not universally accepted (Boss, Kang, & Branson, 2015). In 
the general population, perceived social isolation has been associated with genetic under 
expression of anti-inflammatory glucocorticoid responses (Cacioppo & Hawkley, 2009). 
Positive links between both perceived and objective social isolation and impaired 
immunity have been reported in animal and human studies (Krügel, Fischer, Bauer, Sack, 
& Himmerich, 2014; Yang, Li, & Frenk, 2014). A recent review reported higher 
perceived social isolation was linked to increased pro-inflammatory cytokine response to 
stress and increased pro-inflammatory gene expression (Hawkley & Cacioppo, 2015).  
Furthermore, higher rates of loneliness are consistently associated with higher levels of 
IL-6 (Hansel et al., 2010). 
 Among healthy and older adults, evidence supports that greater social isolation is 
associated with higher inflammatory burden (Yang et al., 2013) and more perceived 
loneliness predicts greater levels of IL-6, TNF-α (Jaremka et al., 2013), interleukins, and 
MCP-1 (Hackett, Hamer, Endrighi, Brydon, & Steptoe, 2012) in regression analyses. 
Similarly, Cole et al. (2015) reported that greater loneliness predicted up–regulation of 
pro-inflammatory gene expression (p<.05) in community dwelling older adults. In older 
adults, significant, although weak, relationships between social isolation and CRP and 
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fibrinogen have been found (Shankar et al., 2011). Several studies have reported no 
relationships between loneliness and IL-6 (Shankar et al., 2011; Creswell et al., 2012), 
CRP (Creswell et al., 2012), and genetic markers of inflammation (Wang et al., 2013). 
 A literature review of primary research studies evaluating perceived social 
isolation and inflammation in breast cancer patients was conducted in Pubmed from 2005 
to 2015.  First, a search of these variables was conducted using the key words: perceived 
social isolation, loneliness, inflammat*, proinflammat*, cytokines, IL-6, TNF-α, 
psychoneuroimmunology, and breast cancer.  Studies that included data on relationships 
between perceived social isolation and inflammation in the identified populations were 
included. Animal and in vitro studies, studies evaluating risk for developing breast 
cancer, and pharmaceutical clinical trials were excluded. The search was expanded to all 
oncology populations (key words: cancer and oncology) for a more comprehensive 
understanding of the relationships among people who experience a cancer diagnosis. The 
findings of this review are reported in Table 2.2.  
Five studies were identified and three of the studies were conducted with breast 
cancer patients or survivors (Jaremka et al., Marucha, Crespin, Shelby, & Andersen, 
2005; Muscatell, Eisenberger, Dutcher, Cole, & Bower, 2015). Evidence on relationships 
between loneliness and IL-6, (Jaremka et al., 2013; Nausheen et al., 2010), TNF- α was 
mixed (Jaremka et al., 2013; Marucha et al., 2005) in oncology populations. Moderate 
negative correlations between social support and CRP (Muscatell et al., 2015) and 
between loneliness and vascular endothelial growth factor (VEGF) levels (Nausheem et 
al., 2010) have been reported. Yang et al. (2014) reported that adult cancer survivors with 
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Summary 
Taken together, few studies have evaluated perceived social isolation in BCS 
greater than one year after the end of primary treatment. The data from the reviewed 
studies is equivocal in regards to relationships between perceived social isolation and 
levels of inflammatory markers and there is heterogeneity in the type of biomarkers 
utilized. Further research is necessary to understand if there are relationships between 
these factors and if so, the quality of such relationships.  
Behavioral Factors and Inflammation 
Physical Activity and Inflammation 
Physical activity and exercise have been found to help regulate pro-inflammatory 
pathways in the body (Nascimento et al., 2014). According to a systematic review, 
exercise induces a short-term inflammatory response and long-term anti-inflammatory 
effects (Kasapis & Thompson, 2005). In population-based studies, an inverse, 
independent, dose–response relationship has consistently been demonstrated between 
physical activity (“any bodily movement produced by skeletal muscles that results in 
energy expenditure” (Caspersen, Powell, & Christenson, 1985, p. 128) and markers of 
systemic inflammation—especially IL-6, TNF-α, and CRP (Beavers, et al. 2010).  The 
relationship between CRP and physical activity is more consistently seen in men—“This 
sex discrepancy may be due to the fact that women have greater adiposity than men, a 
potential confounding factor in the association between physical activity and 
inflammation” (Beavers et al., 2010, p. 786).  
In healthy adults, more physical activity, both subjective and objectively 
measured, has been associated with lower levels of inflammatory levels such as IL-6, 
CRP, IL-1b, and TNF-α (Adams et al., 2015; Fischer, Berntsen, Perstrup, Eskildsen, & 
Pedersen, 2007; Lee et al., 2012; Wu et al., 2014). Similarly, relationships between less 
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physical activity and higher levels of cytokines (IL-6, CRP, TNF- α) have been 
consistently reported cross-sectionally (Colbert et al., 2004; Taaffe, Harris, Ferrucci, 
Rowe, & Seeman, 2000). Lower levels of inflammatory cytokines (IL-6 and TNF-α) have 
been reported in controlled trials evaluating the effects of exercise in older adults 
(Nascimento et al., 2014; Starkweather, 2007). Additionally, it has been reported that 
those that are more physically fit have a lower inflammatory response to stress (Hammer 
& Steptoe, 2007). In a review of effects of exercise on inflammatory markers in persons 
with chronic inflammatory diseases, evidence supported that long-term endurance 
exercise can attenuate systemic inflammation in patients with chronic heart failure and 
type II diabetes (Ploeger, Takken, de Greef, Mathieu & Timmons, 2009). In the context 
of oncology, evidence supports the role of exercise in reducing inflammation (IL-6, TNF-
α, MCP-1) especially in breast and colon cancer populations (Ballard-Barbash et al., 
2012; Murphy, Enos & Velazquez, 2015). 
A literature review of primary research studies evaluating physical activity and 
inflammation in oncology populations was performed in PubMed from 2005 to 2015. 
First, a search of these variables was conducted using the key words: physical activity, 
physical inactivity, exercise, inflammat*, proinflammat*, cytokines, IL-6, TNF-α, 
psychoneuroimmunology, and breast cancer.  Studies that included data on relationships 
between physical activity or exercise and inflammation in the identified populations were 
included. Animal and in vitro studies, studies evaluating risk for developing breast 
cancer, and pharmaceutical clinical trials were excluded. The search was expanded to all 
oncology populations (key words: cancer and oncology) for a more comprehensive 
understanding of the relationships among people who experience a cancer diagnosis and 
the findings reported in Table 2.3. 
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Table 2.3   
Physical Activity, Sleep Quality and Inflammation 
First 
Author, 















CRP, and TNF-α 
in an exercise 
group compared 















Mean age 56 
PA (PA 
Questionnai





CRP; IL-6; TNF-α 
(serum, ELISA) 
No significant effect of 
exercise on changes in 
inflammatory marker 
concentrations between 
women randomized to 
exercise versus usual care 
 
IL-6 and CRP were inversely 
correlated with pedometer 
steps per day (r =0.42, r 
=0.44; p < 0.001),  
 
TNF-α was not associated 
with either measure of 
baseline physical activity 
Pakiz, 
2011 
To explore the 
effect of physical 
activity on 
inflammatory 
markers at the end 





















8; VEGF (serum, 
ELISA) 
Increased physical activity 
from baseline to 16 weeks 
was associated with favorable 
changes in IL-6 (r=−0.35, 
p<.05) and VEGF (r=−0.46,  
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Table 2.3 (continued) 
 activity, 







Intervention group controlling 
for change in weight and 
change in heart rate/min after 
the stepping test, increased 
level of PA was associated 
with favorable changes in IL-

















strength  total 
weekly 






















IL-6, IL-8, IL-10, 
and TNF-α 
(serum) 
Positive effect size of 
physical activity on fatigue 
was significantly mediated by 
IL-6 (82%), IL-10 
(94%), IL-6/IL-10 (49%), and 





To replicate the 
associations found 
in our previous 




interleukin 6 (IL6) 





























IL1R1, IL2, IL8, 
In the analysis for IL13 
rs1800925 carrying one or 
two doses of a rare T allele 
was associated with a 2.21-
fold increase in the odds of 
belonging to the high 
sustained sleep disturbance 
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Table 2.3 (continued) 








In the analysis for NFKB2 
rs1056890 carrying one or 
two doses of a rare T allele 
was associated with a 47% 
decrease in the odds of 
belonging to the high 
sustained sleep disturbance 
























1ra, and CRP 
(plasma ELISA) 
Sleep problems were 
correlated with fatigue but not 
with inflammatory markers 


















months of the 










(SNPs) in the 
promoter regions 
of three cytokine 










Neither the genetic risk index 
nor any of the individual 
SNPs were significantly 

















IL-6 (ELISA) Significant (p< .05) 
relationship between sleep 
disturbance and IL-6 at T1 
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plasma IL-6 in 
women with 
ovarian cancer 
prior to surgery 
T1: before 
surgery 
T2: 1 year 









and T2 (β=0.21, β=0.23) 
controlling for covariates 
 
Changes in sleep over time 
were significantly associated 
with percent change in IL-6 
from T1 to T2 (β=.27, p < 
.01)—   10% decrease in IL-6 
results in 0.13 point 
improvement in the global 
sleep change score 
Sprod, 
2010 
To compare the 






sleep quality and 
mediators of sleep 
Randomized, 
controlled 













Significant relationships were 
reported between  TNF-α and 
sleep quality (r=0.33, p<.05) 




between sleep duration and 
IL-6 (r=-0.49) in the 
intervention group 
 
sTNF-R was negatively 
associated with subjective 
sleep quality (r = − 0.36; p = 
0.026, CI= − 0.610, − 0.046); 
sleep disturbances (r = − 
0.42; p = 0.009; CI = − 0.651, 
− 0.115); and the use of sleep 
medications (r = − 0.33; p  = 
0.045; CI =− 0.586, − 0.008). 
IL-6 was positively 
associated with sleep duration 
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Table 2.3 (continued) 
 
 
(r = 0.35; p  = 0.031; CI = 
0.035, 0.603) and sleep 
efficiency (r  = 0.39; p = 
0.015; CI = 0.081, 0.613). 
 
Better sleep quality related to 
lower TNF- α; and higher 
concentrations of sTNFR 
overall and better sleep 
quality related to lower il-6 in 
intervention group 
Note. PA, Physical Activity 
Bio Markers: ELISA, enzyme-linked immunosorbent assay, HbA1c, hemoglobin A1c; IL, interleukin; IFN, interferon; IGF-1, Insulin 
Growth Like Factor- 1; CRP, c-reactive protein; sTNF-αRII, soluble TNF-α Receptor II; VEGF, vascular endothelial growth factor  
 
Self Report Scales: RAPA (Rapid Assessment of Physical Activity) PANAS (Positive an Negative Affect Scale); POMS (Profile of 
Moods Scale); PSS (Perceived Stress Scale); SOSI (Symptoms of Stress Inventory); SNI (Social Network Index); UCLA-R (UCLA 
Loneliness Scale Revived); TSST (Trier Social Stress Test); PSQI (Pittsburgh Sleep Quality Index) 
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Three randomized control trials were found evaluating the effects of physical 
activity or weight loss interventions on inflammatory markers in BCS. The findings on 
the effects of physical activity on IL-6, TNF- α were mixed. Jones et al. (2013) reported 
no significant effect of a RCT exercise intervention of 150 min of aerobic exercise for 
five weeks. Pakitz et al. (2012) reported that after controlling for weight loss and age, the 
intervention group’s increases in physical activity explained 18% of the variance in 
favorable IL-6 changes (p<.03) after completing a year of a cognitive behavioral 
intervention.  Additionally, moderate inverse relationships between increased physical 
activity and lower levels of IL-6, CRP and VEGF were found (Jones et al., 2013; Pakitz 
et al., 2011), and Rogers et al. (2013) reported that IL-6, IL-10, and TNF-α significantly 
mediated the effects of physical activity on self reported fatigue in BCS who underwent a 
combined aerobic and strength training exercise intervention over 12 weeks.  
Summary 
These studies highlight evidence supporting moderate, negative relationships 
between physical activity and inflammatory cytokines, especially IL-6, CRP, and TNF-α.  
This review provides preliminary evidence to support that inflammation may mediate the 
effect of physical activity on the health outcome fatigue; however, more research is 
necessary to understand how inflammation may mediate the effects of physical activity 
on other health outcomes, particularly cognitive function in BCS. 
Sleep Quality and Inflammation 
It is hypothesized that poor sleep quality (e.g. sleep disturbance and sleep 
restriction) may drive inflammation and subsequent cancer-related symptoms, including 
cognitive dysfunction (Miller, 2008; Irwin, 2013; Irwin, 2015). It is widely accepted that 
there are reciprocal relationships between sleep and immune responses—quality of sleep 
can impact the immune system and immune processes can impact sleep (Del Gallo, Opp 
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& Imeri, 2014). Clevenger et al. (2012) explain the bidirectional relationship between 
inflammation and sleep saying, “Inflammatory processes appear to be able to induce 
sleep disturbances via alterations in sleep architecture; conversely, sleep disturbances 
have been shown to induce inflammatory cytokines” (p. 7). Sleep loss is considered a risk 
factor for inflammatory diseases such as heart disease, Alzheimer’s disease, and cancer 
(Hurtado-Alvarado et al., 2013). In a population-based study of women and men 
(N=4,642), a significant relationship between less sleep and higher levels of IL-6 (p<.05) 
was reported in women (Miller et al., 2009). Evidence supports significant negative 
relationships between poor sleep quality, fewer hours spent sleeping, and worse sleep 
efficiency and higher levels of IL-6 (Heffner et al., 2012; Kanel et al., 2006; Miller et al., 
2009) in the general and elderly populations. 
A literature review of primary research on sleep quality and inflammation in 
oncology populations was performed in PubMed from 2005 to 2015. First, a search of 
these variables was conducted using the key words: sleep, sleep initiation and 
maintenance disorders, insomnia, inflammat*, proinflammat*, cytokines, IL-6, TNF-α, 
psychoneuroimmunology, and breast cancer.  Studies that included data on relationships 
between sleep quality or insomnia and inflammation in the identified populations were 
included. Animal and in vitro studies, studies evaluating risk for developing breast 
cancer, and pharmaceutical clinical trials were excluded. The search was expanded to all 
oncology populations (key words: cancer and oncology) for a more comprehensive 
understanding of the relationships among people who experience a cancer diagnosis and 
the findings reported in in Table 2.3.  
Five studies were identified and all samples included breast cancer patients or 
survivors. One study also included ovarian cancer survivors (Clevenger, 2012) and 
another included prostate cancer patients (Sprod, 2010). The majority of these studies 
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utilized the Pittsburgh Sleep Quality Index to evaluate sleep quality and there was 
heterogeneity in terms of inflammatory markers measured.  Two studies looked at genetic 
markers— multiple SNPs associated with pro-inflammatory genes (Alfaro et al., 2014; 
Bower, 2013), and three evaluated peripheral circulating cytokines— sTNF-RII, IL-1ra, 
CRP, IL-6, and TNF-α (Bower, 2011; Clevenger, 2012; Sprod, 2010). In the studies 
evaluating peripheral cytokines a moderate positive relationship between sleep quality 
and TNF-α (r=0.33) (higher scores on PSQI indicate worse sleep quality) and a moderate 
negative relationship between sleep duration and sTNF-R (r’s=-0.33 to -.42) (Sprod, 
2010) were reported.  Additionally, sleep disturbance predicted changes in IL-6 
(Clevenger, 2012); however, one of the studies found no significant relationships 
between sleep and sTNF-RII, IL-1ra, and CRP (p’s >.80; Bower, 2011). The results of 
the studies evaluating genetic pro-inflammatory factors in relation to sleep disturbance 
were mixed (Alfaro et al., 2014; Bower, 2013).  
Summary 
In summary, these studies were mainly conducted on cancer patients undergoing 
treatment, and may not reflect accurate data for survivors who have completed active 
treatment. These studies suggest that moderate relationships may exist between sleep 
quality and inflammatory markers, but further research is necessary to understand the 
direction and quality of these relationships in BCS six months to 10 years into 
survivorship.  
MODFIABLE FACTORS AND COGNITIVE FUNCTION 
Evidence also supports associations between the aforementioned modifiable 
factors and cognitive function in the general adult population but these relationships have 
not been specifically evaluated in BCS. 
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Psychosocial Factors and Cognitive Function 
Perceived Stress and Cognitive Function 
The relationships between psychological stress and cognitive function are well 
documented (Marin et al., 2011; Leng et al., 2013). For example, a population-based 
study of adults 65 years or older (N=6,207) reported independent relationships between 
perceived stress and both cognitive scores and cognitive decline on a task of perceptual 
speed (p<0.001; Aggarwal et al., 2014). In recent years, theories have been proposed to 
suggest that the etiology of CRCI might be explained by psychosocial factors such as 
allostatic load (Andreaotti et al., 2015) and overloaded self-regulatory systems  (Arndt, 
Reid-Arndt, Das, Cameron, Ahles, & Schagen, 2014; Cacioppo & Hawkley, 2009). It has 
been suggested that exposure to prolonged psychological stressors (including cancer and 
cancer treatment) can overload a persons’ neurological allostasis and result in neural 
biological changes and subsequent cognitive changes (Andreaotti et al., 2015).  
A literature review of primary research on perceived stress and cognitive function 
in oncology populations was performed in PubMed from 2005 to 2015. First, a search of 
these variables was conducted using the key words: perceived stress, psychological 
stress, cognitive function, cognitive dysfunction, cogniti*, cognitive decline, and breast 
cancer.  Studies that included data on relationships between perceived stress cognitive 
function in the identified populations were included. Animal and in vitro studies, studies 
evaluating risk for developing breast cancer, and pharmaceutical clinical trials were 
excluded and the findings reported in in Table 2.4.  
Significant moderate relationships were reported between perceived stress and 
both perceived cognitive function (Li, Yu, Long, Li, & Cao, 2014; Myers, Wick, & 
Klemp, 2015; Ottati & Feuerstein, 2013) and cognitive performance—general cognitive 
decline (Mehlsen, Pedersen, Jensen, & Zachariae, 2009), immediate memory(r=.43), 
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Table 2.4.  















To develop a brief 
self report measure 
of work-related 









Job stress (1 
item: “How 
often do you 
experience 














Job related stress 
significantly correlated 
with FACT-COG 




Li, 2014 To investigate how 
chemo and 
psychological 
























negatively related to 
avoidance (r=-.45, 
p<.001) and hyper-
arousal (r=-.57, p<.001) 
Mehlsen, 
2009 
To examine if 
cancer patients 
receiving chemo 





T1 (0-7 days 
before chemo) 
T2 (4-6 weeks 















Baseline stress was the 
only significant 
predictor of general 
cognitive decline in the 
breast cancer patients 
(Odds ratio: 1.3, p<. 01) 
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Table 2.4 (continued) 
 and healthy 
controls 



























No differences with 
respect to changes in 
cognitive performance 






cognitive effects of 
adjuvant tamoxifen 
and letrozole in 
postmenopausal 























visual learning, verbal 
learning (set of 
computerized 
cognitive tests) 
No correlation was 
observed between 
cognitive composite 
score and perceived 
psychological distress 
 
Those taking letrozole 
had better overall 
cognitive function than 
those 
taking tamoxifen (mean 
difference in composite 
z-scores. 0.28, p= 0.04, 











l Stress  
Perceived Memory Women in the sample 
identified that they had 
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Table 2.4 (continued) 
 










dysfunction in stressful 





To examine the 
need for 
interventions 




cancer patients and 
healthcare staff 



























that an intervention 




would be “quite a bit 








BCSs compare to 
controls 



























associated with distress 
(r = -.40, p<.0001) 
 
AFI were associated 
with distress (r = -.40, 
p<.0001) 
 
Significant group effect 
was seen for PCI (F (6, 
355)=7.01, p<0.0001)—
controls reported less 
PCI than other groups 
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To evaluate the 
relationship 
between stress and 
cognitive 
impairments and 
the potential role of 
coping style as a 
mediator 














WAIS Digit Span)  
Perceived stress was 
significantly related to 
scores on measures of 
immediate memory (r=-
.43, p<.01), delayed 
memory (r=-.43, p 
<.01), verbal fluency 
(r=-.37 p<.05), and 
attention (r=-.42, p<.01) 
 
Helplessness mediates 
the relationship between 
self reported stress and 
cognitive functioning 
(p<.01) 









patients on their 
experiences and 























26% of participants 
attributed cognitive 




To evaluate social 
and emotional 
loneliness in older 
Prospective 
T1: baseline 
T2: 1 year after 









Older survivors who 
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were at increased risk of 
becoming lonely (OR 
2.84 95% CI 1.5-5.37) 
 
Older survivors who 
became cognitively 
impaired were at 
increased risk of 
becoming lonely (OR 
3.00 95% CI 1.65-5.44) 
 
Older survivors who 
were persistently 
cognitively impaired 
were at increased risk of 
becoming lonely (OR 
5.77 95% CI 3.08-10.81) 
 
At baseline, older cancer 
patients were less lonely 
compared with older 
people without cancer 
 
At time 2 emotional 
loneliness had 
significantly increased 
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Table 2.4 (continued) 
 
p = 0.02) but not for 








function in BCSs 
using 3 samples (* 
only Study 1 
reported here, 
studies 2a and 2b 
included healthy 
controls with breast 
cancer participants) 
Study 1 part of 




















Lonelier BCSs reported 
more cognitive difficulty 
than less lonely 
survivors (b= .03, 







To examine if 
cancer patients 
receiving chemo 








T1 (0-7 days 
before chemo) 
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Social support was not a 
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Table 2.4 (continued) 
 
(n=17) 
Note. Self Report Measures: AFI, Attentional Function Index; AGECAT, Automated Geriatric Examination for Computer Assisted 
Taxonomy BAI, Beck Anxiety Inventory; CES-D, Center for Epidemiologic Studies Depression Scale Revised; CSC-W59, Cognitive 
Symptom Checklist Work-59; EORTC-CFS, European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire C30 version 3.0; FACT-COG, Functional Assessment of Cancer Treatment Cognition; FEDA, GSDS, General Sleep 
Disturbance Scale; GHQ-12, General Health Questionnaire- 12; GLT-EQ, Godin Leisure Time- Exercise Questionnaire; HADS, 
Hospital Anxiety Depression Scale;  IES-R, Impact of Event Scale—Revised; LSNS-6, Lubben Social Network Scale–6; MMQ, 
Memory Questionnaire Ability Scale; MAC, Mental Adjustment to Cancer; MASQ, Multiple Ability Self-Report Questionnaire; 
PANAS, Positive and Negative Affect Schedule; PAOFI, Patient's Complaints of Own Functioning Inventory; PSS, Perceived Stress 
Scale; PSQI, Pittsburgh Sleep Quality Index; PTSD, Post Traumatic Stress Disorder; UCLA-R, UCLA Loneliness Scale Revised 
 
NP Tests: COWAT; Controlled Oral Word Association Test; HVLT-R, Hopkins Verbal Learning Test Revised; RAVLT, Rey 
Auditory Verbal Learning Test; RCFT; Rey Complex Figure Test; TMT A/B, Trail Making Test A or B; WAIS-III, Wechsler Adult 
Intelligence Scale 3rd edition; WCST, Wisconsin Card Sorting Test; WMS-III, Wechsler Memory Scale III 
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delayed memory (r=-.43), verbal fluency (r=-.37), and attention (r=-.42 p’s<.05; Reid-
Arndt, 2011).  Perceived stress was identified as a predictor of cognitive decline in BCS 
(Mehlsen et al., 2009). In three qualitative studies, BCS identified that their stress 
negatively impacts their cognitive abilities (Boykoff et al., 2009; Munir et al., 2011). 
Only one study of BCS failed to find significant relationship between perceived stress 
and cognitive performance (Philips et al., 2010).  
Summary 
Taken together, there is strong evidence to support the relationship between 
perceived stress and perceived cognitive function in BCS and breast cancer patients. Two 
of the studies evaluated these concepts in BCS more than one year after treatment 
(Myers, 2015; Phillips, 2010). There was heterogeneity in cognitive tasks utilized to 
evaluate cognitive performance across the reviewed studies, making it is difficult to 
aggregate all the data; therefore, more data is needed to better understand the relationship 
between perceived stress and cognitive performance in BCS more than one year after 
primary treatment ends. 
Perceived Social Isolation and Cognitive Function 
Quality and frequency of social interactions are also associated with cognitive 
functioning (Kremen, Lachman, Pruessner, Sliwinski, & Wilson, 2012). Perceived social 
isolation, which is tied to the quality (rather than the quantity) of social interactions, has 
been shown to predict various health outcomes above and beyond objective measures of 
social isolation. Research indicates that perceived social isolation, or loneliness, is a risk 
factor for poorer cognitive performance and faster cognitive decline (Cacioppo & 
Hawkley, 2009). For instance, in an experimental manipulation of loneliness, imagined 
future isolation predicted cognitive changes even though objective isolation was not 
manipulated (Cacioppo et al., 2006 cited in Cacioppo & Hawkley, 2009). Furthermore, 
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higher perceived social isolation has been linked to impaired executive control and 
regulation (Hawkley & Capitanio, 2015), global cognition, processing speed, immediate 
and delayed recall (Boss et al., 2015).  
Perceived social isolation is an established predictor of cognitive decline in older 
adults and is known to impair executive function in healthy adults (Cacioppo & Hawkley, 
2009). In older adults, evidence suggests that more loneliness (Holwerda et al., 2012; 
O’Launaigh et al., 2014; Shankar, Hamer, McMunn, & Steptoe, 2013) or social isolation 
(DiNapoli, Wu, B Gow, Corley, Starr, & Deary & Scogin, 2014) is related to worse 
cognitive function. More social support (Gow et al., 2013) and better social integration 
(Ertel, Glymour, M., & Berkman, 2008) are related to better cognitive functioning. In one 
study of older adults social isolation was not related to cognitive functioning (Holwerda 
et al., 2012). Moreover, psychosocial isolation as a result of feeling overly stressed 
directly impairs neurocognitive function (Shankar et al., 2011) and perceived social 
isolation has been linked to poor sleep quality and shorter sleep duration (Hawkley & 
Capitanio, 2015).   
A literature review of primary research on perceived social isolation and 
inflammation in oncology populations was performed in PubMed from 2005 to 2015. 
First, a search of these variables was conducted using the key words: perceived social 
isolation, loneliness, cognitive function, cognitive dysfunction, cogniti*, cognitive 
decline, and breast cancer.  Studies that included data on relationships between perceived 
stress and cognitive function in the identified populations were included. Animal and in 
vitro studies, studies evaluating risk for developing breast cancer, and pharmaceutical 
clinical trials were excluded and the findings are reported in in Table 2.4.  
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Summary 
In breast cancer patients and survivors loneliness was linked to worse cognitive 
functioning and cognitive decline (Cheung, et al. 2012; Jaremka et al., 2014; Mehlsen et 
al., 2009). Interestingly, one study found that cognitive decline was a significant risk 
factor for developing loneliness for older cancer survivors, suggesting that there may be a 
bidirectional relationship between loneliness and cognitive functioning in older survivors 
of various cancer types (Deckx et al., 2015).  More research is needed to better 
understand the quality and strength of the relationship between perceived social isolation, 
or loneliness, and cognitive functioning in BCS, especially greater than one year after 
primary treatment.  
Behavioral Factors and Cognitive Function 
Physical Activity and Cognitive Function 
Vascular health has been linked to cognitive status in the aging literature.  It is 
proposed that one of the key mechanisms of improved cognitive abilities is through 
exercise, which preserves vessel elasticity (Gauthier et al., 2015). Several meta-analyses 
support that physical activity is associated with improvements in cognitive performance 
in older adults (Angevaren, Aufdemkampe, Verhaar, Aleman, & Vanhees, 2008; Uffelen 
et al., 2008; Smith et al., 2010).  It is well documented that higher physical activity levels 
are associated with better cognitive function in older adults (Bherer et al., 2013; Bherer, 
2015; Yaffe, Falvey, & Hoang, 2014) and that physical activity is a significant mediator 
of cognitive decline in healthy older adults (Bherer et al., 2013). Additionally, there is an 
inverse relationship between amount of physical exercise and risk for dementia along 
with cognitive decline in aging adults (Palliard, 2015). In older adult populations, 
significant positive effects of exercise interventions on cognitive performance and 
perceived cognitive function were reported in three RCT’s (Nascimento et al., 2014; 
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Nishiguchi et al., 2015; Rahe et al., 2015) and a bidirectional relationship between 
physical activity and memory was also reported (Krall, Carlson, Fried, & Xue, 2014).  
A literature review of primary research on physical activity and cognitive function 
in breast cancer populations was performed in PubMed from 2005 to 2015. Ten studies 
were identified, therefore, the population parameter was not expanded to all oncology 
populations. First, a search of these variables was conducted using the key words: 
physical activity, physical inactivity, exercise, cognitive function, cognitive dysfunction, 
cogniti*, cognitive decline, and breast cancer.  Studies that included data on relationships 
between physical activity and cognitive function in the identified populations were 
included. Animal and in vitro studies, studies evaluating risk for developing breast 
cancer, and pharmaceutical clinical trials were excluded and the findings are reported in 
in Table 2.5.  
Summary 
Physical activity has been evaluated in oncology populations and in BCS more 
physical activity is related to visual memory (Crowgey et al., 2014), better frontal lobe 
controlled cognitive functions (Miki, Kataoka, & Okamura, 2014), and has been found to 
mediate the negative effects of high BMI on perceived cognitive functioning (Myers et 
al., 2015). Lower cardiorespiratory fitness is significantly related to lower hippocampal 
volume (Chaddock-Heyman et al., 2015). Having regularly participated in exercise in the 
previous three months was significantly related to better attention function in a large 
group of young BCS (Pradhan, Stump, Monahan, & Champion, 2014). Being in the 
highest and middle tertiles of physical activity were associated with better executive 
functioning and attention in BCS (Hartman et al., 2015). Not meeting CDC guidelines for 
physical activity was affiliated with an increased likelihood to have cognitive efficiency 
problems in adult survivors of childhood cancers (Krull et al., 2011).  In two qualitative 
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Table 2.5   
Physical Activity, Sleep Quality and Cognitive Function 
First 
Author, 




Variable (s) Key Findings 
Physical Activity 




To explore whether 
cardiorespiratory 
fitness may hold 
promise for 
lessening declines in 
brain and cognitive 
health of a sample 
of BCS within 3 
years of completion 
of primary cancer 
treatment 
 






















Cardiorespiratory fitness and total 
hippocampal volume were positively 
correlated in the cancer survivor (r = 
0.37, p = 0.04) but not controls 
 
More fit BCS had comparable 
hippocampal volumes to non-cancer 
control participants (Cohen’s d = 0.13; p 
> 0.3) 
 
Less fit BCS showed significantly 
smaller hippocampal volumes compared 
to both lower fit and higher fit control 
participants (Cohen’s d = 0.87, p < 0.05) 
 
Higher fit and lower fit cancer survivors 
did not differ from higher fit and lower 









patients on their 
experiences ad 








Mean age 52 
Stages I-IV  
Physical Activity Perceived 
cognitive 
changes 
Many women (56%) attributed cognitive 
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cognitive function  
Cross-sectional ER+, HER-, 
Breast cancer 



















Significant positive relationship between 
exercise behavior and visual memory 
(r=.47, p=.004)   
 
Trend towards significance for the 
relationship between memory composite 
and exercise (r=.31, p=.067) 
 
All other relationship were generally 
weak and non-significant 
Galantino, 
2012 
To identify the 














T2: 6 weeks 
during chemo 
T3: 12 weeks 
during chemo, 
T4: 1 month 
after treatment 
conclusion  
T5: 3 months 
after treatment 
conclusion  
Stage II breast 
cancer (N=4), 





(balance) and Sit 












After 12 weeks of a yoga intervention 
(2x per week)—  
There was a reduction in errors and 
improvement in speed in at least half of 
the women in our case series 
Hartman, 
2015 
To assess the 
relationship of 
obesity, physical 




Cross Sectional BCS, stages 1-3 
(N= 136) Mean 
















Highest tertile of physical activity  
significantly related to better 
performance on the executive 
functioning domain (β = 5.13, SE = 
2.42, p = 0.036) and attention domain (β 
= 4.26, SE = 2.07, p = 0.042) 
Middle tertile of physical activity 
significantly related to better 
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motor skills  
performance on the visual–spatial 
domain  
(β = 9.00, SE = 3.09, p = 0.004). 




relation to health 




























Survivors with neurocognitive problems 
in task efficiency (RR = 0.77, 95% CI = 
0.72–0.84) were less likely to meet CDC 
guidelines for physical activity 
Miki, 2014 To demonstrate the 
feasibility and 
efficacy of speed 
feedback therapy 
with a bicycle 
ergometer on 
cognitive function 












or prostate), > 













Mean score of Frontal Assessment 
Battery for the intervention group was 
higher than that for the control group at 
week 4, mean of 16.61(1.37) compared 
to 14.95 (2.25), (p<.01) 
Myers, 
2015  




impairments in BCS 
compare to controls 















Exercise moderated the negative effect 
of BMI on perceived cognitive 
impairments in the chemo group (F 





To provide an in 
depth description of 




























11/18 participants reported that exercise 
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To test the 
hypothesis that 
lower self-reported 
attention function in 
BCS would be 
associated with less 
exercise and higher 
BMI 
Cross sectional 505 young BCS 












performed any of 
the following 
activities over 




Controlling for fatigue, depression, and 
anxiety, better attention function was 
associated with a greater likelihood of 







To explore EEG 
biofeedback as a 
potentially 
restorative 
intervention for post 
chemo cognitive 





served as own 
wait list control 












Significant negative correlation between 
FACT-Cog quality of life subscale and 
PSQI sleep quality subscale (r= -.56, 
p<.01) 
 
Significant negative correlation between 
FACT-Cog quality of life subscale and 





















group (n= 16) 
Sleep (ISI, Daily 



















Significant difference in verbal episodic 
memory domain (p =.004) in those with 
insomnia compared to good sleepers  
 
Those with insomnia symptoms 
performed significantly worse on the 
immediate recall and delayed recall tasks 
for logical memory and verbal episodic 
memory (d=.88) than the good sleepers 
 
Significant between group difference on 
executive functioning (p=.02, effect size 
d=.7) between insomnia group and the 
good sleepers 
 
No significant difference between 
insomnia and good sleepers on visual 
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episodic memory or attention and 
processing speed domains 
 
No significant difference on CFQ 
between insomnia group and the good 
sleepers 
 
Significant age X insomnia interactions 
found in executive functioning  
Chen, 2012 
 
To explore the 
changes in 
perceived attention 
function in women 
with breast cancer 
over time (2 years)  
Prospective 
observational 
study (12 time 
points from 
before surgery 










Sleep (GSDS) Perceived 
Attention (AFI) 
Perceived attention function declined in 
54% of women at 1 month after surgery 
 
41% and 30% of women perceived 
attention decline at one and two years 
post surgery 
 
Perceived attention function related to 
sleep disturbance (r=-.43 to -.64, p<.01) 
across time  
Hartman, 
2015 
To assess the 
relationship of 
obesity, physical 




Cross Sectional BCS, stages 1-3 
(N= 136) Mean 
age 62.6 years 
(6.6), 65% 
received chemo 
Total number of 
hours per night 














motor skills  
More hours of sleep per night 
significantly associated with better 
performance 
on the verbal functioning domain (β = 

















Age 49.7 (9.2) 
Stage I-III 






PSQI and FACT-COG, moderately -
highly correlated across 3 times points 
(p<.01) 
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Table 2.5 (continued) 
 




To examine the 
effect of CBT for 
insomnia on sleep 
improvement, 
daytime symptoms, 
and quality of life 





















In the cognitive behavioral group for 
insomnia, trend towards significance 
found for cognitive function 





To examine if 
cancer patients 
receiving chemo 
differ in cognitive 
changes during 
treatment from 
cardiac patients and 
healthy controls  
Prospective 
observational 
T1 (0-7 days 
before chemo) 
T2 (4-6 weeks 






























Sleep quality was not a significant 
predictor of cognitive decline across 







levels and sleep in 
disease-free women 
who do and do not 
meet criteria for 
cancer-related 
fatigue syndrome 
Cross sectional BCS 3 months 





















Search,  Verbal 
Recognition 
Memory,  
Significant between groups differences 
in insomnia prevalence— fatigued group 
had higher rates  (44% vs. 16%; 
p=0.001) 
 
Significant between groups differences 
in mood (anxiety and depression)— 
fatigued group had higher scores (14.8 
vs. 7.3, p<.001) 
 
In objective cognitive testing the 
fatigued group performed significantly 
worse than the non fatigued group on 
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Set Shift)     
tests of sustained attention, reaction time 
and verbal memory (all p<0.03) 
Myers, 
2015  




impairments in BCS 
compare to controls 
Cross sectional BCS (n=317) 
Mean ages 
range 53.1-62.3  














In the chemo group: 
Perceived cognitive impairments were 







To provide an in 
depth description of 
















25-65 years old 
Stage I-IV 
Chemo  
Perceived Sleep  Perceived 
global cognition 
 
Participants described that periodic naps 
(or rest) throughout the day helped to 











anxiety, and sleep 
disturbance) 
Cross sectional 88 BCS who 
were on average 
56.7 (SD 8.5) 
years old and 
5.3 (SD 4.1) 
years post-
treatment 












The perceived cognitive impairments 
and perceived cognitive abilities were 
both significantly associated with 
depressive symptoms, fatigue, and 
anxiety 
 
Only perceived cognitive impairments 
was related to poor global sleep quality 
 
Sleep was significantly (p<.05) 
correlated with perceived cognitive 
function (r=.31); perceived cognitive 
impairments (r=.29) 
Note. MCI, Mild Cognitive Impairment 
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Table 2.5 (continued) 
 
Inflammatory Factors: TNF- α, Tumor Necrosis Factor alpha; BDNF, Brain-derived neurotrophic factor; IL-6, interleukin 6 
Self Report Scales:  AAHPERD, American Alliance of Health and Physical Education Recreation and Dance; AFI, Attentional Function Index; BAI, Beck 
Anxiety Inventory; CFQ, Cognitive Failures Questionnaire; CSC-W59, Cognitive Symptom Checklist Work-59; FACT-COG, Functional Assessment of 
Cancer Treatment Cognition; EORTC-CFS, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0; 
FEDA, GHQ-12, General Health Questionnaire- 12; GSDS, General Sleep Disturbance Scale; GLT-EQ, Godin Leisure Time- Exercise Questionnaire; 
HADS, Hospital Anxiety Depression Scale; IPAQ, International Physical Activity Questionnaire; ISI, Insomnia Severity Index; MASQ, Multiple Ability 
Self-Report Questionnaire; MMQ, Memory Questionnaire Ability Scale; MoCA, Montreal Cognitive Assessment; PANAS, Positive and Negative Affect 
Schedule; PAOFI, Patient's Complaints of Own Functioning Inventory; PSQI, Pittsburgh Sleep Quality Index; VAS, Visual Analogue Scale 
NP Tests: COWAT; Controlled Oral Word Association Test; CVLT-II, California Verbal Learning Test; D-KEFS, The Delis–Kaplan Executive Function 
System; HVLT-R, Hopkins Verbal Learning Test Revised; MMSE, Mini Mental State Exam; PASAT, Paced Auditory Serial Addition Test; RAVLT, Rey 
Auditory Verbal Learning Test; RCFT, Rey Complex Figure Test; SDMT, Symbol Digit Modalities Test; TMT A/B, Trail Making Test A or B; WAIS-III, 
Wechsler Adult Intelligence Scale 4th edition; WCST, Wisconsin Card Sorting Test; WMS III/ WMS-R, Wechsler Memory Scale III/ Revised 
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studies, BCS associated their exercise behaviors with improved cognitive functioning 
(Cheung et al., 2012; Myers et al., 2012). Taken together, this review highlights the likely 
relationship between physical activity and cognitive function in BCS; however, the 
measurement of physical activity across these studies is questionable.  More research is 
needed on physical activity and cognitive function using valid and reliable measures of 
self-reported physical activity. 
Sleep Quality and Cognitive Function 
The concept of sleep quality includes sleep disturbance and is related to insomnia. 
It is known that insomnia can negatively impact cognitive functioning. It has been 
consistently reported that those with insomnia have more cognitive difficulties and 
exhibit significant impairments on tasks assessing episodic memory (ES=0.51), problem 
solving (ES=0.42), working memory manipulation (ES=0.42), and working memory 
retention (ES= 0.22; Fortier-Brochu, Beaulieu-Bonneau, Ivers, & Morin, 2012). 
Neuroimaging data indicates that the prefrontal cortex region is vulnerable to the effects 
of sleep loss; however, behavioral data utilizing executive function tasks does not always 
support this (Killgore, 2010). Evidence suggests a relationship between insomnia and 
increased risk for development of neurodegenerative disorders and different dementia 
types (Yaffe et al., 2014). One of the proposed mechanisms for how sleep disturbances, 
such as insomnia, increase one’s risk for dementia is through inflammatory pathways 
(Yaffe et al., 2014).  
Even though results are mixed, there is a general consensus that poorer sleep 
quality in older adults is related to worse cognitive outcomes (Yaffe et al., 2014). 
Furthermore, there is evidence that sleep loss affects specific aspects of higher-level 
cognitive capacity and emotional regulation beyond global cognitive effects (Killgore, 
2010; Walker 2010; Whitney & Hinson, 2010). In older adults, better sleep quality 
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measured both objectively with polysomnography and subjectively with questionnaires or 
sleep diaries, is associated with better global cognitive function, memory, and attention 
(Bastien et al., 2003; Fortier-Brochi & Morin, 2013). One study did not find such 
associations (Sivertsen, et al., 2013).   
A literature review of primary research on sleep quality and cognitive function in 
breast cancer populations was performed in PubMed from 2005 to 2015. Eleven studies 
were identified, therefore, the population parameter was not expanded to all oncology 
populations. First, a search of these variables was conducted using the key words: sleep, 
sleep initiation and maintenance disorders, insomnia, cognitive function, cognitive 
dysfunction, cogniti*, cognitive decline, and breast cancer.  Studies that included data on 
relationships between sleep quality and cognitive function in the identified populations 
were included. Animal and in vitro studies, studies evaluating risk for developing breast 
cancer, and pharmaceutical clinical trials were excluded and the findings are reported in 
in Table 2.5.  
Summary 
In breast cancer patients and survivors consistent relationships between aspects of 
sleep quality and cognitive functioning (both perceived and performance-based) were 
reported— specifically, between sleep quality (Sanford et al., 2014; Von Ah & Tallman, 
2015), daytime functioning (Alvarez, 2013), sleep disturbance (Chen, Miaskowski, Liu, 
& Chen, 2012; Myers et al., 2015) and cognitive function. Insomnia symptoms were also 
consistently related to poorer cognitive functioning in episodic memory, immediate and 
delayed memory, executive function (Caplette-gringras et al., 2013; Mathews et al., 
2014) but not consistently with attention and processing speed (Caplette-gringras et al., 
2013; Minton & Stone, 2012). Hartman et al, (2015) reported that more hours of sleep per 
night was significantly associated with better verbal functioning on cognitive 
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performance measures. Only one study of BCS reported non-significant relationships 
between sleep quality and cognitive performance measures (Mehlsen et al., 2009). Across 
the reviewed studies, the Pittsburgh Sleep Quality Index is the most consistently used 
valid and reliable measure of self-reported sleep.  There was heterogeneity across studies 
in terms of NP tests that were used to evaluate cognitive performance, making it difficult 
to draw conclusions regarding the specific cognitive domains that are related to sleep. 
More research is needed to better understand the nuances of the relationships between 
cognitive function and aspects of sleep quality—onset, duration, interference, and 
daytime sleepiness. 
CHAPTER SUMMARY 
Cognitive problems may persist for many BCS months to decades after 
chemotherapy ends; however, the exact mechanism of CRCI following the end of 
adjuvant therapy remains unclear. The most recent research on CRCI in BCS has linked 
inflammation to cognitive function both during and immediately following treatment 
(Cheung et al., 2014, Ganz et al., 2013; Kesler et al., 2013; Janelsins et al., 2012). 
However, inflammatory factors need to be evaluated in survivors 6 months to ten years 
after chemotherapy to better understand whether inflammation contributes to cognitive 
function after recovery (or partial recovery) occurs. Additionally, modifiable 
psychosocial (stress, social isolation) or behavioral (physical activity, sleep quality) 
factors that may also be directly or indirectly (through inflammatory mediators IL-6 and 
TNF-α) contributing to cognitive function have not been evaluated in BCS. 
Psychosocial (stress, social isolation) and behavioral (physical activity, sleep 
quality) factors have been associated with both inflammation (IL-6, TNF-α) and 
cognitive function (memory, attention, processing speed, executive function) in the 
general and elderly populations and there is preliminary evidence in the oncology 
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literature that supports these relationships as well. However, the relationships of these 
constructs have not been examined simultaneously in BCS 6 months to ten years after 
treatment. The next logical step is to examine these relationships through a biobehavioral 
theoretical lens to provide foundational evidence for future prospective research studies 
and targets for behavioral interventions. This dissertation study is a critical first step in 
filling this gap in the literature, intended to both improve scientific knowledge of 
modifiable factors influencing inflammatory mechanisms of cognitive dysfunction and to 
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Chapter 3:  Methods 
This chapter provides the design, study procedures (sampling approach, 
measurement and instrumentation for data collection), and data analyses for the study.  
Procedures for protecting human subjects are also detailed.  
DESIGN 
The goal of this nonexperimental, cross-sectional study was to determine whether 
stress, perceived social isolation, physical activity, sleep quality, and inflammation are 
significant predictors of cognitive function in BCS (six months to 10 years following 
chemotherapy) and whether inflammation mediates the effects of these psychosocial and 
behavioral factors on cognitive function. Although this design is limited because it does 
not allow for the determination of causality, it does allow a large amount of data to be 
collected and is an appropriate way to explore the strength and quality of relationships 
among variables (Polit & Beck, 2011). 
STUDY PROCEDURES 
Prior to recruitment and enrollment, all study instruments and procedures were 
approved by the University of Texas at Austin Institutional Review Board.  See Appendix 
A for approval letter.  
Sample 
Seventy-Five BCS who were 6 months to ten years post chemotherapy were 
recruited for this study. A linear multiple regression (fixed model, R2 increase) power 
analysis was conducted in G*Power 3.1 to determine an appropriate sample size for the 
analyses in Aims 1 and 2. An effect size of  f2=0.21, two-tailed α = .05, power of 0.80, 
five tested predictors (those entered after covariates), and 12 total predictors (covariates 
and predictor variables) yielded a sample size of 68. The Principal Investigator (PI) 
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oversampled by 7 participants for a total sample size of 75 to compensate for missing or 
incomplete data and to allow for exploratory analyses in Aim 3. The effect size was 
determined based on the published significant relationship between TNF-α and IL-6 and 
verbal memory performance in BCS (Hopkins Verbal Learning Test-Revised [HVLT-R]: 
beta = -2.46, p=.006; Kesler, Janelsins, Koovakkattu, Palesh, Mustian, Morrow, & 
Dhabhar, 2013). 
The sample of BCS was recruited primarily from the greater Austin, TX 
metropolitan area from May 1, 2016 through January 16, 2017. The Austin metropolitan 
area comprising over 1.8 million people as of 2010: 54% Non-Hispanic white, 32% 
Hispanic, 6.9% Black, 7.1% other (“Texas Population”, 2014). In 2009, the number of 
female Texans with a diagnosis of breast cancer in the previous 10 years was 98,038 (592 
men were also diagnosed with breast cancer) and the 5-year survival rate for those 
diagnosed in 1995-2009 for all races/ethnicities and stages of breast cancer was 86.5% 
(Risser et al., 2012).  As of 2011, there were 3,725 women living with a history of breast 
cancer stages I-III living in the greater Austin, TX metropolitan area—73.7% Non-
Hispanic white, 7.4% Black, 14% Hispanic, and 2.3% Asian/Pacific Islander (Risser, 
2014).  
The sample was also recruited nationally, through The Army of Women program 
(AOW).  The AOW is part of the Dr. Susan Love Research Foundation, a not-for-profit 
California corporation.  The AOW unites researchers with women and men willing to 
participate in research studies related to breast cancer.  The AOW enables women and 
men of all ages, ethnicities and levels of breast cancer risk to volunteer to participate in 
research studies focused on understanding the means to prevent breast cancer before it 
starts. There are currently over 380,000 members in the AOW database, 1517 of which 
registered in the Austin area. The AOW's scientific advisory council reviewed this study 
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protocol and approved this study to be broadcasted to the Army of Women database and 
listed on the armyofwomen.org website (See Appendix B for AOW Approval 
Letter).  The AOW assisted with content development of an e-blast letter (See Appendix 
C for the E-blast Letter) that was sent to the entire AOW national database. Those AOW 
volunteers who were interested contacted the AOW staff directly and the AOW staff sent 
the PI a weekly email with the contact information for those interested AOW members. 
Additionally, the AOW posted the study information on their website throughout the life 
of the study. 
Inclusion Criteria 
All participants were female, with a history of breast cancer (stage I-III) that 
received chemotherapy as part of their treatment, and have been without cancer 
recurrence or secondary cancers for six months to 10 years. Women currently receiving 
hormonal therapy were included. Participants were between the ages of 21 to 65 years 
old, able to read and write in English, and of any ethnic/racial group. 
Exclusion Criteria 
Women older than 65 were excluded to control for age-related cognitive decline 
(Aartsen, Knipscheer, Smits, & Deeg, 2002). Women on systemic steroids (in the 
previous month) or biologic response modifiers, those with a history of inflammatory 
breast cancer, women with physician diagnosed inflammatory diseases (diabetes mellitus, 
rheumatoid arthritis, autoimmune diseases) or pre-cancer history of sleep disorders, 
severe insomnia, severe cognitive impairments (diagnosed by a physician), a verbal 
learning disability, or other neurological or psychiatric disorders that can impact 
cognition or emotions and interfere with completion of questionnaires were also 
excluded. These criteria were outlined in the pre-screening form. 
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Recruitment and Screening 
Participants were recruited through community oncology centers (Texas 
Oncology [TxO]; 80% of cancer patients and survivors receive healthcare in these 
settings, Richardson & Tangka, 2007), a breast cancer patient and survivor navigation 
center that serves the greater Austin metropolitan area (Breast Cancer Resource Center 
[BCRC]), over 200 oncology nurses who are members of the Central Texas Oncology 
Nursing Society (CTONS), the Army of Women (AOW, a national non-profit that 
recruits women with and without breast cancer who are interested in being involved in 
breast cancer research; https://www.armyofwomen.org), and through social networking 
within the Austin community. TxO posted flyers in their clinics and allowed the PI to 
educate clinicians in person on the inclusion/exclusion criteria. The BCRC allowed the PI 
to educate their patient navigators in person on the inclusion/exclusion criteria and 
provided study information to survivors at support groups and online twice a month 
throughout the life of the study. The PI also presented her study and provided recruitment 
flyers to CTONS members. The AOW sent out an E-blast email to all members nation 
wide with detailed study information and posted the study information on their website. 
Additionally, if someone in the community expressed interest in the study, the PI 
provided her business card and a recruitment flyer to the interested person. The 
recruitment flyer clearly stated the study’s purpose, the expectations for participants, 
eligibility requirements, the investigator’s contact information, and the University of 
Texas IRB protocol number (Appendices D, E, F, and G for Letters of Support and the 
Recruitment Flyer).  
Potential participants were screened for eligibility via the telephone (Appendix 
H). A prescreening form was used to ensure that participants were eligible to participate 
in the study based on the inclusion and exclusion criteria. If eligible, the participant’s 
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willingness to participate and verbal consent were obtained. Consent forms were sent to 
participants via mail or email depending on the participants’ preferences (Appendix I).  
One hundred and nine women were screened for this study. Of these, 21 did not 
meet study inclusion criteria. Six had a history of stage IV breast cancer, nine did not 
complete chemotherapy within the outlined timeframe (six months < chemo completion 
date < 10 years). Four women had a history of inflammatory comorbidities or other 
comorbities that interfere with normal cognitive processes. One woman was older that 65 
years, and another was on steroid treatment. Of the 88 women who met the inclusion 
criteria, two lived too far away to participate, and 11 did not respond to scheduling 
attempts. Thus, 75 women were enrolled in the study from April 2016— January 2017. 
The PI was unable to successfully access the veins on nine of the participants due to 
lymphedema, sclerosed veins, or other anatomical reasons. Therefore, blood samples 
were obtained from 66 of the 75 participants. The final sample used for the primary aims 
of this study was 66 for aims 1 and 2, and all 75 were used for aim 3 and in additional 
exploratory analyses. 
Data Collection  
All data was collected specifically for this research project. The data included 
questionnaire responses, anthropometric measures, standardized NP tests, and blood. This 
data allowed for the measurement of demographic and disease and treatment-related 
factors; stress, perceived social isolation, physical activity, and sleep quality; 
inflammatory markers (IL-6, TNF-α); and cognitive function (memory, attention, 
processing speed, and executive function performance, perceived cognitive function). See 
Appendix J for all the Study Instruments. Once participants completed a phone screening 
and verbal consent, an appointment was scheduled for a day that was convenient for the 
participant. Data collection appointments were scheduled 1-4 hours after they woke up 
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that morning. Prior to the scheduled appointment, participants were mailed/or emailed a 
written consent form and a link to Part 1 of the structured questionnaire (Perceived Stress 
Scale [Cohen, Kamarck, & Mermelstein, 1983], UCLA-R Loneliness Scale [Russel, 
1996], Pittsburgh Sleep Quality Index [Buysse, Reynolds, Monk, Berman, & Kupfer, 
1989], PROMIS Item Bank v1.0 – Emotional Distress – Anxiety – Short Form 8a, 
PROMIS Item Bank v1.0 – Emotional Distress – Depression – Short Form 8a, PROMIS 
Item Bank v1.0 – Fatigue – Short Form 8a [http://www.healthmeasures.net/explore-
measurement-systems/promis]. They returned the consent and Part 1 of the questionnaire 
prior to or at a scheduled appointment at the UT School of Nursing Family Wellness 
Center.  
Face-to-face data collection included anthropometric assessment (weight, height, 
waist circumference, hip circumference) and standardized NP testing by the PI (Hopkins 
Verbal Learning Test Revised [Benedict, Schretlen, Groninger, & Brandt, 1998], Trail 
Making Tests A and B [Tombaugh, 1994], Controlled Oral Word Association Test 
[Benton, & Lester, 1994]). The PI was properly trained to perform and analyze the NP 
tests and was supervised by her dissertation members, Dr.’s Heather Becker and Shelli 
Kesler, during data collection. During the period of time needed to perform the delayed 
section of the HVLT-R, Part 2 of the structured questionnaire was administered 
(demographic questions, Charlson Comorbidity Index [Charlson, Pompei, Ales, & 
MacKenzie, 1987], International Physical Activity Questionnaire [Craig et al., 2003], and 
Epworth Daytime Sleepiness Scale [Johns, 1991]). Non-fasting blood samples were 
drawn by the PI for all participants between 1-4 hours of waking to control for potential 
circadian variation. Ten milliliters of blood was taken from a vein [e.g. antecubital area, 
metacarpal plexus, dorsal venous arch, etc.)  per standard operating procedures using 
aseptic technique and a butterfly needle blood collection set (See Appendix K for 
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standard operating procedure). Blood was collected into 10 ml serum separator tubes (BD 
Franklin Lakes, New Jersey) and allowed to clot at room temperature for 30 min – 2 hr 
per the manufacturer’s instructions.  Data collection required approximately 60 minutes 
per participant.  
Protection of Human Subjects 
The University of Texas at Austin Institutional Review Board approved all study 
procedures and forms prior to the initiation of recruitment and enrollment. Potential 
participants were screened for eligibility via the telephone. If eligible, the participant’s 
willingness to participate and verbal consent were obtained. A written consent was 
provided and explained to participants via email or mail per participant preference.  It 
was emphasized that participation was voluntary and they could withdraw at any time. 
Each participant was assigned a unique identification number and the list linking 
the individuals’ names and addresses to the ID number was kept on the investigator’s 
encrypted laptop in a password-protected file. Confidentiality of data records was 
maintained by keeping signed consent forms separate from data files in locked cabinets in 
the Dissertation Chair’s research office. Only the PI and her dissertation chair have 
access to the password-protected file. All data from participants were entered into the 
separate computer that houses the data under a high-security password interface. All 
research computers are encrypted, with secure university back up for all files.  
The PI wrote the assigned record number on completed questionnaires and NP 
testing materials and placed them in the locked file cabinet, in a locked office, within the 
School of Nursing that has a security guard on duty whenever the front door is open. The 
PI only worked with questionnaires with code numbers, not names. All the blood 
samples, instruments and lab specimens were labeled with the assigned code numbers. 
Hard copies of the questionnaires are kept in a locked file cabinet in a locked research 
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office in a locked campus building. Electronic copies of the electronic surveys (with 
unique id numbers) are kept within the University of Texas Qualtrics secured, cloud-
based database. Blood samples are stored in a freezer in the BioBehavioral Lab, which is 
a locked lab. Written questionnaire data will be kept for 5 years after publication of all 
findings and then destroyed according to university policies— written documents will be 
shredded. Blood samples will be kept five years after study publications and then 
disposed of in biohazard containers according to University Environmental Health and 
Safety policies. 
The data or samples was only shared with members of the PI’s Dissertation 
Committee who supervised the conduct of this research project, and have not been shared 
with other researchers for purposes not detailed in this study. Data were not anonymous 
but will be kept confidential through the use of numerical identifiers. 
MEASUREMENT AND INSTRUMENTS 
A summary of the instruments used in this study can be found in Table 3.1 
Summary of Study Instruments. 
Individual Factors and Demographics 
Demographic Variables 
An information sheet was used to collect demographic information (age, 
education, race, ethnicity, marital status, income, employment) as well as information on 
disease and treatment (type of breast cancer, type of cancer treatments, date of 
chemotherapy completion, current medications, comorbidities, menopausal status, and 
genetic testing information). These data were used to describe the sample and in the 
selection of covariates. 
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Table 3.1.  
Summary of Study Instruments 








PROMIS Item Bank v1.0 – Emotional 







feelings in the 
last 7 days 





Wenzel et al., 
2015) 
PROMIS Item Bank v1.0 – Emotional 







the last 7 days 






Wenzel et al., 
2015) 
Validated in breast 
cancer patients 
(Teo, Novy, 
Chang, Cox, & 
Fingeret, 2015) 
PROMIS Item Bank v1.0 – Fatigue – 






Fatigue in the 
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Table 3.1 (continued) 
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Table 3.1 (continued) 
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Body Mass Index (BMI) 
BMI was measured because inflammatory markers including IL- 6, TNF-α, IL-8, 
IL-18, and IL-1ra are consistently associated with obesity indices in large population- 
based studies (O’Connor et al., 2009).  Height was measured to the nearest 0.5 cm with 
participants’ back to the wall, without shoes, looking straight ahead. All participants’ 
were weighed with the same digital scale (Tanita Model WB-300 Plus Arlington Heights, 
Illinois) to the nearest 100 g, wearing no shoes and light clothing. BMI was calculated 
using weight in kilograms and height in cm. Waist circumference was measured (in cm) 
between the 12th rib and the iliac crest, and the hip circumference was measured (in cm) 
around the buttocks at the maximum extension according to the World Health 
Organization (“Waist circumference and waist–hip ratio: report of a WHO expert 
consultation”, 2008) and the hip to waist ratio (HWR) will be calculated. A ratio of 0.8 or 
greater is considered a measure of central adipose tissue. 
Illness and Treatment related Variables (Tamoxifen-use and History of Anthracycline 
based chemotherapy) 
Tamoxifen use was determined using a dichotomized variable of history of 
tamoxifen use or no history. History was determined from participants’ answer to the  
following question on the information sheet, “What treatments are you presently using 
for your breast cancer treatment?”. Answer choices included: no medications, steroids, 
aromatiase inhibitors (e.g. Arimidex®, Aromasin®, Femara®), selective estrogen 
receptor modulators (e.g. tamoxifen, Evista®, Fareston®), Estrogen receptor down 
regulators (e.g. Faslodex®), or other. History of anthracycline-based chemotherapy was 
determined by using a dichotomized variable of history of anthracycline treatment or no 
history. History was determined from the following question included in the information 
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sheet that asks, “What types of treatments did you receive for your breast cancer 
treatment? Circle all that apply.” Answer choices for chemotherapy types included 
anthracycline (Adriamycin, Doxil, doxorubicin); methotrexate (Amethopterin, Mexate, 
Folex); paclitaxel (Taxol); docetaxel (Taxotere); fluorouracil, 5-fluorouracil, 5-FU 
(Adrucil); carboplatin (Paraplatin); and cyclophosphamide (Cytoxan). 
Psychosocial Factors 
Emotional Distress 
Emotional Distress, defined in this study as depressive and anxiety related 
symptoms, was measured using two PROMIS© scales, the Emotional Distress – Anxiety 
– Short Form 8a and Emotional Distress – Depression–Short Form 8a (Cella et al., 2010).  
PROMIS scales are designed to capture health related outcomes from patient perspectives 
and have undergone extensive psychometric evaluation within the National Institutes of 
Health (Cella et al., 2010).  These scales are available on the NIH website 
(http://www.healthmeasures.net/explore-measurement-systems/promis).   
The Emotional Distress- Anxiety Short form 8a is an 8-item scale that asks how 
often a person experienced anxiety related feelings in the past seven days.  Answer 
choices range from 1 (“never”) to 5 (“always”) and total scores can range from 8-40 with 
higher scores indicated more anxiety related symptoms.  
The Emotional Distress- Depression Short form 8a is an 8-item scale that asks 
how frequently a person experienced depressive feelings in the past seven days.  Answer 
choices range from 1 (“never”) to 5 (“always”) and total scores can range from 8-40 with 
higher scores indicated more depressive symptoms. Both the Anxiety and Depression 
Short forms have demonstrated adequate reliability across populations, including cervical 
cancer survivors (α’s >.95, Wenzel et al., 2015) and the PROMIS Depression has been 
validated in breast cancer patients (Teo, Novy, Chang, Cox, & Fingeret, 2015).  
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Fatigue 
Fatigue, defined in this study as perceived feelings of tiredness, was measured 
using the PROMIS Fatigue Short form 8a, an 8 item scale that asks how frequently a 
person experienced fatigue related feelings in the past seven days.  Answer choices range 
from 1 (“not at all”) to 5 (“very much”) and total scores can range from 8-40 with higher 
scores indicating more fatigue related symptoms. This measure has demonstrated 
adequate reliability across populations (Cella et al., 2010), including cancer patients (α’s 
>0.86, Cessna et al., 2016) and has been validated in women undergoing adjuvant 
treatment for breast cancer (Junghaenel, Cohen, Schneider, Neerukonda, & Broderick, 
2015).  
Stress  
Perceived psychological stress was measured using the Perceived Stress Scale 
(Golden-Kreutz, Browne, Frierson, & Andersen, 2004), a 10-item scale measuring the 
degree that life circumstances are appraised as having been stressful in the previous 
week. Responses for each item range from 0 (“never”) to 4 (“very often”). This measure 
has demonstrated adequate reliability and validity in breast cancer patients (α’s ranged 
from .86 to .92; Golden-Kreutz et al., 2004).  
Perceived Social Isolation  
Perceived social isolation, defined as loneliness, was measured using the UCLA-
R Loneliness Scale version 3 Survey (Russel, 1996). This 20-item instrument quantifies 
how people experience their loneliness. Each item asks how often each feeling is 
experienced— answer choices are “never”, “rarely”, “sometimes”, and “always” 
(Russell, 1996). Higher scores indicate more loneliness and perceived isolation. The 
UCLA-R Loneliness Scale, used widely, has been validated in breast cancer survivors 
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and has demonstrated adequate reliability (α=.89; Fogel, Albert, Schnabel, Ditkoff, & 
Neugut, 2002).  
Behavioral Factors 
Physical Activity 
Physical activity was measured using a self-report recall of the frequency of 
various forms of physical activity (job-related, transportation, household, 
recreation/leisure time, time spent sitting/sedentary time) in the last seven days using the 
International Physical Activity Questionnaire (IPAQ) long version. This 27-item 
instrument asks how many days in the last week certain physical activities have been 
performed—for example, “How much time do you usually spend on one of those days 
doing moderate physical activities as part of your work?” Participants’ answers provide 
minutes per day and days per week. A domain-specific score for walking, moderate, and 
vigorous activities, as well as a total score of the metabolic equivalent (MET) can be 
estimated (for exact criteria see Scoring Protocol under 
http://www.ipaq.ki.se/scoring.pdf). The IPAQ is accepted worldwide as an adequate 
measure of physical activity in adults (repeatability coefficient of 0.81; Craig et al., 
2003).  
Sleep Quality 
The operational definition of sleep quality for this study is subjective reports of 
sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbance, use of 
sleep medication, and daytime dysfunction as measured by the Pittsburgh Sleep Quality 
Index (PSQI; Buysse, 1989).  The PSQI is a self-administered 19-item questionnaire 
measuring quality of sleep over the past month, and has been successfully utilized to 
identify sleep disturbances in cancer survivors (Palesh et al., 2012). The PSQI evaluates 
seven aspects of sleep: subjective sleep quality, sleep latency, sleep duration, sleep 
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efficiency, sleep disturbance, use of sleep medication, and daytime dysfunction. Scores 
range from 0 to 21; lower scores indicate better sleep quality. The PSQI is a reliable 
measure of sleep quality in cancer patients (α=.81; Sprod, Palesh, Janelsins, Peppone, 
Heckler, Adams… Mustian, 2010). An additional measure of daytime sleepiness, the 
Epworth Sleepiness Scale (8-items), was used in this study to understand the effects of 
sleep quality on daytime sleepiness as it relates to cognitive functioning 
(http://epworthsleepinessscale.com/about-epworth-sleepiness/). Each item response 
choices are 0 to 3, with higher scores indicating greater daytime sleepiness. This measure 
has demonstrated reliability in breast cancer patients (α = .78-.79; Enderlin et al., 2011). 
Inflammatory Markers (IL-6 & TNF-α) 
Two markers of inflammation were chosen for this study based on preliminary 
(though inconclusive) evidence supporting their associations with problems with 
cognitive function in BCS, individual factors, psychosocial factors, and behavioral 
factors: interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These circulating 
markers were assessed from serum. The PI used venipuncture to collect non-fasting blood 
(10 ml) into serum separator tube vacutainers 1-4 hours after each participant woke in the 
morning. Samples were allowed to clot for 30 min- 2 hours at room temperature (per the 
manufacturer’s instructions), then transported (in a portable cooler that maintained room 
temperature) to the University of Texas at Austin School of Nursing BioBehavioral lab 
(Biosafety Level 2 facility, EHS Approval # 2012-07-0096) that is located in the School 
of Pharmacy.  In the lab, the samples were centrifuged at 3,330 rpm for 15 min, then 
serum was aliquoted using a filtered pipette into 1ml polypropylene tubes, and stored at -
80°C according to environmental health and safety biohazard policies at UT.  
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Cognitive Function  
Perceived Cognitive Functioning 
Perceived cognitive function was measured with the Functional Assessment of 
Cancer Therapy-Cognitive Function Instrument version 3 (FACT-Cog), a 34-item self-
administered questionnaire that measures how often cognitive dysfunction has been 
experienced in the last 7 days. Responses range from 0 (“never”) to 4 (“several times a 
day”).  The FACT-Cog is made up of 4 sub scales: perceived cognitive impairments, 
impact on quality of life, comments from others, and perceived cognitive abilities. 
Negatively stated items are reversed scored. Total scores can range from 0 to 148; higher 
scores indicate better cognitive function and quality of life. This instrument is often 
utilized in studies of breast cancer survivors’ cognitive function and is a valid measure of 
cancer patients’ perceived cognitive deterioration (Cheung et al., 2014). The 4 sub-scales 
were found to be reliable (α’s = .67 - .94) when used for 204 breast cancer patients 6 
months after chemotherapy (Wagner, Sweet, Butt, Lai, & Cella, 2009). 
Cognitive Performance  
The cognitive domains most affected in BCS are memory, attention, processing 
speed, and executive function. The International Cognition and Cancer Task Force 
recommends that the following well-established valid and reliable NP measures be used 
in cancer and cognition-related research: the Hopkins Verbal Learning Test-Revised 
(HVLT-R, a measure of verbal memory; Benedict et al. 1998), the Trail Making Test A 
and B (Trails A and B, a measure of processing speed, executive function, attention, and 
cognitive flexibility; Tombaugh, 2004), and the Controlled Oral Word Association Test 
(COWAT; a measure of verbal fluency and word finding; Wefel, Vardy, Ahles, & 




           
 97 
For the HVLT-R, participants were instructed to listen to a list of 12 words and 
repeat back as many of the words that they could remember.  The list was repeated and 
participants asked to say as many words that they could remember included those they 
already said.  This process was repeated a third time.  For delayed recall, 20-25 min later, 
participants were asked to remember and say as many of the 12 words from the original 
list that they could one time. Finally, for forced recognition, participants were read a 
longer list of 24 words that included the original 12 words along with distractor words.  
Each word is read aloud and the participant says “yes” if the word was on the original list 
and “no” if it was not. In a study of older adult cancer survivors the test/retest correlation 
for the HVLT-R delayed subscale was .66 (McDougall, Becker, Acee, Vaughan, & 
Delville, 2011) and is sensitive to distinguish between breast cancer survivors who 
received chemotherapy from survivors who did not receive chemotherapy (Kesler et al., 
2013).  
For the Trail Making Test Part A, participants were first presented with a piece of 
paper that had a sample of 8 numbered circles and instructed to connect the numbers in 
ascending order (1, 2, 3, etc.) as quickly as possible. Their time in seconds was recorded. 
Then the paper was turned over and on the other side were 25 numbered circles and the 
participants were instructed to connect the numbers in ascending order (1, 2, 3, etc.) as 
quickly as possible. Their time in seconds was recorded. For the Trail Making Test Part 
B, participants are presented with a piece of paper that had numbered circles (1-4) and 
letters (A-D) and instructed to connect the numbers in ascending order (1-A-2-B-3-C, 
etc.) as quickly as possible. Their time was recorded in seconds. Then the paper was 
turned over and on the other side were more numbered circles (1-13) and letters (A-L) 
and the participant was instructed to connect the numbers in ascending order (1-A-2-B-3-
C, etc.) as quickly as possible. Their time was recorded in seconds. For both trials, the 
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participants were watched and errors pointed out by the tester so that they could be 
corrected. This test has been accepted as valid measure for differentiating those with 
organic brain damage (e.g. brain tumor, penetrating head injury, closed head injury, 
cerebral vascular accident, cerebral abscess, cerebral atrophy, subdural hematoma) from 
those without damage for many years (Reitan, 1958) and has demonstrated adequate 
reliability (coefficients 0.89 and 0.92; Mitrushina, Boone, & Razani, 2005). 
For the COWAT, participants were asked to name as many words they could 
think of (not proper nouns) that begin with the letter “F” over the course of 1 minute.  
This was repeated for letters “A” and “S”. The tester wrote down the words as the 
participant said them out loud. This measure is reliable and generally stable over time (α 
.82 and test retest coefficient .74; Ruff, Light, Parker, & Levin, 1996).   
DATA CLEANING AND CHECKING 
All data were entered into SPSS 24.0 (IBM, 2016). First, data were cleaned— 
frequencies on each variable were run, and missing values checked for errors versus 
missing data. NP tests were scored following the instructions in the manuals. 100% of the 
NP data were audited—each test score was double-checked by another trained research 
assistant working in our research lab at the University of Texas at Austin School of 
Nursing. Ten percent of all the survey data were audited. Only 9 errors were identified 
out of 2064 potential values, which is equivalent to a 0.4% error rate, suggesting a low 
rate of random human error and minimal concern for systemic data entry errors. 
DATA ANALYSES 
Cytokines 
 Blood samples were collected, stored, prepared, and processed according to the 
manufacturer’s protocol (EMD Millipore; Darmstadt, Germany, See Appendix L) under 
the supervision of committee member, Dr. Kesler. The serum aliquots were transferred 
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from the School of Nursing Biobehavioral Lab to the Health & Integrative Physiology 
Lab at the University of Texas at Austin and stored at -80 degrees Celsius.  
Human high sensitivity T cell magnetic bead panel (multiplex) assays were used 
for the simultaneous quantification of IL-6 and TNF-α in participants’ serum. These 
immunoassays utilize antigen-antibody reactions to quantify levels of biomarkers in 
serum.  This process involved mixing beads were complexed with antibodies for either 
IL-6 or TNF-α with each participants’ serum in separate wells of a 96-well plate. The 
complexed antibodies bound with the free floating antigens for IL-6 and TNF-α in the 
participants’ serum while incubating overnight at 4°C. Following incubation, a second 
biotinylated “detection” antibody was added to each of the wells to form a ‘sandwich’ of 
antigen-antibody complexes. Since the antibodies were complexed to beads that were 
magnetic, a magnet was used to hold the beads at the bottom of the wells during 
subsequent washing steps to remove remaining serum and reagents. Then a streptavidin-
phycoerythrin substrate was added to the wells so the antigen-antibody complexes could 
be visualized.  
The 96-well plate was then run on a Luminex 200, which utilized flow cytometry, 
to determine the concentrations of analytes in the samples. The antigen-antibody 
complexes fluoresce and the instrument provided a Mean Fluorescent Intensity (MFI) 
value that correlated to the amount of analyte in the original sample. MFI values were 
provided for seven standards that were included with the kit. These standards were 
treated just like samples and are also run on the LUMINEX 200. Known concentrations 
were plotted against MFI units for each of the standards and a 5-parameter logistic 
regression was used to generate a line of best fit so that unknown concentrations could be 
determined. Additionally, two separate quality controls were run to ensure the validity of 
the multiplex assay kits and samples were run in duplicate in order to use an average 
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value for each person and increase the reliability. According to the manufacturer, there is 
no cross reactivity between the antibodies for the IL-6 and TNF-α analytes. The 
minimum detectable concentration for IL-6 is 0.11 pg/mL and for TNF-α is 0.16 pg/mL. 
The intra assay precision (%CV) for IL-6 is <5% and for TNF- α is <5%. The inter-assay 
precision (%CV) for IL-6 is <20% and for TNF-α is <15%. 
Cognitive Performance  
Cognitive function was the key dependent variable in this study and was 
operationalized as both cognitive performance and perceived cognitive function. 
Cognitive performance was measured with NP tests including the HVLT-R Immediate 
and Delayed, COWAT, TMT A&B. NP scores were converted to normalized scores 
(adjusted for age and years of education) for the purpose of better profiling and 
describing the sample.  
Basic Assumption Checking and Univariate Analyses 
All study variables were analyzed separately looking at assumptions of normality 
and identifying outliers— using central tendencies, histograms, box plots and statistics 
for kurtosis and skewness. If distributions of biomarkers were skewed, the log 10 
transformation was utilized to normalize the data. In the event of missing data, mean 
substitution was used when the participant completed 80% or more of a given scale.  
Assumption checking for Multivariate Analyses  
The statistical assumptions for ordinary least squares regression were checked to 
ensure that the probability of rejecting the null hypothesis was not higher than the chosen 
significance level and power of this statistical analysis. The assumptions for correlation 
and regression based tests include normality, independence, linearity, and 
homoscedasticity. Normality was assessed for all the study variables to ensure that the 
errors in estimates of Y, or the dependent variable, were evenly distributed using 
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histograms with overlain normal distribution curves, skewness and kurtosis statistics, and 
Shapiro-Wilks Test. The independence assumption was logically assessed by the 
principal investigator’s knowledge of participants. The linearity assumption was assessed 
using both correlation analyses and by examining scatter plots (when Y is plotted as a 
function of X). To evaluate whether the homescedasticity assumption was met, the 
standardized residuals were plotted with a line of best fit to ensure that the errors in 
estimation were equally variable conditioned on Y for each regression analysis. This is 
important because violations of this assumption impact inference through the effects on 
the standard error of the regression coefficient (Hayes, 2013). 
Hypothesis Testing 
Alphas were set at 0.05 for all analyses in this study. The following analysis plan 
was constructed to address the three study aims and adjusted as needed based on the 
study results: 
Aim 1: To assess the impact of psychosocial (stress, perceived social isolation) 
and behavioral (physical activity, sleep quality) factors on inflammatory markers (IL-6, 
TNF-α). Several hierarchical multiple regression models (two-tailed, p<0.05) were 
intended to be used to determine the variance of inflammatory factors explained by 
psychosocial and behavioral factors after controlling for selected individual factors. The 
individual covariates were intended to be chosen based on the exploratory Pearson’s 
correlations conducted during the univariate analyses. Those variables that had the largest 
correlations with cytokines and had the greatest degree of linearity were intended to be 
chosen as covariates in these analyses. The theoretical framework described in Chapter 1 
in addition to the results from the correlation analyses scatterplot graphs, were intended 
to guide the predictor entry for each analysis.  
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Aim 2: To assess the impact of inflammatory markers (IL-6, TNF-α, IL-6*TNF-
α) on cognitive function (memory, attention, processing speed, executive function 
performance, perceived cognitive functioning) after controlling for selected individual 
factors. Several Hierarchical Multiple Regression (two-tailed, p<0.05) were intended to 
be used to determine the variance in each measure of cognitive function (cognitive 
performance, perceived cognitive functioning) explained by IL-6 and TNF-α, and IL-
6*TNF-α after controlling for selected individual factors. The theoretical framework 
described above in addition to the results from the correlation analyses scatterplot graphs 
were intended to guide the order of predictor entry for each analysis.  
Aim 3 (exploratory): To explore direct and indirect (through inflammatory 
mediators IL-6 and TNF-α) effects of psychosocial (stress, perceived social isolation) and 
behavioral (physical activity, sleep quality) factors on cognitive function (memory, 
attention, processing speed, executive function performance, perceived cognitive 
function) after controlling for selected individual factors. The individual covariates were 
intended to be chosen based on the exploratory Pearson’s correlations conducted during 
the univariate analyses. Those variables that had the largest correlations with both the 
cytokines and cognitive outcomes were intended to be used in these analyses as 
covariates. Simple mediation analyses using ordinary least squares path analysis was 
were intended to be used to explore the direct and indirect (through inflammatory 
mediators) effects of psychosocial and behavioral factors on cognitive function. Andrew 
Haye’s PROCESS procedure for mediation analysis was utilized, because this method 
has advantages over the traditional causal steps approach—it is a more powerful 
statistical analysis (one-step hypothesis testing vs. three), and it allows for inferential 
quantification of the indirect effects on dependent variables through mediator variables 
(Hayes, 2013). This method utilizes bootstrap confidence intervals to estimate and 
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interpret the effect size of the indirect effects of the independent variables on the 
dependent variables. “Bootstrapping is less susceptible to the influence of outliers in 
small populations than other methods…and it doesn’t rely on large sample asymptotics” 
(Andrew Hayes, PhD, personal communication, February 20, 2015). The direct effects of 
predictor variables on cognitive function were determined by the regression coefficient 
magnitude and significance (p<.05), and the indirect effect of the inflammatory markers 
was determined by a significant effect size (95% Bootstrap CI does not include “0”).  
CHAPTER SUMMARY 
This non-experimental, cross-sectional study was an analysis of data from BCS 
six months to 10 years post chemotherapy. The goal of the study was to determine 
whether stress, perceived social isolation, physical activity, sleep quality, and 
inflammation are significant predictors of cognitive function and whether inflammation 
mediates the effects of psychosocial and behavioral factors on cognitive function. These 
variables were measured with valid and reliable measures. For study aims one and two, 
hierarchical regression were intended to be used to evaluate the variance in inflammation 
(or cognitive function) explained by modifiable factors above and beyond the individual 
factors. Exploratory analyses using ordinary least squares path analysis was intended to 
be used to explore the direct and indirect (through inflammatory mediators) effects of 
psychosocial and behavioral factors on cognitive function. The University of Texas at 
Austin Institutional Review Board approved all study procedures and protection of 
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Chapter 4:  Findings 
Chapter 4 presents the results of this dissertation study. Data were extracted from 
survey questionnaires, NP test records, height, weight, hip and waist measurements, and 
immunoassay results and entered into SPSS 24.0 (IBM, 2016). The SPSS data file was 
proofread against the original data for accuracy by the principal investigator and a 
volunteer research assistant. The data cleaning and proofing procedures are described in 
full detail in Chapter 3. Descriptive statistics, correlations, multiple regression models, 
and hierarchical regression models were conducted in SPSS 24.0 and R Studio (Boston, 
MA) and the results reported in this chapter. The first section presents the sample 
description derived from frequencies, means, standard deviations, and ranges. The second 
section provides the results of univariate analyses used to better understand the study 
variables of interest and to verify that assumptions were met for each statistical test. The 
variables of interest include: BMI, hip/waist circumference ratio (HWR), cognitive 
reserve (i.e. years of education completed), perceived stress, loneliness, anxiety, 
depression, fatigue, self reported physical activity, sleep quality, daytime sleepiness, 
verbal learning performance, verbal fluency performance, executive functioning 
performance, serum IL-6 concentration, and serum TNF-α concentration. The third 
section presents multivariate analyses used for to address each aim, along with additional 
exploratory analyses. 
SAMPLE DESCRIPTION 
Demographic and treatment characteristics of both the 66 participants with 
complete data and the 75 participants (without cytokine data) in this study are displayed 
in Table 4.1. The sample with complete data (n=66) will be described here. The sample 
was on average years old 49 years of age (SD 8.77). The majority were white (93.4%), 
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Table 4.1 
Demographic and Treatment Variables for Sample with Complete Data including Cytokines (n=66) and Incomplete data (N=75) 
 Complete Data (n=66) Incomplete Data (N=75) 
Characteristic n (%) Mean (SD) Min, Max n (%) Mean (SD) Min, Max 
Age   49 (8.77) 27, 65  49.08 (9.04) 24, 65 
Race       
White 62 (93.4%)   68 (90.7%)   
African American 1 (1.5%)   4 (5.3%)   
Asian 3 (4.5%)   3 (4.0%)   
Ethnicity       
Hispanic 3 (4.5%)   4 (5.3%)   
Non-Hispanic 63 (95.5%)   71 (94.7%)   
Years of Education  16.7 (2.16) 12, 22  16.6 (2.16) 12, 22 
Highest Degree       
Highschool/Vocational 8 (12.1%)   11 (14.6%)   
Associates 5 (7.6%)   5 (6.7)   
Bachelors 30 (45.5%)   35 (46.7%)   
Graduate 23 (34.8%)   24 (32%)   
Maritial Status       
Married/Living with Sig. 
Other 46 (69.7%)   50 (66.7%)   
Divorced/Separated 6 (9.1%)   10 (13.3%)   
Never Married 14 (21.1%)   15 (20%)   
Have Children 42 (63.6%)   48 (64%)   
Employment Status       
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Table 4.1 (continued) 
 
Work full time/fulltime 
student 39 (59.1%)   48 (64%)   
Work part time 18 (27.3%)   18 (24%)   
Fulltime home-maker 3 (4.5%)   3 (4%)   
Unemployed 1 (1.5%)   4 (5.3%   
Retired 2 (3%)   2 (2.7%)   
Household Income (n=64, 2 
missing)       
$0-50,000 7 (10.6%)   9 (12%)   
$50,000-99,999 22 (33.3%)   28 (37.3%)   
$100,000-149,000 16 (24.2%)   16 (21.3%)   
$150,000-199,999 10 (15.2%)   10 (13.3%)   
$200,00 or more 9 (13.6)   10 (13.3%)   
BC Type       
IDC 46 (69.7%)   50 (66.7%)   
DCIS 10 (15.2%)   14 (18.7%)   
ILC 5 (7.6%)   6 (8%)   
Multiple 
(IDC/DCIS/ILC) 5 (7.6%)   5 (6.7%)   
Stage       
1 12 (18.2%)   13 (17.3%)   
2 41 (62.1%)   46 (61.3%)   
3 13 (19.7%)   16 (21.3%)   
ER Recepter + 56 (84.8%)   63 (84%)   
HER 2 + 26 (39.4%)   28 (37.5%)   
Chemo Regimens       
Anthracyclines 37 (56.1%)   42 (56%)   
Non-Anthracyclines 29 (43.9%)   33 (44%)   
Months since Chemo  35.7 (27.12) 6.83, 120.84  37.00 (27.67) 6.83, 120.84 
6mo-12mo 13 (19.7%)   16 (21.3%)   
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Table 4.1 (continued) 
 1yr-2 yr 14 (21.1%)   14 (18.7%)   
2yr- 4yr 23 (34.8%)   25 (33.3%)   
4yr-6yr 10 (15.2%)   12 (16%)   
6yr- 10yr 6 (9.1%)   8 (10.7%)   
Hormonal Treatment (n=61)       
tamoxifen 40 (60.6%)   
43 
(68.25%)   
Non-tamoxifen 21 (34.3%)   
20 
(31.75%)   
Treatment Modalities       
Surgery 65 (98.5%)   74 (98.7%)   
Radiation 40 (60.6%)   47 (62.7%)   
Hormones 56 (84.8%   63 (84%)   
Herceptin 26 (39.4%)   28 (37.3%   
Menopausal Status       
Pre 10 (15.2%)   11 (14.7%)   
Peri 9 (13.6%)   10 (13.3%)   
Gone through 13 (19.7%)   15 (20%)   
Chemical/surgical 
induced 34 (51.5%)   39 (52%)   
Currently on Hormonal Therapy 44 (66.6%)   48 (64%)   
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non-Hispanic (95.5%) college educated (80.3%), married or living with a significant 
other (69.7%).  Almost half were living on a household income of <$99,000 (43.9%) and 
the other half above $99,000 (53%).   
The majority of the women had a history of stage II or III (81.8%) invasive ductal 
carcinoma breast cancer (69.7%) that was hormone receptor positive (84.8%). Almost all 
were treated with surgery (98.5%); the majority had radiation therapy (60.6%) in addition 
to anthracycline-based chemotherapy (56.1%) and some type of hormonal therapy 
(92.4%). Approximately 72% had gone through menopause already, either naturally or 
chemically/ surgically induced, and 66.6% were currently on hormonal therapy.  On 
average, the women in the sample had completed chemotherapy three years prior (37 
months ± 27.67 months)— approximately 75% were within four years of chemotherapy 
completion. 
UNIVARIATE ANALYSES 
The descriptive statistics and reliability for all the scales and subscales in the 
sample with complete data (n=66) are presented in Table 4.2 below (mean, standard 
deviation, median, minimum and maximum values, Shapiro-Wilk significance value, 
Skewness statistic, Kurtosis statistic, Chronbach’s Alpha). The descriptive statistics and 
reliability for all the scales and subscales in the sample with incomplete data (N=75) are 
almost identical and are presented in Appendix M.  
Individual Factors  
BMI and HWR. On average the sample had a BMI of 27.36 (SD 5.46). BMI’s 
ranged from 18.62 to 42.46 with a median of 25.79. According to the World Heath 
Organization, a healthy BMI is 18- 25, overweight ranges from 25-30, and those greater 
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Table 4.2 
Study Variable Descriptive Statistics (n=66) 









BMI 27.36 (5.46) 18.62, 42.46 25.79 .001 0.87(0.30) 0.04 (0.58)  
HWR 0.82 (0.18) 0.62, 1.51 0.79 .000 2.83(0.38) 8.43 (0.58)  
Years Education 16.71 (2.16) 12, 22 16 .000 0.14 (0.30) 0.32 (0.58)  
PROMIS Anxiety 16.61 (7.88) 8, 40 16 .000 1.01 (0.30) 0.82 (0.58) .96 
PROMIS Depression 13.41 (6.21) 8, 32 11 .000 1.33 (0.30) 1.21 (0.58) .94 
PROMIS Fatigue 21.21 (8.05) 8, 39 20 .081 0.40 (0.30) -0.49 (0.58) .96 
PSS 14.07 (8.03) 0, 31 14.5 .025 0.13 (0.30) -0.83 (0.58) .94 
UCLA-R 37.93 (11.14) 20, 60 36 .000 0.25 (0.30) -0.81 (0.58) .95 
IPAQ    .000    
Tot Active 
Min 975.29 (712.73) 0, 2400 752.50 .000 0.80 (0.30) -0.54 (0.58)  
Tot Sit Min 
3050.83 
(1087.38) 540, 5130 2790 .023 0.29 (0.30) -0.26 (0.58)  
PSQI Total 7.61 (4.35) 0, 17 7.0 .000 0.31 (0.30) -0.77 (0.58) .74 
Sleep Quality 0.97 (0.70) 0, 3 1.0 .000 0.04 (0.30) -0.91 (0.58)  
Latency 1.05 (1.16) 0, 3 1.0 .000 0.59 (0.30) -1.18 (0.58)  
Duration 0.73 (0.87) 0, 3 1.0 .000 1.15 (0.30) 0.75 (0.58)  
Efficiency 1.03 (1.26) 0, 3 0.0 .000 0.70 (0.30) -1.27 (0.58)  
Disturbance 1.61 (0.60) 0, 3 2.0 .000 -0.42 (0.30) -0.02 (0.58)  
Sleepaid 1.24 (1.38) 0, 3 0 .000 0.34 (0.30) -1.79 (0.58)  
Daytime 
Dysfunction 0.98 (0.73) 0, 3 1.0 .000 0.27 (0.30) -0.39 (0.58)  
ESS 6.98 (4.59) 0, 18 6 .000 0.64 (0.30) -0.66 (0.58) .84 
IL-6 (pg/ml) 2.25 (1.80) .05, 7.62 1.95 .000 1.36 (0.30) 1.56 (0.58)  
TNF-α (pg/ml) 5.91 (1.40) 2.98, 10.09 5.98 .121 0.51 (0.30) 0.40 (0.58)  
IL-6*TNF-α (pg/ml) 13.72 (12.43) 0.32, 64.92 10.20 .000 1.74 (0.30) 3.74 (0.58)  
log 10 IL-6 0.19 (0.44) -1.30, 0.88 0.29 .001 -1.17 (0.30) 2.1 (0.58)  
log 10 TNF-α 0.76 (0.10) 0.47, 1.00 0.77 .510 -0.18 (0.30) 0.02 (0.58)  
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Table 4.2 (continued) 
 
Note. BMI= Body Mass Index; HWR= Hip to Waist Ratio; PSS= Perceived Stress Scale; UCLA-R= UCLA Loneliness Scale Revised 
version 3; IPAQ= International Physical Activity Questionnaire; PSQI= Pittsburgh Sleep Quality Index; ESS= Epworth Sleepiness Scale; 
IL-6= Interleukin 6; TNF- α = Tumor Necrosis Factor- α; FACT-Cog Version 3= Functional Assessment of Cancer Treatment- Cognition 
Version 3; PCI= Perceived Cognitive Impairments Subscale; PCA= Perceived Cognitive Abilities Subscale; Others= Comments from 
Others Subscale, Impact= Impact on Quality of Life; HVLT=Hopkins Verbal Learning Test; COWAT= Controlled Oral Word Association 
Test; TMT= Trail Making Test 
 For the Shapiro-Wilk Test, the null hypothesis of this test is that the population is normally distributed. Thus, if the p-value is less than 
the chosen alpha level then the null hypothesis is rejected and there is evidence that the data tested are not from a normally distributed 
population 
^ Fact Cog Total: lower scores indicate lower overall functioning; PCI: lower scores indicate worse cognitive impairments; Impact on 
QOL: Higher scores, better QOL lower scores worse QOL; Comments from Others: lower scores, worse comments from others ; PCA: 
Higher scores, better abilities, lower scores worse perceived abilities 
log 10 IL-6* log 10 
TNF-α 0.15 (0.35) -1.1, 0.82 0.21 .003 -1.1 (0.30) 2.1 (0.58)  
FACT- Cog Total^ 94.99 (34.87) 19, 147 95.5 .013 -0.43 (0.30) -0.70 (0.58) .98 
PCI 47.59 (20.93) 3, 79 50.5 .010 -0.35 (0.30) -0.89 (0.58) .97 
Impact on 
QOL 10.79 (5.03) 0, 16 12 .000 -0.89 (0.30) -0.32 (0.58) .95 
Others 14.06 (3.19) 3, 16 16 .000 -1.95 (0.30) 3.12 (0.58) .90 
PCA 22.55 (8.77) 4, 36 221 .050 -0.15 (0.30) -0.83 (0.58) .93 
HVLT Immediate Raw 29.80 (3.60) 21, 36 30 .019 -0.51 (0.30) -0.50 (0.58) - 
HVLT DelayedRaw 10.61 (1.47) 6, 12 11 .000 -1.10 (0.30) 0.84 (0.58) - 
COWAT Raw 40.18 (11.29) 16, 71 39.5 .404 0.41 (0.30) 0.31 (0.58) - 
Trails A Raw 26.36 (9.17) 11.5, 54 24.3 .000 1.16 (0.30) 0.77 (0.58)  
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than 30 are considered obese 
(http://www.who.int/mediacentre/factsheets/fs311/en/). The average HWR in the study 
was 0.82 (SD 0.18), and the median HWR was 0.79. A HWR of 0.80 or greater is 
considered a marker of central obesity (“Waist circumference and waist–hip ratio: report 
of a WHO expert consultation”, 2008). Although the Shapiro-Wilk test for both of these 
measures was significant, the skewness and kurtosis absolute values are less than 1.0, and 
the mean and median similar, suggesting normal distribution. 
Cognitive Reserve (Years education). On average the participants in this study 
had completed 16.71 years of formal education (SD 2.16), which equates to completion 
of high school and a four-year bachelor’s degree. The median for years of education was 
also 16. Although the Shapiro-Wilk test this measure was significant, the skewness and 
kurtosis absolute values are less than 1.0, and the mean and median similar, suggesting 
normal distribution. 
Psychosocial Factors 
Emotional Distress and Fatigue. Three of the NIH PROMIS scales were used to 
assess aspects of emotional distress and fatigue— PROMIS Item Bank v1.0 – Emotional 
Distress – Anxiety – Short Form 8a, PROMIS Item Bank v1.0 – Emotional Distress – 
Depression – Short Form 8a, and the PROMIS Item Bank v1.0 – Emotional Distress – 
Fatigue – Short Form 8a.  The average score on the PROMIS Anxiety was 16.61 (SD 
7.88) and the median was also 16. The highest possible score on this scale is 40, and 
higher scores indicate more anxiety. For the PROMIS Depression, participants averaged 
a score of 13.41 (SD 6.21), with a median score of 11. The highest possible score on this 
scale is 40, and higher scores indicate more depressive symptoms. The highest average 
was found on the PROMIS Fatigue with a mean of 21.21 (SD 8.05) and a median of 20. 
The highest possible score on this scale is 40, and higher scores indicate more fatigue. 
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The Shapiro-Wilk tests for all these scales were all significant (except for the PROMIS 
Fatigue); however, the skewness and kurtosis absolute values were less than 1.33, 
suggesting normal distribution. Furthermore, the Chronbach’s alphas ranged from 0.94-
0.96 for the PROMIS scales. 
Perceived Stress. On average, participants scored 14.07 (SD 8.03) on the PSS.  
Total scores ranged from 0 to 31, with a median of 14.5. The highest possible score on 
this scale is 40, higher scores indicate higher perceived stress. The Shapiro-Wilk test for 
this measure was non-significant and the skewness and kurtosis absolute values both less 
than 1.0 suggesting normal distribution. The Chronbach’s alpha in this study was 0.94. 
Social Isolation. The average score on the UCLA-R was 37.93 (SD 11.14) and a 
median of 36.  Total scores ranged from 20-60. The maximum possible score on this 
scale is 80, indicating greater degrees of perceived social isolation. The Shapiro-Wilk test 
this measure was significant; however, the skewness and kurtosis absolute values both 
less than 1.0 suggesting normal distribution. The Chronbach’s alpha in this study was 
0.95. 
Behavioral Factors 
Physical Activity. Two subscales of the IPAQ were evaluated: total minutes 
spent doing physical activity (Total Active Min) and total minutes spent sitting (Total Sit 
Min).  Originally, the distributions of these two variables were not normal. The mean for 
Total Active Min was 1,095 min (SD 1068) median 752, was skewed (2.31) with a large 
value of kurtosis (6.55). Similarly, the mean for Total Sit Min was 3,138 (SD 1320, 
median 2790) was skewed (1.27) with a large kurtosis value (2.99). Therefore, the 
outliers were examined for each subscale. For the Total Active Min scale, five outliers 
were identified and the four outliers with the highest values were adjusted to the value of 
the lowest of all five outliers— 2400 min. The same process was used to identify the 
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outliers for Total Min Sit subscale, and the top four outliers were changed to the lowest 
value of all five outliers—5130 min. After these adjustments were made, the distributions 
for these two subscales were normal. For the Total Active Min scale, the mean was of 
975.29 min (SD 712.73), median 752.5 and scores ranged from 0 to 2400. The skewness 
statistic was reduced to 0.80 and kurtosis to -0.5. For Total Sit Min subscale, the mean 
was 3050.83 (SD 1087.38), median 2790, with scores ranging from 540-5130. The 
skewness value was reduced to 0.29 and kurtosis to -0.26. These two scales were used in 
the multivariate analyses. When frequencies were evaluated, 46% of participants reported 
engaging in 500-1500 min of activity in the previous week, and over 60% reported sitting 
between 2000-4000 min the previous week. The frequency distribution for IPAQ Act 
Min and IPAQ Min Sit are graphically depicted in the bar graphs in Appendix N. 
Sleep Quality. The PSQI has seven components or subscales that are summed to 
form a total sleep quality score. Higher scores indicate poorer sleep quality. The 
participants in this study scored on average 7.61 (SD 4.35) on the total scale, with a 
minimum of 0 and a maximum of 17 and the median score 7. The clinical cut off for the 
PDQI is six. Those who score six or greater on the PSQI are considered poor sleepers. 
The average score on PSQI in this sample was comparable to other studies conducted 
with breast cancer survivors (Berger et al., 2012; Enderlin et al., 2011; Mustian et al., 
2012; Otte et al., 2010). The Shapiro-Wilk test for the PDQI total and the subscales the 
Shapiro-Wilk tests were all significant. The skewness and kurtosis absolute values are 
less than 1.79 for all the subscales suggesting close to normal distribution. The reliability 
of the PSQI was satisfactory, at 0.74. The ESS, a measure of daytime sleepiness was also 
used to assess sleep quality. Score on this measure ranged from 0 to 18, with an average 
score of 6.98 (SD 4.59) and a median of 6. This average is similar to another study 
conducted with breast cancer survivors (Enderlin et al., 2011). The Chronbach’s alpha 
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was 0.84. Both PSQI total score and ESS were used in multivariate analyses depending 
on the model being tested.  
Biological Factors 
Cytokines. Human high sensitivity T cell magnetic bead panel (multiplex) assays 
were used for the simultaneous quantification of IL-6 and TNF-α in participants’ serum 
following the manufacturer’s procedures (EMD Millipore). The samples were run in 
duplicates, and in the event that an intra assay precision (CV%) was greater than 15%, 
the sample was re-run. According to the FDA, intra assay precision CV percent’s up to 
15% are acceptable. The quality controls for both IL-6 and TNF-α were within the 
expected ranges. The standards for both analytes were used to make the standard curve of 
MFI to analyte concentration (Figures 4.1 and 4.2). The R2 for IL-6 was 1.0 and for TNF-
α it was 1.0.  A R2 close to 1.0 is desired.   
The levels (pg/ml) of IL-6 ranged from 0.05 to 99.79 pg/ml.  The participant with 
99.79 pg/ml was an outlier, the next highest value was only 7.62 pg/ml.  To preserve the 
sample size, rather than dropping the participant with the 99.79 pg/ml value for IL-6, the 
value for this participant was changed to 7.62 pg/ml the next most extreme score 
(Munroe, 2005). With this adjustment, the average concentration of IL-6 was 2.25 pg/ml 
(SD 1.80) with a median of 1.95 pg/ml. The Shapiro-Wilk test was significant, and the 
absolute skewness and kurtosis values less 1.56 or less, suggesting abnormal distribution. 
The levels (pg/ml) of TNF-α ranged from 2.98 to 10.09 pg/ml, with an average of 5.91 
pg/ml (SD 1.40) and a median of 5.98. The Shapiro-Wilk test was non-significant, and 
the absolute skewness and kurtosis values less than 1.0, suggesting normal distribution. 
Since IL-6 has been described as both pro-inflammatory and anti-inflammatory, it’s 
possible that the interaction between for IL-6 and TNF-α could provide a better 
understanding of these cytokines in the context of the biobehavioral model. Therefore, an  
  
 




Figure 4.1 Standard curve of MFI to IL-6 Concentration 
 
Figure 4.1. The standard curve of MFI to concentration of IL-6 calculated from the standards in the Multiplex Kit. An R2 close 
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Figure 4.2 Standard curve of MFI to TNF-α Concentration 
 
 
Figure 4.2. The standard curve of MFI to concentration of TNF-α calculated from the standards in the Multiplex Kit. An R2 
close to 1 is desired
  
 
           
 117 
interaction variable for IL-6 and TNF-α (IL-6*TNF-α) was also created. The levels 
(pg/ml) of IL-6*TNF-α interaction ranged from 0.32- 64.92 pg/ml, with an average of 
13.72 pg/ml (SD 12.43) and a median of 10.20. The Shapiro-Wilk test was significant, 
and the absolute skewness and kurtosis values less than 1.74-3.74, suggesting non-normal 
distribution, therefore, both IL-6 and TNF-α were transformed using the log10 
transformation, and a new interaction term was created by multiplying the log10 of IL-6 
and the log10 of TNF-α. 
Cognitive Outcomes 
Perceived Cognitive Function. The FACT-Cog was used to evaluate perceived 
cognitive function in this sample. This instrument has a total score and four subscales. 
Higher scores indicate better cognitive functioning. For the total scale score, participants 
ranged from 19 to 147, and averaged 94.99 (SD 34.87), with a median of 95.5. For this 
instrument, lower scores indicate poorer functioning, or worse quality of life. On the 
Perceived Cognitive Impairments subscale (PCI), the average score was 47.59 (SD 20.93) 
but scores ranged from 3 to 79. On the Impact on Quality of Life Scale, the average score 
was 10.79 (SD 5.03), and for the Comments from Others subscale the mean 14.06 (SD 
3.19). Finally for the Perceived Cognitive Abilities Subscale (PCA), scores ranged from 4 
to 36, with the average score being 22.55 (SD 8.77). The Shapiro-Wilk tests for all these 
scales were significant (except for the total scale); however, the skewness and kurtosis 
absolute values were less than 1.0 (except on the Comments from Others subscales), 
suggesting close to normal distribution. Furthermore, the Chronbach’s alphas in this 
study ranged from 0.90 to 0.98 on the FACT-Cog total and subscales. The FACT-Cog 
Total, PCA, and the PCI scores were used as outcome variables in multivariate analyses. 
Cognitive Performance. The brief NP battery administered to each participant 
consisted of four tests evaluating short and long term verbal memory (HVLT-Immediate, 
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HVLT-Delayed), verbal fluency (COWAT), attention (Trails A) and executive 
functioning (Trails B). First, all NP measures were age and education-adjusted based on 
the established norms, in order to profile and describe the sample.  These standardized 
scores are illustrated in boxplots below in Figures 4.3 - 4.5.  On both the HVLT-
Immediate and Delayed recall, participants scored between 0 and 1 standard deviation 
above the mean. Adjusted scores on the COWAT were just above average— mean 
around 60%. Scores on the Trails A and Trails B were average.  
Within the field of CRCI, mild cognitive impairment has been classified as -1.5 
SD below the age and education adjusted mean. For descriptive purposes, standardized 
scores for each of the NP normed scores were dichotomized into impaired or not 
impaired.  For HVLT-I, 4.5% of the sample were considered impaired; for HVLT-D, 
4.5% were considered impaired; for COWA, 6.1% were considered impaired; for Trails 
A, 9.1% were considered impaired; and for Trails B, 7.6% were considered impaired. 
Across all tested domains, nine participants (13.6%) displayed mild cognitive impairment 
in one cognitive domain; one participant (1.5%) displayed mild cognitive impairment in 
two cognitive domains; two participants (3%) displayed mild cognitive impairment in 
three cognitive domains; and one participant (1.5%) displayed mild cognitive impairment 
in four cognitive domains. Approximately 20% of the sample displayed mild cognitive 
impairment in at least one cognitive domain. 
Raw test scores were used in all univariate and multivariate analyses. All 
descriptive data for the NP scores can be found above in Table 4.2. Both the Trails A and 
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Figure 4.3 Box plots of Standardized HVLT Scores (Immediate and Delayed) 
 
 
Figure 4.3. Boxplot distribution of the HVLT-Immediate (red) and Delayed (blue) scores after age and education adjustments, 
presented in standard deviation. 
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Figure 4.4 Box plots distribution of standardized (age and education adjusted) COWAT scores, displayed as percentiles. 
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Figure 4.5 Box plots distributions of Trails A (green) and B (orange) t scores, adjusted for age, education, and race.
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transformed according to Munroe (2005). The square root transformation was used for 
Trails A and the log 10 used for Trails B.  
Outliers and Basic Assumptions 
The Shapiro-Wilk statistic was significant for all of the scales except for the 
HVLT-Immediate, COWAT, PROMIS Fatigue, IPAQ Total Sit Min, TNF-α, and FACT-
Cog Total, suggesting that vast majority of the data collected in this sample were not 
normally distributed. This test was interpreted with caution because sample size can 
impact the significance of the Shapiro-Wilk test (Ghasemi & Zahediasl, 2012), thus other 
methods of evaluating distribution were employed. When evaluating normality based on 
skewness, with a criteria for skewness being an absolute value greater than 1.5, skewed 
distributions were found for the following measures: HWR (2.83); IL-6 and TNF-α 
interaction term (1.74); FACT-Cog Comments from others subscale (-1.95); and Trails B 
Raw score (2.80). 
Several outliers were identified during univariate analyses on the following 
measures: 1) HVLT-Delayed; 2) COWAT; 3) Trails A; 4) Trails B; 5) FACT-Cog 
Comments from Others Subscale; 6) PROMIS Depression; 7) IPAQ Tot Active Min 
(these outliers were changed to 2400 min); 8) IPAQ Sit Min (these outliers were changed 
to 5130 min); 9) HWR; 10) Years of Education; 11) IL-6; 12) TNF- α; and 13) IL-
6*TNF- α interaction. Each case was located in the dataset and compared against original 
survey and test data to ensure that the correct data were entered. Furthermore, any notes 
that were made in the participant file were reviewed to identify any contextual reasoning 
behind the outlying value. See “Predictor Variables and Dependent Variables Outliers 
and Assumptions Table” in Appendix O for a summary of all results of the study variable 
outliers and assumption checks.  
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The only data that were transformed were the cytokine data (log10 
transformations), Trails A raw scores (square root transformation), and Trails B raw 
scores (log10 transformation). The other data that were skewed to lesser degrees were not 
transformed because transforming data can make interpretation difficult (Munroe, 2005).   
MULTIVARIATE ANALYSES 
Correlations Among Variables 
Zero order correlations were examined to identify high levels of shared variance 
among the predictor variables (>.85) and to facilitate linearity assessment. These 
correlations are displayed in Tables 4.3-4.5. Pearson’s correlations were used for 
continuous variables, and Kendall’s Tau correlations were used for ordinal and nominal 
associations.  
First, the correlations were examined between the individual factors of interest 
(Age, BMI, HWR, Anthracycline Chemotherapy, Tamoxifen Treatment, Race, Ethnicity, 
breast cancer stage, and months since end of chemotherapy), predictor variables 
(PROMIS Anxiety, PROMIS Depressive Symptoms, PROMIS Fatigue, PSQI, IPAQ, 
ESS, PSS, UCLA-R), and log10 transformed cytokine concentrations (IL-6, TNF-α, IL-
6*TNF-α) and are displayed in Table 4.3. Only one small-positive significant correlation 
was found between BMI and log10TNF-α (r = .26, p < .05) suggesting that as BMI 
increases so does the log10 value of TNF-α. All remaining correlations were small and 
non-significant.  
Next, the correlations between the log10 transformed cytokine concentrations (IL-
6, TNF-α, IL-6*TNF-α) and the cognitive outcomes (FACT-COG Total, PCI subscale, 
PCA subscale, HVLT-I Raw Scores, HVLT-D Raw Scores, COWAT Total Raw Scores, 
Trails A transformed scores, and Trails B transformed scores) were examined and are
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Table 4.3  
Correlations between Individual Factors, Predictor Variables, and log10 Cytokine Concentrations (n=66) 
 log10IL-6 log10TNF-α log10IL-6* log10TNF-α 
Age .09 -.10 .07 
BMI .00 .26* .03 
HWR -.10 .16 -.10 
Anthracycline Chemo  -.19 .18 -.19 
Tamoxifen Treatment -.04 -.08 -.05 
Ethnicity .06 .08 .04 
Race .13 .02 .12 
Breast Cancer Stage -.14 .13 -.13 
Months Since end of Chemo -.01 -.13 -.03 
PROMIS Anxiety .07 -.10 .06 
PROMIS Depressive  .10 -.03 .10 
PROMIS Fatigue .02 -.08 .03 
PSQI Total .02 -.16 -.01 
IPAQ  Tot Min Sit -.06 .14 -.05 
IPAQ  Tot Active Min .22# -.01 .20 
UCLA-R -.04 -.08 -.03 
PSS -.12 -.15 -.13 
ESS -.13 -.11 -.12 
Note. Significance not corrected for multiple comparisons for exploratory descriptive purposes.  
Pearson’s R used for interval level variables, all categorical variables were dummy coded and Kendall’s tau correlations were used. 
  =0=non anthracycline, 1= anthracycline 
 = 0=no tamoxifen, 1= tamoxifen 
= 0=Non-Hispanic; 1= Hispanic 
* p<.05,# p<0.10 
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displayed in Table 4.4. No significant relationships were identified between these 
variables.   
Finally, correlations were examined between the individual factors, predictor 
variables, and the cognitive outcomes—both the perceived cognitive function (FACT-
Cog, PCI, PCA) and cognitive performance (HVLT-I, HVLT-D, COWAT, Trails A 
transformed, and Trails B transformed). Since these data were available for all 75 
participants, the correlations were evaluated using this larger sample and displayed in 
Table 4.5. Among the individual factors and perceived cognitive function, small negative 
relationships were found between BMI and FACT-Cog Total and PCA (r’s= -.23 to -.25, 
p’s < .05) and small negative relationships approached significance between FACT-Cog 
scores and ethnicity (r’s= - .16 to -.17, p’s < .10). Moderate to large negative significant 
relationships were found between PROMIS Anxiety, Depression, and Fatigue and the 
FACT-Cog total and subscales (r’s= -.50to -.66, p’s < .001). The predictor variables were 
measured with the PSQI, IPAQ Min Sit, IPAQ Act Min, ESS, PSS, and UCLA-R scales. 
Among the predictor variables, moderate to large negative relationships were found 
between PSQI and the FACT-Cog (r’s= -.43 to -.49, p’s< .001); the UCLA-R and the 
FACT-Cog (r’s= -.46 to -.56, p’s < .001); PSS and FACT-Cog (r’s= -.60 to -.71, p’s < 
.001); and the ESS and FACT-Cog (r’s= -.35 to -.42, p’s <.001). 
Among the individual factors and cognitive performance, age was significantly 
related to HVLT-D and transformed Trails A & B (absolute value of r’s = .26 to .42, p’s 
< .05). Small positive relationships were found between years of education and HVLT-D 
(r= .26, p< .05) and COWAT scores (r= .28, p < .05). Treatment with anthracycline-
based chemotherapy was significantly related to COWAT scores (r= .20, p < .05). Breast 
cancer stage was significantly related to transformed Trails B scores (r= -.19, p < .05). 
Ethnicity was significantly related to COWAT scores(r=-.20, p <.05). Among the  
  
 


























Table 4.4  
Pearson’s Correlations between Cytokines and Cognitive Measures (n=66) 
 log10IL-6 log10TNF-α log10IL-6* log10TNF-α 
FACT-Cog .04 .13 .04 
PCI .06 .15 .05 
PCA .06 .10 .05 
HVLT-Immediate -.15 .02 -.16 
HVLT  Delayed -.04 .02 -.06 
COWAT -.17 -.06 -.14 
TMT Aa .09 .02 .08 
TMT Bb .11 .14 .12 
Note. a= Transformed data used (sq rt transformation); b= Transformed data used (log 10 
transformation)   
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Table. 4.5 
Correlations between Individual Factors, Predictor Variables, and Cognitive Outcomes (N=75) 
 FACT-Cog PCI PCA HVLT-I HVLT-D COWAT TMT Aa TMT Bb 
Age .06 .03 .07 -.10 -.26* -.07 .42*** .36** 
BMI -.23* -.25* -.21# .05 .00 -.15 .15 .10 
HWR .06 .06 .10 .10 .17 .12 -.14 -.11 
Years 
Education 
.07 .06 .10 .22# .26* .28* -.08 -.07 
Anthracycline 
Chemo  
.06 .07 .05 -.05 .02 .20* -.17# -.10 
Tamoxifen 
Treatment 
-.14 -.15 -.15 .10 .07 -.04 .06 .09 
Ethnicity -.17# -.17# -.16# -.17# -.05 -.20* -.05 -.01 
Race -.10 -.09 .04 .09 .18# .09 -.13 -.16# 
Breast Cancer 
Stage 
-.03 -.01 -.04 -.15 -.11 -0.14 -.01 -.14 
Months Since 
end of Chemo 
-.09 -.10 -.02 .05 -.15 -.09 .13 .08 
PROMIS 
Anxiety 
-.65*** -.62*** -.52*** -.06 -.09 -.05 .04 .03 
PROMIS 
Depressive  
-.61*** -.57*** -.50*** -.10 -.15 -.10 .09 .08 
PROMIS 
Fatigue 
-.66*** -.61*** -.59*** -.02 -.09 -.10 -.03 .09 
PSQI Total -.49*** -.46*** -.43*** -.01 -.22# -.05 .09 .10 
IPAQ Sit Min -.12 -.17 -.09 .01 .22# .08 .05 -.01 
IPAQ Active 
Min 
.01 .01 .04 -.09 -.17 -.16 .19 .25* 
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Table 4.5 (continued) 
 
 
UCLA-R -.56*** -.55*** -.46*** .06 -.04 -.07 .03 -.09 
PSS -.71*** -.68*** -.60*** -.10 -.07 -.13 .14 .09 
ESS -.40*** -.42*** -.35*** .17 .23* -.14 -.17 -.12 
FACT-Cog 1.0 .98*** .89*** .04 .09 .15 -.15 -.06 
Note.  Significance not corrected for multiple comparisons for exploratory descriptive purposes.  
*** p<.001,** p <.01, * p<.05, # p<.01 
Pearson’s R used for interval level variables, all categorical variables were dummy coded and Kendall’s tau correlations were used. 
  =0=non anthracycline, 1= anthracycline 
 = 0=no tamoxifen, 1= tamoxifen 
= 0=Non-Hispanic; 1= Hispanic 
a= Transformed data used (sq rt transformation)   
b= Transformed data used (log 10 transformation)   
PCI=FACT-Cog Perceived Cognitive Impairments Subscale, PCA= FACT-Cog Perceived Cognitive Abilities Subscale 
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predictor variables, measured with the PSQI, IPAQ Min Sit, IPAQ Act Min, ESS, PSS, 
and UCLA-R scales, small relationships approached significance between HVLT-D and 
PSQI (r= -.22, p < .10), ESS Scores (r= .23, p < .05), and IPAQ Min Sit (r= .22, p < .10). 
IPAQ Act Min was significantly related to Trails B scores (r= .25, p < .05). No 
significant relationships were found between the psychosocial variables (stress, perceived 
social isolation, anxiety, fatigue, depression) and the cognitive performance variables. 
Among the perceived cognitive function and cognitive performance variables, no 
significant relationships were found. 
Regression analyses 
Statistical Testing Assumptions 
Normality, independence, linearity, and homoscedasticity assumptions for 
ordinary least squares regression were checked to ensure the validity, or probability of 
rejecting the null hypothesis was not higher than the chosen significance level, and power 
of this statistical analyses.  
Normality was already assessed in the univariate analyses presented above. 
According to Hayes (2013), this assumption is one of the least important in regression 
analyses and simulation statistical research suggests that only severe violations of this 
assumption can affect the validity of statistical inference. Hayes also explains that when 
modeling non-normal variables using OLS regression, the errors in estimation tend to be 
not normal as well.  The Shapiro-Wilk test was used to statistically analyze normality of 
the variables. Ghasemi & Zahediasl (2012) explain that even small deviations from 
normality will result in significant Shapiro-Wilk tests in larger samples (greater than 30-
40), which explains why almost all of Shapiro-Wilk tests were significant in this study. 
Another assumption of OLS regression is that the errors in estimation are statistically 
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independent. The PI verified that the assumption of independence was met by her 
knowledge of participants enrolled in the study.  
Linearity. Linear regression is largely based on linear associations between 
variables. These associations were first explored and reported in the “Correlations 
Among Variables” section above.   Scatter plots (Y is plotted as a function of X) were 
examined first between the predictor variables (PROMIS scales, IPAQ Tot Min Sit, 
IPAQ Tot Act Min, PSQI Total, UCLA-R, PSS, ESS) and log10 transformed cytokines. A 
line of best fit was added to each scatterplot to determine nature of each relationship. The 
scatterplots revealed that relationships between predictor variables (psychosocial and 
behavioral factors) and cytokines were very small linear or non-linear. Nonlinear 
functions (i.e. quadratic, cubic) were evaluated to fit the data points in each scatterplot. It 
was determined that cubic functions fit these data best; therefore, the linear assumption 
was violated. The values for both Linear and Cubic R2 lines of fit for each scatter plot are 
displayed in Table 4.6. The cubic regression models provided a better fit to the data. 
Next, scatter plots were examined between the log10 transformed cytokines and 
the cognitive outcomes (FACT-Cog Total, PCI, PCA, HVLT-I, HVLT-D, COWAT, 
Trails A, Trails B). A line of best fit was added to each scatterplot to determine nature of 
each relationship. The scatterplots revealed that relationships between the cytokines and 
cognitive outcomes were very small linear or non-linear. Nonlinear functions (i.e. 
quadratic, cubic) were evaluated to fit the data points in each scatterplot. It was 
determined that cubic functions these data best, therefore, the linear assumption was 
violated. Both Linear and Cubic R2 values for these scatter plots are displayed in Table 
4.7.   
Finally, scatter plots were examined between the predictor variables (IPAQ 
Sitting, IPAQ Active, PSQI Total, UCLA-R, PSS) and Cognitive Outcomes (NP 
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 Table 4.6  
R2 values for Scatterplot Lines of Best fit between Individual Factors, Predictors Variables, and 
Cytokines (n=66) 
 
log10IL-6 log10TNF- α 
log10IL-6* log10TNF-
α 
PROMIS Anxiety R2 Linear = .005 
R2 Cubic = .011 
R2 Linear = .009 
R2 Cubic = .013 
R2 Linear = .003 
R2 Cubic = .008 
PROMIS Depressive  R2 Linear = .010 
R2 Cubic = .011 
R2 Linear = .001 
R2 Cubic = .001 
R2 Linear = .010 
R2 Cubic = .011 
PROMIS Fatigue R2 Linear = .000 
R2 Cubic = .042 
R2 Linear = .006 
R2 Cubic = .059 
R2 Linear = .001 
R2 Cubic = .040 
PSQI Total R2 Linear = .001 
R2 Cubic = .006 
R2 Linear = .025 
R2 Cubic = .039 
R2 Linear = .000 
R2 Cubic = .008 
IPAQ  Tot Min Sit R2 Linear = .003 
R2 Cubic = .027 
R2 Linear = .020 
R2 Cubic = .114 
R2 Linear = .002 
R2 Cubic = .026 
IPAQ  Tot Min Act R2 Linear = .045 
R2 Cubic = .096 
R2 Linear = .000 
R2 Cubic = .015 
R2 Linear = .041 
R2 Cubic = .083 
UCLA-R R2 Linear = .001 
R2 Cubic = .036 
R2 Linear = .007 
R2 Cubic = .018 
R2 Linear = .001 
R2 Cubic = .040 
PSS R2 Linear = .014 
R2 Cubic = .050 
R2 Linear = .024 
R2 Cubic = .048 
R2 Linear = .016 
R2 Cubic = .048 
ESS R2 Linear = .017 
R2 Cubic = .149 
R2 Linear = .012 
R2 Cubic = .032 
R2 Linear = .011 
R2 Cubic = .115 
Note. Line of best fit added to each scatterplot to determine nature of relationship with 
highest R2. Cubic R2 ≥ Quadratic R2 in all the scatterplots; therefore only Linear and 
Cubic R2 included in table. 
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Table 4.7    
R2 values for Scatterplot Line of Best fit Cytokines (X axis) and Cognitive Measures (Y axis) (n=66) 
 log10IL-6 log10TNF-α log10IL-6* log10TNF-α 
HVLT-Immediate 
R2 Linear = .022 
R2 Cubic = .045 
R2 Linear = .0003 
R2 Cubic = .031 
R2 Linear = .025 
R2 Cubic = .034 
HVLT  Delayed 
R2 Linear = .002 
R2 Cubic = .040 
R2 Linear = .0005 
R2 Cubic = .113 
R2 Linear = .004 
R2 Cubic = .020 
COWAT 
R2 Linear = .013 
R2 Cubic = .022 
R2 Linear = .003 
R2 Cubic = .063 
R2 Linear = .020 
R2 Cubic = .031 
Trails Aa 
R2 Linear = .008 
R2 Cubic = .025 
R2 Linear = .0004 
R2 Cubic = .003 
R2 Linear = .007 
R2 Cubic = .032 
Trails Bb 
R2 Linear = .013 
R2 Cubic = .023 
R2 Linear = .020 
R2 Cubic = .028 
R2 Linear = .013 
R2 Cubic = .045 
FACT- Cog Total 
R2 Linear = .002 
R2 Cubic = .005 
R2 Linear = .017 
R2 Cubic = .059 
R2 Linear = .001 
R2 Cubic = .003 
PCI 
R2 Linear = .003 
R2 Cubic = .006 
R2 Linear = .023 
R2 Cubic = .075 
R2 Linear = .003 
R2 Cubic = .004 
PCA 
R2 Linear = .003 
R2 Cubic = .004 
R2 Linear = .009 
R2 Cubic = .045 
R2 Linear = .002 
R2 Cubic = .003 
Note. Line of best fit added to each scatterplot to determine nature of relationship with highest R2. 
Cubic R2 ≥ Quadratic R2 in all the scatterplots; therefore only Linear and Cubic R2 included in 
table.  In these scatterplots, cytokines were on the X axis, and cognitive measures on the Y axis 
a= Transformed data used (sq rt transformation)  
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Individual Tests, FACT-Cog, PCI, PCA). Linear relationships were found between 
FACT-Cog Total and subscales and the PROMIS Scales (R2 ranged from 0.219-0.413); 
PSQI Total (R2 ranged from 0.18-0.0.24); UCLA-R (R2 ranged from 0.178-0.267); PSS 
(R2 ranged from 0.333-0.45); but not between the FACT-Cog and IPAQ scales. Very 
small linear or non-linear relationships were found, between all the predictors and the 
cognitive performance measures, however those relationships between the behavioral 
variables (sleep and physical activity) appeared the largest. The R2 values for each 
scatterplot are displayed in Table 4.8 below. 
Covariate Selection 
The literature presented in Chapter 2 supports the likelihood that certain 
individual treatment factors (abdominal obesity, a history of anthracycline based 
chemotherapy, and treatment with tamoxifen) could explain differences in either cytokine 
concentrations or cognitive functioning. Therefore, the sample was dichotomized into 
anthracycline (coded 1) versus non-anthracyclione (coded 0) and independent t tests were 
run on the outcome variables (cytokines, cognitive function) to see if group differences in 
these variables exist. The same was done for the sample based on tamoxifen treatment 
(coded 1), no tamoxifen treatment (coded 0), and for the presence of abdominal obesity, 
defined as a HWR >0.80 (coded 1), or less that 0.80 (coded 0). An additional t test was 
run on pre menopausal (coded 0) and post menopausal (coded 1) women because post 
menopausal status, and subsequent lower levels of estrogen, have been associated with 
cognitive deficits and brain atrophy in the literature (Eberling, 2004). The independent t 
test results are displayed in Appendix P. One significant group differences was found 
between those who had undergone anthracycline-based chemotherapy and those who had  
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Table 4.8    
R2 values for Scatterplot Line of Best fit (Linear and Cubic) Between Individual Factors, Predictor Variables and Cognitive Measures (N=75) 
 HVLT-I HVLT-D COWAT TMT Aa TMT Bb FACT- Cog  PCI PCA 
PROMIS 
Anxiety 
R2 Lin = .000 
R2 Cub =.051 
R2 Lin = .002 
R2 Cub =.033 
R2 Lin = .015 
R2 Cub =.035 
R2 Lin = .002 
R2 Cub=.017 
R2 Lin = .001 
R2 Cub =.013 
R2 Lin = 
.362 
 
R2 Lin = 
.315 
 





R2 Lin = .000 
R2 Cu =.057 
R2 Lin =.001 
R2 Cub =.046 
R2 Lin = .017 
R2 Cub =.019 
R2 Lin = .015 
R2 Cub =.062 
R2 Lin = .007 
R2 Cub =.027 
R2 Lin = 
.315 
 
R2 Lin = 
.268 
 





R2 Lin = .007 
R2 Cub =.045 
R2 Lin = .000 
R2 Cub =.006 
R2 Lin = .014 
R2 Cub =.042 
R2 Lin = .000 
R2 Cub =.010 
R2 Lin = .009 
R2 Cub =.069 
R2 Lin = 
.413 
 
R2 Lin = 
.364 
 
R2 Lin = 
.330 
 
PSQI Total R2 Lin = .007 
R2 Cub =.039 
R2 Lin = .030 
R2 Cub =.060 
R2 Lin = .002 
R2 Cub =.005 
R2 Lin = .010 
R2 Cub =.013 
R2 Lin = .009 
R2 Cub=.048 
R2 Lin = .24 
 
R2 Lin = 
.225 
 





R2 Lin = .001 
R2 Cub =.025 
R2 Lin =.050 
R2 Cub =.081 
R2 Lin = .000 
R2 Cub =.037 
R2 Lin = .007 
R2 Cub =.021 
R2 Lin =.001 
R2 Cub =.026 














R2 Lin = .011 
R2 Cub =.013 
R2 Lin = .062 
R2 Cub =.129 
R2 Lin = .025 
R2 Cub =.038 
R2 Lin = .037 
R2 Cub =.050 
R2 Lin = .069 
R2 Cub =.080 
R2 Lin= .001 
R2 Cub 
=.007 








UCLA-R R2 Lin = .018 
R2 Cub =.026 
R2 Lin = .001 
R2 Cub =.026 
R2 Lin = .014 
R2 Cub =.028 
R2 Lin = .004 
R2 Cub =.021 
R2 Lin = .009 
R2 Cub =.012 
R2 Lin = 
.267 
 
R2 Lin = 
.265 
R2 Lin = 
.178 
PSS R2 Lin = .004 
R2 Cub =.074 
R2 Lin = .001 
R2 Cub =.076 
R2 Lin = .038 
R2 Cub=.058 
R2 Lin = .029 
R2 Cub =.077 
R2 Lin = .010 
R2 Cub =.123 
R2 Lin = .45 
 
R2 Lin = 
.400 
R2 Lin = 
.333 
ESS R2 Lin = .011 
R2 Cub =.013 
R2 Lin = .027 
R2 Cub=.133 
R2 Lin = .031 
R2 Cub =.059 
R2 Lin = .029 
R2 Cub =.044 
R2 Lin = .018 
R2 Cub =.045 
R2 Lin = 
.189 
 
R2 Lin = 
.201 
R2 Lin = 
.145 
Note. Line of best fit added to each scatterplot to determine nature of relationship with highest R2. Cubic R2 ≥ Quadratic R2 in all the scatterplots; 
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Table 4.8 (continued) 
 
therefore only Linear and Cubic R2 included in table. If a linear relationship had a R2>.010, it was included in the table. 
a= Transformed data used (sq rt transformation)  
b= Transformed data used (log 10 transformation)   
R2 Lin=  R2 Linear  
R2 Cub=  R2 Cubic 
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not in Trails A (transformed data, t = 2.51,  p= 0.03). One significant group difference 
was found between those with abdominal obesity and those without in TNF-α levels (t = 
2.24, p = 0.04).  
There was not a consistent pattern in terms of correlations between individual 
factors, cytokines and cognitive outcomes. The largest correlation between individual 
factors and cytokine levels was between BMI and TNF-α (Table 4.3). The largest 
correlations between individual factors and cognitive outcomes were between age, years 
of education, BMI, and cognitive function measures (presented in Table 4.5 above). 
Although the original data analysis plan included controlling for individual factors as 
covariates in step 1 of hierarchical multiple regression analyses, the preliminary analyses 
for aims 1 and 2 clearly illustrated non-linear relationships, thus hierarchical multiple 
regressions were not used for aims 1 and 2, and covariates not selected for entry in Step 
1.  
Non-linear (curvilinear) regression models were used instead for aims 1 and 2, 
and covariates were not used in these models. First, simple non-linear (cubic) regression 
models were used to determine the variance of inflammatory factors explained by 
psychosocial and behavioral factors. These curvilinear (cubic function) regression 
analyses were exploratory in nature; therefore, no specific hypotheses were tested. 
Additionally, beta weights were not examined or included because the beta weights of 
cubic functions are not meaningful for interpretation (Cohen, 2003.). This process was 
repeated to determine the variance of cognitive outcomes explained by inflammatory 
factors. 
Covariates for aim 3 hierarchical regression were selected based on exploratory 
correlation analyses, significant t tests, and those individual factors that had the largest 
correlations with cognitive outcomes. Separate covariates were chosen for aim 3 
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depending on the cognitive variable used as the dependent variable in the regression 
models and are displayed in a table in Appendix Q. 
Homoscedasticity. For Aim 3 Hierarchical Regression Analyses, scatter plots of 
the residuals as a function of Ŷ were used in order to verify if the assumption of 
homoscedasticity—whether the errors in estimation are equally variable conditioned on 
the predicted outcome variable. The residuals for each regression model were plotted 
(Yplot ZRESID, Xplot ZPRED), then a line of best fit added, and the distance between 
the line and the actual residuals visually examined. A sign of heteroscedasticity, or a 
violation of homoscedasticity, is a funnel shaped distribution of the residuals around the 
line of best fit. Simulation research suggests that small violations of this assumption do 
not affect the validity of statistical inference, but that more severe violations of this 
assumption impact inference through its effects on standard error of the regression 
coefficient (Hayes, 2013). These assumptions were checked with each regression analysis 
and are displayed within the findings tables.  
Regression Diagnostics. Durban Watson values were examined to ensure that 
residuals were independent, and there was no autocorrelation occurring. These values 
were deemed “problematic” if they were less than one or greater than three (Plitcha, 
2013). Coliniearity diagnositics were also conducted using tolerance and variance 
inflation factor (VIF) values for each of the predictors in the regression models. A 
general rule of thumb is that tolerance should be greater than 0.1 or 0.2 or that VIF 
should be less that 10 for all variables. The values for all of these diagnostics within each 
regression analyses were deemed acceptable and are included in each of the multiple 
regression tables in the findings. 
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Findings 
The findings from the univariate analyses, correlation analyses, and assumption 
checks informed the choices for multivariate analyses used to address each aim. The 
theoretical model depicted in Chapter 1, Figure 1.1, was refined based on these analyses 
and is shown below in Figure 4.6. Specifically, the individual factor of history of 
tamoxifen was removed from the model. Pieces of the full model were evaluated 
separately in the data analyses depending on the aim that was being addressed and are 
illustrated within each section below (Figures 4.7-4.17). The decision making process 
will be explained for each of the models in each section below.  
Aim 1: To assess the impact of psychosocial (stress, social isolation) and behavioral 
(physical activity, sleep quality) factors on inflammatory markers (IL-6, TNF-α) after 
controlling for selected individual factors. 
The original data analysis plan for Aim 1 included hierarchical multiple 
regression. First, bivariate correlational analyses were conducted between psychosocial 
(stress, social isolation), behavioral (physical activity, sleep quality) factors and 
inflammatory markers (IL-6, TNF-α) and showed very small, non-significant, or no 
relationships (Table 4.4). Next, scatter plots were constructed to further evaluate the 
nature of these relationships and showed that cubic functions better fit the data between 
the psychosocial factors and cytokines, and the behavioral factors and the cytokines 
(Table 4.7). Next, all the predictor variables (psychosocial and behavioral) were median 
centered and bivariate correlation analyses were repeated, but the correlations remained 
very small, and non-significant. Thus, it was determined that the hypotheses originally 
proposed could not be evaluated. Instead the following research questions were addressed 
using the conceptual models below. 
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Figure 4.6. Refined conceptual model used for the data analyses for aims 1-6. Individual Factors, Psychosocial Factors, 
Behavioral Factors, and Biological factors are all predictors of the Health Outcome, Cognitive Function. Individual Factors, 
Psychosocial Factors, Behavioral Factors are predictors of the Biological Factor as well. Developed from the theoretical model 
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RQ 1.1: Are stress, social isolation, physical activity, and sleep quality significant 
predictors levels of IL-6 concentrations? 
RQ 1.2: Are stress, social isolation, physical activity, and sleep quality significant 
predictors levels of TNF-α concentrations? 
For RQ 1.1, the conceptual model from Figure 4.7 was used. Simple and multiple 
non-linear regression models were used to answer these research questions. No individual 
factors were selected as covariates in this model, because there were no significant 
correlations identified between IL-6 and any of the individual factors as seen in Table 
4.3. The predictor variables stress, social isolation, physical activity, and sleep quality 
were operationalized using PSS, UCLA-R, IPAQ Tot Act Min, IPAQ Tot Min Sit, PSQI 
Total and ESS total. In order to reduce the number of statistical tests, and because of the 
focus of this study on factors other than emotional distress and fatigue, the PROMIS 
scales were not evaluated as predictors in these simple non-linear regression analyses.  
First, each of the predictor variables were entered as independent variables with 
the log10 IL-6 as the dependent variable in separate curvilinear regression models, using 
cubic functions. The results of these analyses are displayed in Table. 4.9 and include the 
R2, adjusted R2, Standard Error, F statistic, and p values. ESS significantly explained 
11% of the variance in log10 IL-6 (p<0.05). The other predictors, UCLA-R, PSS, IPAQ, 
and PSQI total did not significantly explain any of the variance of IL-6. Multiple non-
linear regression with IL-6 as a dependent variable was not conducted based on the 
results of the simple regression analyses— only one predictor significantly explained any 
variance in IL-6 concentrations. 
To evaluate RQ.1.2, a conceptual model with TNF-α as the dependent variable 
was used and is displayed in Figure 4.8. The predictor variables stress, social isolation, 
physical activity, and sleep quality were operationalized using PSS, UCLA-R, IPAQ Tot 
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Figure 4.7: Part of conceptual model used to answer RQ 1.1. All independent variables entered into separate non-linear 
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Table 4.9  
Curvilinear Simple Regression Models with log10 IL-6 as Dependent Variable (n=66) 
IV R2 Adj R2 St.E F Sig 
UCLA .036 -.11 .45 0.78 .513 
PSS .050 .004 .44 1.08 .360 
IPAQ Act Min .096 .052 .43 2.19 .098 
IPAQ Min Sit .027 -.02 .44 0.58 .628 
PSQI .006 -.42 .45 0.13 .940 
ESS .15 .11 .42 3.61 .018 
Note. Each IV was entered into separate regression models 
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Act Min, IPAQ Tot Min Sit, PSQI Total and ESS total. In order to reduce the number of 
statistical tests, and because of the focus of this study on factors other than emotional 
distress and fatigue, the PROMIS scales were not evaluated in these simple non-linear 
regression analyses.  
Each of the predictor variables were entered as independent variables with the 
log10 TNF-α as the dependent variable in separate curvilinear regression models, using 
cubic functions. The results of these analyses are displayed in Table. 4.10 and include the 
R2, adjusted R2, Standard Error, F statistic, and p values. Only 7.1% of the variance in 
TNF-α was explained by IPAQ Min sitting, but this predictor only approached 
significance (p<0.10). Multiple non-linear regression with TNF-α as a dependent variable 
was not conducted based on the results of the simple regression analyses— none of the 
predictor significantly explained any variance in TNF-α concentrations. 
Aim 2: To assess the impact of inflammatory markers (IL-6, TNF-α, IL-6* TNF α) on 
cognitive function (cognitive performance, perceived cognitive functioning) after controlling 
for selected individual factors. 
The original data analyses plan for Aim 2 included hierarchical multiple 
regression. First, bivariate correlational analyses were conducted between inflammatory 
markers (IL-6, TNF-α, IL-6*TNF-α) and cognitive function (cognitive performance, 
perceived cognitive functioning) and showed very small, non-significant, or no 
relationships (Table 4.4). Next, scatter plots were constructed to further evaluate the 
nature of these relationships and showed that cubic functions better fit the data between 
the cytokines and cognitive outcomes (Table 4.7). Next, all the predictor variables (IL-6, 
TNF-α, L-6* TNF-α) were median centered and bivariate correlations were repeated, but 
the correlations remained very small, and non-significant. Thus, it was determined that 
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Figure 4.8. Part of Conceptual Model used to answer RQ 1.2. Would have controlled for BMI due to the relationship with 
TNF- α (r=0.26, p< 0.05), but could not in the non-linear model. No covariates in this model due to limitations of non-linear 
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Table 4.10  
Curvilinear Simple Regression Models with log10TNF-α as Dependent Variable (n=66) 
IV R2 Adj R2 St.Er 
UCLA .018 -.029 .105 
PSS .048 .002 .103 
IPAQ Act Min .015 -.032 .105 
IPAQ Min Sit .114 .071 .10 
PSQI .039 -0.008 .104 
ESS .032 -0.015 .104 
Note. Each IV was entered into separate regression models 
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the hypotheses originally proposed could not be evaluated. Instead the following research 
questions were addressed using the conceptual models below in Figures 4.9 to 4.14: 
RQ 2.1: Are IL-6 and TNF-α significant predictors of perceived cognitive 
function? 
RQ 2.2: Are IL-6 and TNF-α significant predictors of immediate verbal memory 
performance? 
RQ 2.3: Are IL-6 and TNF-α significant predictors of delayed verbal memory 
performance? 
RQ 2.4: Are IL-6 and TNF-α significant predictors of verbal fluency 
performance? 
RQ 2.5: Are IL-6 and TNF-α significant predictors of attention performance? 
RQ 2.6: Are IL-6 and TNF-α significant predictors of executive functioning 
performance  
For R.Q 2.1, the conceptual model from Figure 4.9 was used, where FACT-Cog 
Total was the dependent variable. Each of the cytokines (IL-6, TNF-α, IL-6*TNF-α) 
were entered separately as independent variables in separate curvilinear regression 
models, using cubic functions. The results of these analyses are displayed in Table. 4.11 
and include the R2, adjusted R2, Standard Error, F statistic, and p values. None of the 
predictor variables explained significant variance in FACT-Cog Total Scores, therefore, 
multiple non-linear regression with FACT-Cog as a dependent variable was not 
conducted. 
For Research Question 2.2, the conceptual model from Figure 4.10 was used, 
where HVLT-I was the dependent variable. Each of the predictor variables IL-6, TNF-α, 
and the interaction of IL-6 and TNF-α were entered as independent variables with 
  
 
           
 147 









Figure 4.9 Part of the conceptual model used to answer RQ 2.1. Cytokines were predictors of perceived cognitive function in this 
model. No covariates were included in the model due to limitations of non-linear regression modeling.
Table 4.11 
Curvilinear Simple Regression Models with FACT-Cog as Dependent Variable (n=66) 
IV R2 Adj R2 St.E F Sig 
log10IL-6 .005 -.043 35.619 0.10 .96 
log10TNF- α .046 .015 34.6 1.5 .23 
log10IL6* log10TNF-α .003 -.046 35.37 0.05 .98 
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Figure 4.10 Part of the conceptual model used to answer RQ 2.2. Cytokines were predictors of immediate verbal memory 
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HVLT-I scores as the dependent variable in separate curvilinear regression models, using 
cubic functions. The results of these analyses are displayed in Table. 4.12 and include the 
R2, adjusted R2, Standard Error, F statistic, and p values. None of the predictor variables 
explained significant variance in HVLT-I Scores; therefore, multiple non-linear 
regression with HVLT-I as a dependent variable was not conducted. 
For Research Question 2.3, the conceptual model from Figure 4.11 was used, 
where HVLT-D was the dependent variable.  Each of the predictor variables IL-6, TNF-
α, and the interaction of IL-6 and TNF-α were entered as independent variables with 
HVLT-D scores as the dependent variable in separate curvilinear regression models, 
using cubic functions. The results of these analyses are displayed in Table 4.13 and 
include the R2, adjusted R2, Standard Error, F statistic, and p values. TNF-α explained 
8.4% of the variance in HVLT-D Scores (p< 0.05). Multiple non-linear regression with 
HVLT-D as a dependent variable was not conducted based on the results of the simple 
regression analyses— only one predictor significantly explained any variance in HVLT-
D scores. 
For Research Question 2.4, the conceptual model from Figure 4.12 was used, 
where COWAT was the dependent variable.  Each of the predictor variables IL-6, TNF-
α, and the interaction of IL-6 and TNF-α were entered as independent variables with 
COWAT scores as the dependent variable in separate curvilinear regression models, 
using cubic functions. The results of these analyses are displayed in Table 4.14 and 
include the R2, adjusted R2, Standard Error, F statistic, and p values. None of the 
predictor variables explained significant variance in COWAT Scores; therefore, multiple 
non-linear regression with COWAT Scores as a dependent variable was not conducted. 
For Research Question 2.5, the conceptual model from Figure 4.13 was used, 
where Trails A was the dependent variable. Each of the predictor variables IL-6, TNF-α, 
  
 





















Table 4.12  
Curvilinear Simple Regression Models with HVLT-I as Dependent Variable (n=66) 
IV R2 Adj R2 St.E F Sig 
log10IL-6 .045 -.002 3.60 .963 .42 
log10TNF- α .028 -.002 3.6 .92 .40 
log10IL6* log10TNF-α .034 -.013 3.6 .73 .54 
Note. Each IV was entered into separate regression models 
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Figure 4.11 Part of the conceptual model used to answer RQ 2.3. Cytokines were predictors of delayed verbal memory recall (HVLT-
D) in this model. No covariates were included in the model due to limitations of non-linear regression modeling.  
 
 
Table 4.13  
Curvilinear Simple Regression Models with HVLT-D as Dependent Variable (n=66) 
IV R2 Adj R2 St.E F Sig 
log10IL-6 .040 -.006 1.47 0.87 .46 
log10TNF- α .113 .084 1.4 3.99 .02 
log10IL6* log10TNF-α .020 -.027 1.49 0.43 .73 
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Figure 4.12 Part of the conceptual model used to answer RQ 2.4. Cytokines were predictors of verbal fluency (COWAT) in 














Table 4.14  
Curvilinear Simple Regression Models with COWAT as Dependent Variable (n=66) 
IV R2 Adj R2 St.E F Sig 
log10IL-6 .022 -.025 11.43 0.46 .71 
log10TNF- α .062 .033 11.1 2.10 .13 
log10IL6* log10TNF-α .031 -.016 11.28 0.65 .58 
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Figure 4.13 Part of the conceptual model used to answer RQ 2.5. Cytokines were predictors of attention (Trails A) in this 
model. No covariates were included in the model due to limitations of non-linear regression modeling. Transformed Trails A 
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and the interaction of IL-6 and TNF-α were entered as independent variables with Trails 
A scores as the dependent variable in separate curvilinear regression models, using cubic 
functions. The results of these analyses are displayed in Table. 4.15 and include the R2, 
adjusted R2, Standard Error, F statistic, and p values. None of the predictor variables 
explained significant variance in Trails A Scores; therefore, multiple non-linear 
regression with Trails A as a dependent variable was not conducted. 
For Research Question 2.6, the conceptual model from Figure 4.14 was used, 
where Trails B was the dependent variable. Each of the predictor variables IL-6, TNF-α, 
and the interaction of IL-6 and TNF-α were entered as independent variables with Trails 
B scores as the dependent variable in separate curvilinear regression models, using cubic 
functions. The results of these analyses are displayed in Table. 4.19 and include the R2, 
adjusted R2, Standard Error, F statistic, and p values. None of the predictor variables 
explained significant variance in Trails B Scores; therefore, multiple non-linear 
regression with Trails B as a dependent variable was not conducted. 
Aim 3: To explore direct and indirect (through inflammatory mediators IL-6 and TNF-
α) effects of psychosocial (stress, social isolation) and behavioral (physical activity, sleep 
quality) factors on cognitive function (memory, attention, processing speed, executive function 
performance, perceived cognitive function) after controlling for selected individual factors. 
The original data analysis plan for Aim 3 was adjusted based on the results from 
the univariate and correlational analyses, and the findings from the data analyses in Aims 
1 & 2. The mediation analyses originally proposed to examine the indirect effects of the 
predictor variables through inflammatory mediators on cognitive outcomes, could not be 
conducted due to violation of linearity already discussed at length above. Instead, 
research questions were developed to examine the direct effects of psychosocial (stress, 
and social isolation) and behavioral (physical activity, sleep quality) 
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Table 4.15  
Curvilinear Simple Regression Models with Trails A as Dependent Variable (n=66) 
IV R2 Adj R2 St.E F Sig 
log10IL-6 .025 -.022 0.85 0.54 .65 
log10TNF- α .001 -.031 0.85 0.02 .98 
log10IL6* log10TNF-α .032 -.015 0.85 0.67 .57 
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Figure 4.14 Part of the conceptual model used to answer RQ 2.6. Cytokines were predictors of executive functioning 
performance (Trails B) in this model. No covariates were included in the model due to limitations of non-linear regression 








Table 4.16  
Curvilinear Simple Regression Models with Trails B as Dependent Variable (n=66) 
IV R2 Adj R2 St.Er F Sig 
log10IL-6 .037 -.010 0.14 0.79 .50 
log10TNF- α .026 -.005 0.14 0.83 .44 
log10IL6* log10TNF-α .045 -.002 0.14 0.93 .42 
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factors on cognitive function (perceived cognitive function, memory, attention, 
processing speed, executive function performance) after controlling for selected 
individual factors. Since these analyses excluded the inflammatory markers, the larger 
sample (N=75) was used to increase the power of the analyses. The bivariate correlations 
from Table 4.5 along with some additional correlational analyses between all the PSQI 
subscales and the cognitive outcomes (Appendix R) informed the development the 
following research questions: 
RQ 3.1: Will psychosocial variables (stress, social isolation) predict perceived 
cognitive function after controlling for BMI, emotional distress, and fatigue? 
RQ 3.2: Will behavioral variables (physical activity and sleep quality) predict 
perceived cognitive function after controlling for BMI, emotional distress, and fatigue? 
RQ 3.3: Will behavioral variables (physical activity and sleep quality) predict 
delayed verbal memory cognitive performance after controlling for age, and education? 
RQ 3.4: Which of the behavioral variables (of physical activity and sleep quality) 
will predict executive functioning performance after controlling for age? 
For RQ’s 3.1 and 3.2, the conceptual model depicted in Figure 4.15 was used. 
BMI was the selected individual factor and entered in Step 1. The PROMIS Scales 
evaluating anxiety, depression and fatigue were entered in Step 2 since they had large 
correlations with FACT-Cog. Then PSS, UCLA-R, and PSQI scores were entered into 
Step 3 to determine if any additional variance in FACT-Cog scores were significantly 
explained by these variables. The hierarchical regression model results are displayed in 
Table 4.17. The PROMIS Scores explained an additional 57.3% of the variance in FACT-
Cog scores over that of BMI alone (p<0.001). PROMIS Anxiety and Fatigue scales 
remained significant predictors (p’s<0.01) when simultaneously entered into Step 2. 
More perceived anxiety significantly predicted lower scores on FACT-Cog (β=-0.40, 
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Figure 4.15 Part of the conceptual model used for hierarchical multiple regression for perceived cognitive function as 
dependent variable to address RQ’s 3.1- 3.2. 
DV: FACT-Cog Scores 
Step 1: Covariates selected BMI (r=-.23, p<.001),  
Step 2: Emotional Distress and Fatigue factors entered (PROMIS anxiety, depression, fatigue) 
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Table 4.17   
Hierarchical Multiple Regression with FACT-Cog Total Score as Dependent Variable (N=75) 
  B SE B β t p R2* p Δ R2 p 
Step 1 BMI -1.44 0.71 -0.23 -2.02 .047 0.04 0.047 - - 
Step 2 PROMIS Anxiety -1.66 0.46 -0.40 -3.40 .001     
 PROMIS 
Depressive 
-0.45 0.64 -0.09 -0.79 0.49     
 PROMIS Fatigue -1.83 0.36 -0.43 -5.07 .000 0.61 .000 0.573 .000 
Step 3 PSS -0.99 0.54 -0.24 -1.84 0.07     
 UCLA-R -0.39 0.33 -0.13 -1.20 0.24     
 PSQI 0.36 0.81 0.05 0.45 0.66 0.626 .000 .035 .085 
Note. Regression Diagnostics:  Residuals (Standardized Residuals ranged from -2.83 to 2.08), Durban Watson within range 
1-3 (1.77), Cooks distance less than 1 (min 0.00 max 0.20), VIF all values <10, Tolerance all  values >0.3, homoscedasticity 
assumption met 
*Adjusted R2   
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t=-2.15, p<0.01) and more perceived fatigue significantly predicted lower scores on 
FACT-Cog (β=-0.43, t=-5.07, p<0.001). In Step 3, PSS, UCLA-R and PSQI explained an 
additional 3.5% of the variance in FACT-Cog scores (p=0.085). The only predictor in 
this step that approached significance was perceived stress (β=-0.24, t=-1.84, p=0.07).  
The conceptual model in Figure 4.16 was used for the hierarchical multiple 
regression to answer RQ 3.3. Age (r=-0.26, p<.05) and Years of Education (r=0.26, 
p<.05) were selected as covariates in this model and  entered in Step 1. The predictors 
with significant correlations with HVLT-D scores were chosen for Step 2 and included 
IPAQ Min Sit subscale, PSQI total, and ESS Total Scores. Age and Years of education 
explained 9.5% of the variance in HVLT-D Scores (p<0.05). PSQI, ESS and IPAQ scores 
explained an additional 9.1% of the variance in HVLT-D, and this change in R2 
approached significance (p=0.056) The hierarchical regression model results are 
displayed in Table 4.18. After controlling for age and education, and while holding IPAQ 
Min sit and ESS constant, PSQI scores approach significance as predictors of verbal 
memory performance (β=-0.20, t=-1.84, p=0.07). 
The conceptual model in Figure 4.17 was used for the hierarchical multiple 
regression to test hypotheses 3.4. Age (r=0.36, p<.01) was selected as a covariate in this 
model and  entered in Step 1. The predictors with significant correlations with Trails B 
scores were chosen for Step 2 and included IPAQ Act Min subscale and PSQI Sleepaid 
Subscale (correlation can be seen in Appendix “Letter”). Age explained 12% of the 
variance in Trails B scores (p<0.001). ESS and IPAQ scores explained an additional 
7.6% of the variance in Trails B (p=0.04). Of the two predictors entered in Step 2, IPAQ 
Active Min approached significance as a predictor of Trails B scores (β=000, t=1.92, 
p=0.06). These hierarchical regression model results are displayed in Table 4.19. After 
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Figure 4.16 Part of the conceptual model used for the non-linear regression of delayed memory performance as the dependent 
variable to answer RQ 3.3. 
DV: HVLT-D scores 
































Table 4.18  
Hierarchical Multiple Regression with HVLT-D Score as Dependent Variable (N=75) 
  B SE B β t p R2* p Δ R2 p 
Step 1 Age -0.04 0.02 -0.23 -2.05 0.04     
 Yrs Education 0.19 0.09 0.23 2.08 0.04 0.095 0.010   
Step 2 ESS 0.07 0.04 0.17 1.50 0.14     
 PSQI -0.08 0.04 -0.20 -1.84 0.07     
 IPAQ Min Sit .00 .00 .14 1.25 0.22 0.153 0.010 0.091 0.056 
Note. Regression Diagnostics:  Residuals (Standardized Residuals ranged from -2.5 to 1.08), Durban Watson within range 
1-3 (1.99), Cooks distance less than 1 (min 0.00 max 0.09), VIF all values <10, Tolerance all  values >0.3, 
homoscedasticity assumption questionable. 
*Adjusted R2   
  
 
           
 163 
 
















Figure 4.17 Part of the conceptual model used for non-linear regression of executive function performance as the dependent 
variable to answer RQ 3.4. 
DV: Trails B scores 
Step 1: Covariates selected Age (r=.36, p< .01)  
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Table 4.19   
Hierarchical Multiple Regression with Trails Bb Score as Dependent Variable (N=75) 
  B SE B β t p R2* p Δ R2 p 
Step 1 Age 0.01 0.00 0.36 3.31 0.001 0.12 0.001   
Step 2 PSQI Sleepaid 
Subscale   0.02 0.01 0.15 1.36 0.178   
  
 IPAQ Active Min 0.000 0.000 .021 1.92 0.060 0.17 0.001 0.076 0.04 
b= Transformed data used (log 10 transformation)   
Regression Diagnostics:  Residuals (Standardized Residuals ranged from -1.97 to 3.82), Durban Watson within range 1-
3 (1.79), Cooks distance less than 1 (min 0.00 max 0.29), VIF all values <10, Tolerance all  values >0.3, 
homoscedasticity assumption met. 
*Adjusted R2   
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controlling for age, and holding PSQI Sleepaid subscale constant, physical activity 
approached significance as a predictor of log10 Trails B scores. 
Additional Analyses 
Aim 4: To describe the nature of the relationships between psychosocial, behavioral 
factor and cytokines, and between cytokines and cognitive outcomes. 
The results from aims 1 and 2 led to the development of an additional aim to 
better describe the nature of relationships among the psychosocial factors, behavioral 
factors and cytokines, and between the cytokines and cognitive outcomes. Two research 
questions were developed:  
RQ 4.1. What patterns of non-linear relationships can be visualized between the 
psychosocial factors, behavioral factors, and cytokines? 
RQ 4.2. What patterns of non-linear relationships can be visualized between the 
cytokines and cognitive outcomes? 
Non-parametric fit lines, specifically Loess, can be used to visualize and 
understand complex bivariate relationships that may otherwise be missed using 
traditional parametric tests (Jacoby, 2000). In some cases, locally weighted regression, 
Loess regression, can yield more information about the true nature of the complex 
associations than parametric methods. It is said that Loess regression preserves the 
simplicity of parametric modeling but has more flexibility in terms of parameters and 
assumptions. Parametric regression modeling fits data to one global function, whereas 
loess regression fits the data locally—in sequential, weighted, polynomial regression 
models (Cleveland, 1979; Jacoby, 2000; Tan, 2012). Loess regression uses a 
mathematical algorithm to follow concentrations of points in a scatter plot along the 
horizontal axis of the scatter plot, resulting in a line that passes through the most dense 
spots of the graph regardless of the shape the line makes, using ordinary least squares 
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(OLS) in sliding windows of the data (Jacoby 2000). This method can characterize almost 
any relationship and the user controls the degree of smoothing.  The major disadvantage 
of using this method is that inference is not as straight forward as parametric methods 
because the results of the analyses are graphical in nature, and do not provide 
interpretable mathematical statistics such as beta weights, p values, or effect sizes. 
Confidence intervals are often used to serve the purpose of inference and the 95% CI can 
be fitted around the Loess curve. 
Two parameters need to be set before running a Loess regression line in a scatter 
plot— the span and number of degrees. The span refers to how much data within each 
“slice” of the scatter plot on the horizontal axis will be used to fit the weighted 
polynomial regression. It can range from 0.1-1.0, with lower values providing a more 
exact, or “jagged” line, and higher values providing a “smoother” curved line. There are 
no strict rules for determining the span.  Jacoby (2000) explains that the objective is “to 
produce a loess curve that is as smooth as possible, but still captures all of the important 
structure that exists within the data”(p.586). The degree parameter refers to the number of 
bends in the regression line. After these parameters are set, the loess function will 
determine the line of best fit based on the locally weighted regression points. For all the 
scatter plots used to address RQ4.1 and 4.2, a span of 0.50 and degree of 2 was used to fit 
the Loess line to the data. Additionally, 95% Confidence Intervals were added to the 
Loess lines in each graph.  
For RQ’s 4.1, separate scatter plots were created between raw scores of IL-6 (y-
axis) and all of the psychosocial and behavioral variables (on the x-axis).  Then, separate 
scatter plots were created between raw scores of TNF-α (y-axis) and all of the 
psychosocial and behavioral variables (on the x-axis). Scatter plots were constructed 
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using R studio (2017, Boston, MA) with Loess Regression Lines. An example of one of 
these graphs is below in Figure 4.18. The remaining graphs can be found in Appendix S. 
For RQ’s 4.2, separate scatter plots were created between perceived cognitive 
function (y-axis) and each cytokine (IL-6, TNF-α; y-axis). Then separate scatter plots 
were created between HVLT-I (y-axis) and each cytokine (IL-6, TNF-α; y-axis), and 
subsequently with HVLT-D, COWAT, Trails A and Trails B on the y-axes and cytokines 
on the x axes. Scatter plots were constructed Using R studio (2017, Boston, MA) and 
Loess Regression Lines added with 95% Confidence intervals. An example of one of 
these graphs is below in Figure 4.19. The remaining graphs can be found in Appendix T. 
Loess modeling was used to explore the complexities of these relationships. These 
non-parametric analyses illustrated the complex nature of relationships involving 
cytokines. In this study the relationships overall, have many bends, and further justify the 
decision to not run linear modeling with these data. The Loess graphs with the cytokines 
regressed on predictor variables exhibited that linear relationships exist between the 
variables and cytokine concentrations, but that these relationships change and vary across 
levels of predictor variables. These relationships appear very steep and strong at certain 
levels of the predictor variables. Similarly, the Loess graphs with the cognitive outcomes 
regressed on the cytokine variables showed linear relationships exist between the 
variables and cognitive function, but that these relationships change and vary across 
levels of cytokines. These relationships appear very steep and strong at certain levels of 
the predictor variables. Only graphs between IL-6 and HVLT-I and TNF-α and Trails A 
and B were essentially straight across all levels of the cytokines suggesting either too 
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Figure 4.18 Loess Regression with IL-6 on the Y axis and Perceived Stress on the X Axis. Graph created in R Studio, parameters were 
a span of 0.50 and 2 degrees. The 95% confidence interval is depicted with the blue dotted line above and below the red Loess line.
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Figure 4.19 Loess Regression with FACT-Cog on the Y axis and TNF-α on the X Axis 
 
 
Figure 4.18 Loess Regression with FACT-Cog on the Y-axis and TNF-α on the X-axis. Graph created in R Studio, parameters were a 
span of 0.50 and 2 degrees. The 95% confidence interval is depicted with the blue dotted line above and below the red Loess line
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Aim 5: To explore direct and indirect effects of psychosocial factors (stress, perceived 
social isolation, emotional distress, and fatigue), and sleep quality on perceived cognitive 
function 
The results from aim 3 showed significant inter-correlations between the 
psychosocial variables, sleep, and perceived cognitive function; therefore, an additional 
aim to explore direct and indirect effects of psychosocial factors (stress, perceived social 
isolation, emotional distress, and fatigue) and sleep on perceived cognitive function was 
derived. The analyses for this aim included 1) detailed bivariate correlation analyses 
between the FACT-Cog subscales, the psychosocial predictors, and sleep quality; 2) 
Hierarchical Multiple regression, and 3) Mediation Analyses using OLS to better 
understand how the psychosocial and sleep variables influence and perceived cognitive 
functioning in breast cancer survivors. The full sample (N= 75) was used in these 
analyses. 
Bivariate Pearson’s correlations were run between the FACT-Cog total and 
subscales, PROMIS Anxiety, PROMIS Depression, PROMIS Fatigue, PSS, UCLA-R, 
and PSQI total and subscales. A Bonferroni adjustment was made to the p value to 
account for multiple comparisons (Munroe, 2005). Those p values less than 0.0011 were 
considered significant and are starred in Table 4.20. Similar patterns of moderate to large 
negative correlations were found between FACT-Cog total, PCI and PCA subscales and 
the psychosocial and sleep variables (r’s ranged from -0.39 to -0.74, p’s< 0.0011). The 
magnitude of the correlations between the psychosocial variables with the PCA scale was 
slightly smaller than with the FACT-Cog total and PCI subscales. The subscales of the 
PSQI that remained significantly related to the FACT-Cog after the Bonferroni correction 
were between PSQI Efficiency and FACT-Cog (r=-0.39), PSIQ Sleep Disturbance and all 
  
 









Pearson’s Correlations between Psychosocial Variables and FACT-Cog total and Subscales (N=75)   
 PCI PCA QOL Comments  FACT-Cog Total 
PROMIS 
Anxiety 
-.62* -.52* -.74* -.38* -.65* 
PROMIS 
Depressive 
-.57* -.50* -.75* -.33 -.61* 
PROMIS Fatigue -.61* -.59* -.64* -.49* -.66* 
UCLA-R -.55* -.46* -.55* -.36 -.56* 
PSS -.68* -.60* -.74* -.46* -.71* 
PSQI Total -.46* -.43* -.45* -.39* -.49* 
Duration -.10 -.15 -.13 -.21 -.14 
Latency -.35 -.34 -.34 -.29 -.38* 
Efficiency -.37 -.39* -.32 -.29 -.39* 
Disturbance -.41* -.33 -.39* -.40* -.43* 
Sleepaid -.20 -.15 -.23 -.05 -.20 
Daytime  
Dysfunction 
-.51* -.33 -.49* .31 -.49* 
Sleep Quality -.23 -.28 -.16 -.37* -.26 
*p<0.0011 (Bonferroni Correction 0.05/45) 
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but the PCA subscale (r’s -0.39 to -0.43), and PSQI Daytime dysfunction and all but the 
PCA subscale (r’s -0.49 to -0.51). 
Based on the findings from the bivariate Pearson’s correlations, FACT-Cog total 
scores were chosen as the dependent variable for hierarchical multiple regression 
Modeling. BMI was selected as a covariate because of its’ significant negative 
relationship with FACT-Cog (r=-0.23, p<0.05). All the PROMIS Scales, PSS, UCLA-R 
and PSQI were entered in Step 2, in order to determine how much variance was explained 
by these variables and to explore the unique relationships between the predictor variables 
while controlling for the other independent variables. The results are displayed in Table 
4.21 below. BMI alone explained 4% of the variance in FACT-Cog scores (p = 0.047), 
and together, the PROMIS Scales, PSS, UCLA-R and PSQI significantly explained an 
additional 60.8% of the variance in FACT-Cog scores. Controlling for PROMIS 
Depression, PROMIS Fatigue, PSS, UCLA-R and PSQI, PROMIS Anxiety remained a 
significant predictor of FACT-Cog (β= -0.29, t=-2.02, p= 0.47). Controlling for PROMIS 
Anxiety, PROMIS Fatigue, PSS, UCLA-R and PSQI, PROMIS Fatigue remained a 
significant predictor of FACT-Cog (β= -0.36, t=-3.04, p= 0.001). 
The findings from the hierarchical multiple regression, suggest that the large 
significant negative relationship between PSS and FACT-Cog (r=-0.71, p<.0011) found 
in the bivariate correlations analysis might be explained by perceived feelings of anxiety 
and fatigue. Thus, a mediation analysis using Andrew Hayes’ PROCESS macro in SPSS 
24.0 was used to test the direct and indirect effects (through feelings of anxiety and 
fatigue) of perceived stress on perceived cognitive functioning while controlling for BMI. 
This analysis allows for inferential quantification of the indirect effects on dependent 
variables through mediator variables (Hayes, 2013). This method utilizes bootstrap 
confidence intervals to estimate and interpret the effect size of the indirect effects of the 
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Table 4.21    
Hierarchical Multiple Regression with Psychosocial and Sleep Predictors and FACT-Cog Total Score as Dependent Variable (N=75) 
  B SE B β t p R2* p Δ R2 p 
Step 1 BMI -1.44 0.71 -0.23 -2.02 .040 0.04 0.047 - - 
Step 2 PROMIS Anxiety -1.22 0.60 -0.29 -2.02 .047     
 PROMIS 
Depressive 
0.14 0.71 0.03 0.20 0.85     
 PROMIS Fatigue -1.53 0.45 -0.36 -3.40 .001     
 PSS -0.99 0.54 -0.24 -1.84 0.07     
 UCLA-R -0.39 0.33 -0.13 -1.20 0.24     
 PSQI 0.36 0.81 0.05 0.45 0.66 0.626 .000 .608 .001 
Note. Regression Diagnostics:  Residuals (Standardized Residuals ranged from -2.83 to 2.08), Durban Watson within range 
1-3 (1.77), Cooks distance less than 1 (min 0.00 max 0.20), VIF all values <10, Tolerance all  values >0.3, homoscedasticity 
assumption met 
*Adjusted R2   
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independent variables on the dependent variables. The direct effects of the independent 
variable on cognitive function was determined by the regression coefficient magnitude 
and significance (p<.05), and the indirect effects of the perceived anxiety and fatigue 
were determined by a significant effect size (95% Bootstrap CI does not include “0”). 
The mediation analysis with multiple mediators is conceptually illustrated in Figure 4.20. 
Using the PROCESS Macro in Linear Regression, FACT-Cog was entered as the 
dependent variable, PSS was entered as the independent variable, PROMIS Anxiety and 
PROMIS Fatigue as the mediators, and BMI as the covariate. PSS had a significant direct 
effect on FACT-Cog scores (direct effect= -1.21, bootstrap SE= 0.51, t= -2.42 , p= 0.02), 
meaning that a participant who scores 1 point higher on the PSS scale, scored on average 
1.2 points lower on the FACT-Cog. There was a significant negative indirect effect of 
PSS on FACT-Cog through PROMIS Anxiety (indirect effect= -0.85 bootstrap SE= 0.45, 
95% Bootstrap CI= -1.81, 0.05), meaning that a participant who scores 1 point higher on 
PSS scored, on average, 0.85 points lower on FACT-Cog through feelings of anxiety (as 
measured by PROMIS Anxiety). There was also a significant negative indirect effect of 
PSS on FACT-Cog through PROMIS Fatigue (indirect effect= -0.83 bootstrap SE= 0.24, 
95% Bootstrap CI= -0.05, -0.001), meaning that a participant who scores 1 point higher 
on PSS is estimated to score 0.83 points lower on FACT-Cog through feelings of fatigue 
(as measured by PROMIS Fatigue). These results suggest that perceived stress has 
significant, and almost equivalent, indirect effects on perceived cognitive function 
through both mediators (PROMIS Anxiety, and PROMIS Fatigue).  
This multiple mediator analysis was repeated with UCLA-R as the independent 
variable, to test the direct and indirect effects (through feelings of anxiety and fatigue) of 
feelings of loneliness on perceived cognitive functioning while controlling for BMI. 
Using the PROCESS Macro in Linear Regression, FACT-Cog was entered as the 
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Figure 4.20 Conceptual model used for aim 5 to explore the mediation pathways of perceived stress (PSS), loneliness (UCLA-
R), and sleep quality (PSQI) through feelings of anxiety and fatigue (PROMIS scales) as mediators on perceived cognitive 
function (FACT-Cog). Three separate multiple mediator analyses using ordinary least squares were conducted with stress, 
loneliness and sleep all as the independent variables. In all three models, anxiety and fatigue were the mediators, and perceived 
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dependent variable, UCLA-R was entered as the independent variable, PROMIS Anxiety 
and PROMIS Fatigue as the mediators, and BMI as the covariate. UCLA-R had a direct 
effect, although not significant, on FACT-Cog scores (direct effect= -0.53, bootstrap SE= 
0.28, t= -1.91, p= 0.06), meaning that a participant who scores 1 point higher on the 
UCLA scale, has on average 0.5 points lower on the FACT-Cog. There was a significant 
negative indirect effect of UCLA-R on FACT-Cog through PROMIS Anxiety (indirect 
effect= -0.59, bootstrap SE= 0.16, 95% Bootstrap CI= -0.95, -0.31), meaning that a 
participant who scores 1 point higher on UCLA-R is estimated score, on average 0.59 
points lower on FACT-Cog through feelings of anxiety (as measured by PROMIS 
Anxiety). There was also a significant negative indirect effect of UCLA-R on FACT-Cog 
through PROMIS Fatigue (indirect effect=-0.61, bootstrap SE= 0.19, 95% Bootstrap 
CI= -1.08, -0.30), meaning that a participant who scores 1 point higher on UCLA-R is 
estimated to score on average 0.83 points lower on FACT-Cog through feelings of fatigue 
(as measured by PROMIS Fatigue). These results suggest that perceived social isolation 
has significant, and almost equivalent, indirect effects on perceived cognitive function 
through both mediators (PROMIS Anxiety, and PROMIS Fatigue). 
The multiple mediator analysis was repeated one last time with PSQI as the 
independent variable, to test the direct and indirect effects (through feelings of anxiety 
and fatigue) of sleep quality on perceived cognitive functioning while controlling for 
BMI. Using the PROCESS Macro in Linear Regression, FACT-Cog was entered as the 
dependent variable, PSQI was entered as the independent variable, PROMIS Anxiety and 
PROMIS Fatigue as the mediators, and BMI as the covariate. PSQI did not have a 
significant direct effect on FACT-Cog scores (direct effect= 0.36, bootstrap SE=0.82, 
t= 0.44, p=0.66). However, there was a significant negative indirect effect of PSQI on 
FACT-Cog through PROMIS Anxiety (indirect effect= -1.84, bootstrap SE= 0.56, 95% 
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Bootstrap CI= -3.07, -0.87), meaning that a participant who scores 1 point higher on 
PSQI is estimated to score on average, 1.84 points lower on FACT-Cog through feelings 
of anxiety (as measured by PROMIS Anxiety). There was also a significant negative 
indirect effect of PSQI on FACT-Cog through PROMIS Fatigue (indirect effect= -2.45, 
bootstrap SE= 0.67, 95% Bootstrap CI= -4.09, -1.43), meaning that a participant who 
scores 1 point higher on PSQI is estimated to score 2.45 points lower on FACT-Cog 
through feelings of fatigue (as measured by PROMIS Fatigue). These results suggest that 
the effects of sleep quality on perceived cognitive function are mediated by feelings of 
anxiety and fatigue (PROMIS Anxiety, and PROMIS Fatigue), with fatigue having a 
larger direct effect.  
Aim 6: To explore patterns of relationships between cytokines (IL-6, TNF-α) and 
cognitive measures (FACT-Cog, HVLT-I, HVLT-D, COWAT, Trails A, Trails B) in BCS 
classified with “mild cognitive impairment” and those classified as “unimpaired”. 
It is possible that the correlations between cytokines and cognitive function are 
only present in cognitively impaired individuals, or those in a more pathological physical 
state, and not present in unimpaired individuals, who are likely in a state of physical 
homeostasis. Similar patterns of relationships have been reported in the field of persistent 
fatigue in BCS— significant relationships between peripheral cytokines and behavioral 
factors in fatigued BCS but not in non-fatigued survivors (Bower & Lamkin, 2013). To 
explore whether patterns of correlations differed by cognitive impairment status, the 
sample was divided into “impaired”, defined as -1.5 SD below the mean on at least one 
NP test (n=13), and “unimpaired” individuals (n=53). Non-parametric correlations 
between the cytokines and cognitive measures were examined in the impaired group 
using Spearman’s rho and Pearson’s r correlations were re-examined in the unimpaired 
group.   
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The pattern of correlations was in fact different between groups and is displayed 
in Table 4.22. In the impaired group, large significant negative relationships were found 
between FACT-Cog and IL-6 (rho= -.55, p < .01) and the interaction between IL-6 and 
TNF-α (rho= -.60, p < .01). In the unimpaired group, no relationships were found 
between FACT-Cog and IL-6 but there was a moderate positive relationship between 
TNF-α (r= .33, p < .05). In the impaired group moderate positive relationships were 
found between Trails A and the interaction of IL-6 and TNF-α (rho= .64, p < .05) and 
Trails B and both TNF-α and the interaction of IL-6 and TNF-α (rho’s= .54 & .64, p’s< 
.05). No significant relationships were found between the cytokines and NP test scores in 
the unimpaired group. These findings suggest that there may be significant linear 
relationships between perceived cognitive function (FACT-Cog), executive functioning 
performance (Trails A and B), and the cytokines (IL-6 and TNF-α) in those BCS who 
have cognitive impairment.  
Differing patterns of correlations were observed in the impaired and unimpaired 
groups, the relationships among cytokines (IL-6, TNF- α) and individual and predictor 
variables (age, education, months since chemotherapy, BMI, PROMIS Scales, PSS, 
UCLA-R, PSQI, ESS, IPAQ) were explored. In the impaired group, a significant positive 
relationship was found between BMI and IL-6 (rho= .58, p < .05) and the interaction of 
IL-6 and TNF-α (rho= .65, p< .05), suggesting that as BMI increases so does IL-6 in this 
group. Again, the opposite pattern was observed in the unimpaired group between BMI 
and IL-6 (r= -0.27, p <0.05) and the interaction IL-6 and TNF-α (r= -0.28, p< 0.05) 
suggesting that as BMI decreases in the unimpaired group, IL-6 levels increase. For the 
predictor variables, a large positive relationship was observed between daytime 
sleepiness (ESS) and IL-6 (rho= .76, p < .01) and the interaction IL-6 and TNF-α (rho= 
.78, p < .01) suggesting that as daytime sleepiness worsens, IL-6 levels increase in the 
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Table. 4.22  
Correlations between, Predictor Variables, Cytokines and Cognitive Outcomes in Impaired Group (n=13) and Unimpaired (n=53) 
 Impaired (n=13)  Unimpaired (n=53)   
 IL-6 TNF- α interaction  IL-6 TNF- α interaction   
Age .37 -.11 .35  -.11 -.13 -.13   
Education .10 -.37 .10  .01 .13 -.01   
BMI .58* .17 .65*  -.27* .14 -.28*   
Months since 
Chemo 
.20 .46 .25  -.06 -.24 -.09   
PROMIS Anxiety .04 .15 -.03  .12 -.09 .10   
PROMIS 
Depressive  
.16 .50 .20  .13 -.17 .11   
PROMIS Fatigue .28 .38 .37  -.01 -.25 -.01   
PSQI Total .09 -.03 .08  .04 -.14 .01   
IPAQ Sit Min .01 -.02 .06  -.13 .10 -.14   
IPAQ Active Min .15 -.15 .17  .24 .04 .24   
UCLA-R .24 .19 .24  -.11 -.11 -.11   
PSS .34 -.01 .32  -.19 -.15 -.20   
ESS .76** .28 .78**  -.37** -.20 -.36**   
FACT-Cog -.55* -.48 -.60*  .12 .33* .13   
HVLT-I .04 -.30 .02  -.15 .06 -.17   
HVLT-D -.17 -.39 -.16  .01 .16 -.02   
COWAT -.19 -.37 -.27  -.04 .01 -.06   
Trails Aa .48 .30 .54*  -.05 -.02 -.07   
Trails Bb .45 .64* .54*  -.02 .07 -.04   
Note. Spearman’s Rho used for impaired group, Pearson’s R used unimpaired group. = log transformed, a= Transformed data used (square 
root transformation), b= Transformed data used (log 10 transformation), ** p <.01, * p<.05 
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impaired group. The opposite pattern was observed in the unimpaired group between 
daytime sleepiness (ESS) and IL-6 (r= -.37, p <.01) and the interaction of IL-6 and TNF-
α (r= -.36, p< .01) suggesting that as daytime sleepiness worsens, that IL-6 levels 
decrease. These findings need to be interpreted with caution because of the small sample 
size. 
CHAPTER SUMMARY 
The majority of this sample was white, well educated, employed, and financially 
stable with an average age of 49 years. Most of the women were three years post-
chemotherapy completion, had a history of stage II or III invasive ductal carcinoma, and 
had undergone surgery, chemotherapy, radiation and hormonal therapies. Univariate 
analyses revealed that the majority of the study variables were psychometrically sound, 
that the sample fell in the “average” range for most of the self-report measures, and that 
the participants exhibited average to above average cognitive performance. Prior to 
conducting regression analyses, assumptions were checked and revealed that the 
assumption of linearity was violated between all cytokines and other variables. Non-
linear (curvilinear) regression models were used for aims 1 and 2 and revealed that 1) 
only daytime sleepiness, (ESS) significantly explained any variance in IL-6 
concentrations; 2) none of the predictors significantly explained any variance in TNF-α 
concentrations; 3) TNF-α explained 8.4% of the variance in HVLT-D scores; and 4) the 
cytokines did not explain any variance in FACT-Cog, HVLT-I, COWAT, or Trails A and 
B scores. For aim 3, hierarchical regression revealed that 1) stress (PSS), loneliness 
(UCLA-R) and sleep quality (PSQI) significantly explained 3.5% of the variance in 
perceived cognitive function (FACT-Cog); 2) sleep quality (PSQI), daytime sleepiness 
(ESS) and physical activity (IPAQ) explained 9.1% of the variance in delayed memory 
(HVLT-D); and 3) daytime sleepiness (ESS) and physical activity (IPAQ) explained an 
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additional 7.6% of the variance in executive function performance (Trails B). For aim 4, 
Loess regression was used to explore the complexities of the relationships between 
psychosocial and behavioral factors and cytokines and between the cytokines and 
cognitive measures. These regression lines revealed that linear relationships exist 
between the variables, but that these relationships change and vary across levels of the 
predictor variables. For aim 5, mediation analyses using ordinary least squares revealed 
that stress (PSS), loneliness (UCLA-R) and sleep quality (PSQI) influence perceived 
cognitive function (FACT-Cog) indirectly through feelings of anxiety and fatigue 
(PROMIS Scales). Finally for aim 6, correlational analyses among cytokines (IL-6, TNF- 
α) and individual and predictor variables (age, education, months since chemotherapy, 
BMI, PROMIS Scales, PSS, UCLA-R, PSQI, ESS, IPAQ) were re-examined separately 
in those BCS who were categorized as “impaired” and those that were “unimpaired”. 
These analyses revealed significant correlations between IL-6, TNF-α, FACT-Cog and 




















Chapter 5 presents a summary and discussion of the study findings including the 
sample description, research questions, broader research considerations, and study 
limitations. The chapter concludes with implications for healthcare practice, future 
research, and public health policy. 
STUDY SUMMARY 
One of the most distressing (Boykoff et al., 2009), feared (Ganz et al., 2013) and 
prevalent (Janelsins et al., 2014) long-term effects of treatment that breast cancer 
survivors (BCS) face are deficits in the cognitive domains of memory, attention, 
processing speed, and executive functioning (Janelsins et al., 2014; Wefel & Schagen, 
2012). Cancer-related cognitive impairments (CRCI) in survivors can impede daily 
functioning and quality of life (Duijits et al., 2014) and have a profound negative impact 
on social functioning, occupational performance, and overall well-being (Nelson & Suls, 
2013). The mechanisms underlying CRCI in BCS remain unclear, but it is most often 
attributed to the neurotoxic effects of chemotherapy (Janelsins et al., 2011; Saykin & 
Ahles, 2007; Vardy, 2009).  Research suggests that elevated inflammation may result in 
CRCI during and after chemotherapy (Cheung et al., 2014; Ganz et al., 2013; Janelsins et 
al., 2012; Kesler et al., 2013; Pomykala et al., 2013). Even though some treatment related 
factors have been identified as risk factors for both inflammation and CRCI in BCS 
(Janelsins et al., 2012; Kesler & Blaney, 2016; Tsvetkov, 2016), these factors are largely 
not modifiable or unavoidable when faced with a breast cancer diagnosis. It is possible 
that other factors may contribute to persistent CRCI either directly or indirectly (through 
inflammatory mediators) such as stress (Aggarwal et al., 2014; Carlson et al., 2007), 
physical activity (Beavers et al., 2010; Bherer, 2013), social isolation (Cacioppo & 
  
 




Hawkley, 2009; Yang et al., 2013), and sleep quality (Clevenger et al., 2012; Miller et al., 
2009; Sprod et al., 2010). These modifiable factors have been associated with 
inflammation and cognitive function in similar populations but have not been 
simultaneously evaluated in BCS.  
The purpose of this study was to identify modifiable psychosocial and behavioral 
factors that may contribute to cognitive function both directly and indirectly through 
inflammatory mediators in BCS (ages 21 to 65), six months to 10 years after 
chemotherapy. Kang et al.’s (2010) integrated biobehavioral model provided a 
framework for exploring the impact of modifiable factors on inflammation and cognitive 
function in BCS. After receiving approval from the University of Texas at Austin’s 
Institutional Review Board, 75 BCS ages 21 to 65 who were six months to 10 years post 
completion of chemotherapy, with a history of non-metastatic, non-inflammatory breast 
cancer were enrolled in the study.  
SAMPLE DESCRIPTION 
Demographic Characteristics 
The demographic characteristics of this sample are similar to other studies within 
the field of CRCI in BCS— 90% of participants were White, well educated, and 
financially stable (Ganz et al., 2013; Janelsins et al., 2016; Kesler et al., 2013). Although 
the incidence of breast cancer in the U.S. is higher in non-Hispanic White women (128 
per 100,000) than non-Hispanic Black women (124 per 100,000), Hispanic women (91 
per 100,000), and Asian women (88 per 100,000), Black women were underrepresented 
in this study (“Breast Cancer Facts”, 2015). Over 88% of the sample was working full or 
part time. More than a third were either divorced or never married, and the mean age of 
participants was 49 years, relatively younger than the median age for breast cancer 
occurrence in the U.S, 61 years of age  (“Breast Cancer Facts”, 2016). Seventy-two 
percent had gone through menopause, either naturally or secondary to BC treatment.  
  
 




Disease and Treatment Characteristics 
Over 70% of the sample had a history of invasive ductal carcinoma breast cancer 
and 84% had estrogen receptor positive breast cancer. The disease and treatment history 
of this sample is reflective of national statistics (“Breast Cancer Facts”, 2016) and similar 
research studies (Kesler et al., 2013; Lyon et al., 2016; Muscatell et al., 2016). The 
percentage of participants in this study that had human epithelial receptor 2 (HER2) 
positive type breast cancer, 37.5%, was much higher than the national average of 14%. 
HER2-positive breast cancers tend to grow faster and are more likely to spread and recur 
compared to HER2-negative breast cancers. This higher percentage is likely attributable 
to how young the sample was and the fact that HER2-positive type breast cancer is more 
common in younger breast cancer patients (Keegan et al., 2012).  
Almost every participant in this study underwent surgery as one of their treatment 
modalities (98.7%), which is slightly higher than national statistics — 94% of patients 
with stage I or II breast cancer undergo surgery, only 72% of those with stage III or IV 
do. Over half the sample had received anthracycline-based chemotherapy (56%), which is 
comparable to a recent nationwide longitudinal study of CRCI in BCS with over 500 
participants (Janelsins et al. 2016).  On average, women in this study completed 
chemotherapy treatment three years earlier, which is similar to several other studies 
(Kesler et al., 2013; Muscatell et al., 2016) conducted with BCS following chemotherapy. 
Like many studies of BCS, the demographic characteristics reflect a fairly homogenous 
sample (that is not as diverse as the population); however, the disease characteristics are 
more reflective of the general population. 
Cognitive Function 
Perceived Function. The FACT-Cog was used to operationalize perceived 
cognitive functioning in this study. Lower scores on this instrument indicate greater 
cognitive difficulties. FACT-Cog scores for participants in this sample were lower than 
  
 




those reported by other researchers (Cheung et al., 2015, Janelisins et al., 2016) but 
higher than another (Bray et al., 2016), suggesting that the perceived cognitive function 
of these women were comparable to other BCS. Janelsins et al. (2016) recently studied 
the FACT-Cog in a nationwide cohort of 581 participants, and reported much higher 
scores than this study, suggesting that women six-months post-chemotherapy reported 
better cognitive functioning than the women in this sample who averaged three years 
post-chemotherapy completion. Worse perceived cognitive functioning in this sample 
could be due to the fact that the cohort of women were younger than those in the 
aforementioned studies. Research supports that younger survivors report more severe 
emotional distress and decreased quality of life than older survivors (Howard-Anderson , 
Ganz, Bower, & Stanton, 2012), and that emotional factors such as depressive symptoms, 
anxiety, and fatigue are inter-related with perceived cognitive functioning (Pullens et al., 
2010, Jenkins et al., 2006; Jansen, 2013). The findings from this study are consistent with 
these reported associations. In fact, Janelsins et al. (2016) found that younger age was 
predictive of worse scores on the FACT-Cog Perceived Cognitive Impairments subscale. 
The same group of researchers found that anxiety and depression were predictive of 
worse scores on the FACT-Cog (Janelsins et al. 2016), much like the findings in this 
study that anxiety and fatigue (PROMIS scales) explained a large amount of variance in 
perceived cognitive functioning (FACT-Cog). It is also possible that survivors at six-
months are less aware of their cognitive functioning than survivors a few more years after 
chemotherapy completion because they are focusing on other, more prominent treatment-
related symptoms. 
Cognitive Performance. Participants’ neuropsychological (NP) scores, after age 
and educational adjustments, indicated average to above average performance. When 
scores on each NP test were dichotomized into impaired or unimpaired based on clinical 
guidelines, approximately 20% of the sample was considered to have at least one “mild 
  
 




cognitive impairment”. These findings are consistent with others in the literature that 
have reported 17-75% of study samples having mild cognitive impairment on at least one 
cognitive domain (Ahles et al., 2012; Wefel & Schagen, 2012). Although, the 
International Cancer and Cognition Task Force recommends the tests used in this study, 
they also recommend that researchers add other tests to their batteries (Wefel et al., 
2011). Therefore, it is possible that the small battery of NP tests used in this study did not 
capture all the impairments that may have been present in the sample and could explain 
why the percentage of women with a mild cognitive impairment fell on the lower end of 
the range reported in the literature. 
Perception and Performance Discrepancies. In this study, there were no 
relationships between the FACT-Cog and any of the NP test scores. These findings are 
consistent with the large body of research that has found weak relationships or no 
relationships between self-reports of cognitive function and NP measures (Andreotti et 
al., 2016; Hutchinson et al., 2012; Janelsins et al., 2014; Jim et al., 2012; Nelson et al., 
2012). Considering that the participants in this sample perceived that problems with their 
cognitive functioning did exist, yet only 20% of the sample displayed mild cognitive 
impairment according to the NP measures, this calls to question whether NP measures are 
adequately capturing cognitive function within this population. 
Even though NP tests are the gold standard for evaluating cognitive function, their 
sensitivity for detecting dysfunction or subtle changes in performance have been called 
into question for some time (Andreotti et al., 2016; Nelson et al., 2012). The test batteries 
that are used to measure cognitive function in cancer survivors were originally designed 
to detect impairments caused by overt brain trauma, brain lesions, or degenerative 
diseases that are typically accompanied by severe impairments. The psychometric 
limitations of these tests have been acknowledged in the field and include ceiling effects, 
restrictive range of scores, and low sensitivity in samples with average scores (Andreotti 
  
 




et al., 2016). Furthermore, scores on standardized tests can be impacted by many factors 
including true neurocognitive performance, practice effects, regression to the mean, 
random measurement error, and human error in testing and interpretation calling into 
question the validity and reliability of these tests in BCS populations (Andreotti et al., 
2016). Taken together, these findings suggest that the NP battery used in this study may 
not have been sensitive enough to capture all the cognitive impairments present in the 
sample. Furthermore, the lack of relationship between perceived cognitive functioning 
and cognitive performance suggest that these two measures may be capturing differing, 
or complementary, aspects of the complex phenomenon of cognition. 
Cytokines 
Normal human circulating IL-6 concentrations are approximately 1 pg/mL, with 
slight variations for women throughout their menstrual cycle (Angstwurm, Gartner, and 
Ziegler-Heitbrock, 1997). Researchers have reported that TNF-α concentrations for 
healthy, lean women average 2.2 pg/ml and for otherwise healthy but obese women 
average 8.6 pg/ml (Tsukui et al., 2000). This sample was slightly higher that normal for 
IL-6 concentrations (2.25 pg/ml ± 1.8) and within the lean to obese range (5.91 ± 1.40 
pg/ml) for healthy women when compared to the study by Tsukui et al. (2000). Both 
cytokines exhibited a narrow range and small standard deviations. 
RELATIONSHIPS AMONG STUDY VARIABLES 
Despite the logic and supporting evidence gathered from the literature and 
presented in Chapter 2, IL-6 and TNF-α did not have significant, linear relationships with 
any of the modifiable psychosocial or behavioral variables or with the cognitive 
outcomes evaluated within this sample as a whole. 
Psychosocial, Behavioral, and Inflammatory Factors 
Researchers have previously reported associations between IL-6 and TNF-α and 
stress (Antoni, 2013; Bower et al., 2007; Carlson et al., 2007; Crosswell et al., 2014; Han 
  
 




et al., 2015), loneliness (Jaremka et al., 2013; Marucha et al., 2005; Muscatell et al., 
2015), sleep quality (Clevenger et al., 2012; Sprod et al., 2010), and physical activity 
(Jones, 2013 et al.; Pakiz et al., 2011, Rogers, 2013). Unlike in previous studies (Jones, 
2013; Pakiz et al., 2011, Rogers et al., 2014 Clevenger et al., 2012; Sprod et al., 2010), 
we found scant significant relationships between the IL-6 and TNF-α and the behavioral 
factors. Linear, quadratic, and cubic functions also did not adequately explain the nature 
of the relationships between the psychosocial and behavioral factors and IL-6 and TNF-α. 
Rather, in this study, these relationships exhibited complex and non-linear patterns. The 
only significant relationship found between predictor variables and inflammatory 
cytokines was between BMI and TNF-α— suggesting that as BMI increases, levels of 
TNF-α also increase, but this relationship was small (r = .26). A small positive 
relationship approached significance between total minutes of physical activity (IPAQ 
Total Act) and IL-6 suggesting that more minutes of activity is associated with higher 
levels of IL-6.  This finding is inconsistent with the literature presented in Chapter 2 that 
supported a negative relationship between IL-6 and physical activity, but could be 
explained by the fact that IL-6 has both pro and anti-inflammatory properties (Hunter & 
Jones, 2015; Kesler et al., 2013).  
It is possible that these non-linear patterns of relationships are attributable to 
methodological problems in this study, or that the true nature of these relationships are in 
fact complex, and non-linear. First, the study was not powered based on the associations 
between the predictor variables and cytokines. Other possible explanations are that the 
measurement error associated with self-report measures (PSS, UCLA-R, IPAQ, PSQI, 
ESS) was too large or that these measures did not adequately measure the phenomena of 
interest— perceived stress, perceived social isolation, physical activity, and sleep quality.  
Using the IPAQ to quantify physical activity proved to be problematic and the instrument 
did not “behave” well psychometrically. It was both difficult to administer and for 
  
 




participants to complete. Perhaps other measures such as the global physical activity 
questionnaire would more adequately capture physical activity (Hartman et al., 2015; 
Marinac et al., 2015).  
It is possible that the amount of time that passed between when participants 
completed the self-report instruments and when they had their blood drawn could explain 
the lack of relationships. The number of days between survey completion and in-person 
appointments ranged from 0 to 22, but the average amount of time was 2.75 days, and the 
median was 1 day. The relationships between number of days between survey completion 
and in person appointment and the cytokine concentrations were evaluated and no 
significant relationships were found.  
It is also plausible that the relationships between the predictor variables and 
cytokines are in fact non-linear, that serum cytokine levels are too unstable, or that the 
cytokine concentrations were influenced by factors not measured in this study. We know 
that the inflammatory cascade in the human body is incredibly complex.  In fact, some 
have proposed that Chaos Theory is the best model for understanding this system 
(Callard, George, & Stark, 1999). IL-6 and TNF-α are involved in many aspects of the 
innate and adaptive immune systems, and their concentrations influenced by many 
upstream and downstream factors such as other chemokines, circulating hormones, 
circadian rhythm, and receptor inhibition (Hunter & Jones, 2015).  These factors were 
taken into account when designing this study and procedures put into place to attempt to 
control for them. For example, all blood draws were completed on participants within 4 
hours of them waking; participants taking any medications that would interfere with their 
inflammatory response (e.g. oral steroids, metformin) were excluded; and participants 
that had any comorbidities that are known to impact inflammation (e.g. autoimmune 
conditions, diabetes mellitus, unmanaged sleep apnea) were excluded. To ensure that 
time since waking in the morning did not influence cytokine concentrations, Pearson’s 
  
 




correlations were run between number of hours after waking in the morning and 
cytokines concentration, and no significant relationships were found. Recent research 
suggests that peripheral cytokines are “noisy” measures of inflammation, and genetic 
markers of pro-inflammatory expression, such as NF-kB, might be more robust and stable 
measures of inflammatory dysregulation (Creswell et al., 2012). It could be that genetic 
markers of inflammation, such as single nucleotide polymorphisms (SNPs), may be more 
stable over time, less sensitive to influence, and may be more robust biobehavioral 
measures (Doong et al., 2015). Genetic markers of inflammation should be considered as 
biomarkers in future studies incorporating inflammation in the conceptual model. 
Inflammatory Factors and Cognitive Outcomes 
No significant correlations were found between the cytokines (IL-6, TNF-α), 
perceived cognitive functioning (FACT-Cog total and subscales), and cognitive 
performance (HVLT-I scores, HVLT-D scores, COWAT scores, Trails A scores, Trails B 
scores). Scatterplots between all of these relationships revealed non-linear relationships 
even after data were transformed and variables median centered. These results are 
inconsistent with the literature supporting relationships between cytokines and cognitive 
outcomes in BCS (Cheung et al., 2015; Ganz et al., 2013; Kesler et al., 2013; Pomykala 
et al., 2013), but do support some findings from other studies (Booth et al., 2006; 
Janelsins et al., 2012). The lack of relationships between these specific cytokines and 
cognitive outcomes could be attributed to several factors— too much variability in length 
of time from chemotherapy completion for participants, lack of variability in cognitive 
performance measures, or not enough variability in cytokine concentration levels as 
discussed above.    
This study included BCS from six months to 10 years after chemotherapy 
completion time, which bolsters external validity but hinders internal validity. It is 
possible that inflammation plays a role in cognitive functioning, but only at certain time 
  
 




points throughout the survivorship trajectory.  In one study, researchers have reported 
that six different cytokines varied in concentrations and associations with measures of 
cognitive performance in BCS as a function of time throughout a two-year period of time 
(Lyon et al., 2016). They specifically reported changes with IL-6 while participants were 
undergoing chemotherapy, and up to one year following treatment. Therefore, the PI ran 
an ANCOVA to look at group differences in cytokine concentrations by time since 
chemotherapy with IL-6 as dependent variable, then with TNF-α as the dependent 
variable, controlling for cancer stage.  The five groups were Group One (six months to 
one year, n=13), Group Two (one to two years, n=14), Group Three (two to four years, 
n=23), Group Four (four to six years, n=10), and Group Five (six to 10 years, n=6). No 
significant group differences were found in cytokine concentrations. It is unlikely that 
time since chemotherapy can explain the lack of association between cytokines and 
cognitive performance in this sample.  
It is also plausible that the study was underpowered to detect existing 
relationships.  The original power analysis a medium-large effect size with f2=0.21, two-
tailed α = .05, power of .80, and five predictors yielded 68 participants. Blood could only 
be obtained from 66 of the participants resulting in only 66 participants included in 
analyses for aims 1 & 2. Although the study was underpowered, it is unlikely that two 
additional participants would have impacted the magnitude and significance of the 
Pearson’s correlations reported in Table. 4.4, which ranged from .04 to .17.  
The findings could also be explained by lack of variability in neurocognitive 
functioning within this group of women who overall exhibited average to above-average 
performance (as seen in the box plots in Figures 4.3-4.5). Even though cognitive 
performance was fairly homogenous in the sample, anecdotally, the vast majority of the 
sample reported cognitive problems to the PI during the data collection meetings. It is 
possible that the sensitivity of IL-6 and TNF-α to cognitive performance is only 
  
 




detectible when there is a larger range of performance scores that include lower 
performance scores (Patel et al., 2015). Similarly, there was not a large range in cytokine 
concentrations themselves, and it is possible that there was not enough variability to 
detect linear relationships. The levels of IL-6 were on average 2.25 pg/ml (SD 1.80). 
These levels were closer to those in the control group than to the breast cancer patient 
group in another study (1.84, SD 1.21; Patel et al., 2015). These researchers reported 
significant relationships between cytokines (IL-6 and sTNF-RII) and memory 
performance in the breast cancer group, which had higher levels and more variability than 
the control group (Patel et al., 2015). It is possible that a linear relationship exists 
between the cytokines and cognitive performance at higher concentrations of IL-6 and 
TNF-α that were not captured in this sample.  Furthermore, this study only evaluated a 
limited number of both cognitive tests and cytokines, and a more comprehensive 
evaluation, including more tests and larger panels of cytokines might be needed in order 
to understand the mechanistic role that inflammation plays in the cognitive functioning of 
BCS.  
Psychosocial and Behavioral Predictors of Cognitive Outcomes 
Several overall patterns of correlations were identified in this study between 
individual factors, psychosocial and behavioral factors, perceived cognitive function, and 
cognitive performance. As expected, age and years of education were significantly 
related to cognitive performance measures, but not perceived cognitive function. Only 
BMI was significantly related to perceived cognitive function, which is inconsistent with 
other reports of BMI having no relationship with FACT-Cog scores in BCS (Myers et al. 
2017). Moderate to large relationships were found between all of the psychosocial and 
sleep variables and perceived cognitive function, suggesting that higher levels of 
emotional distress (PROMIS Anxiety, PROMIS Depression), fatigue (PROMIS Fatigue), 
stress (PSS) and loneliness (UCLA-R) are related to worse perceived cognitive 
  
 




functioning (FACT-Cog). These findings are consistent with the literature (Ottati et al., 
2013; Li et al., 2014; Mehlsen et al., 2009; Myers et al., 2015; Jaremka et al., 2014). 
Surprisingly, there were no significant relationships between physical activity measures 
and perceived cognitive functioning, which is contrary to recent findings that self-
reported exercise was significantly related to FACT-Cog (Myers et al., 2017). This 
inconsistency may be attributed to how Myers et al. (2017) measured self-reported 
exercise—one question asking participants how often they exercised in the past month 
with four answer choices. 
Only two significant relationships were found between the psychosocial and 
behavioral factors and the cognitive performance measures in this study, suggesting that 
as sleep quality worsened (PSQI) so did delayed memory performance (HVLT-D), and as 
number of active minutes per week increases (IPAQ Act Min), executive functioning 
worsens (Trails B), an unexpected finding.  These findings are contrary to other studies 
that found associations between self-reported exercise and cognitive performance 
measures (Hartman et al., 2015; Pradhan et al., 2015). These differences in findings could 
be attributed to the use of a different instruments to capture physical activity and the 
other studies were likely powered adequately to detect the relationships between lifestyle 
factors and cognitive performance (Hartman et al., 2015; Pradhan et al., 2015). 
AIM 1: TO ASSESS THE IMPACT OF PSYCHOSOCIAL (STRESS, SOCIAL ISOLATION) AND 
BEHAVIORAL (PHYSICAL ACTIVITY, SLEEP QUALITY) FACTORS ON INFLAMMATORY MARKERS 
(IL-6, TNF-Α) AFTER CONTROLLING FOR SELECTED INDIVIDUAL FACTORS. 
This study provides a unique contribution to the literature by illustrating the non-
linear relationships between the selected psychosocial and behavioral variables and 
cytokines. It was determined that the assumption of linearity was violated in the 
preliminary analyses, therefore curvilinear (cubic) simple regression models were used to 
determine the variance of cytokines (IL-6 and TNF-α) explained by the predictor 
194 
variables. No studies were identified in the literature describing curvilinear relationships 
between the psychosocial and behavioral variables in this study and either IL-6 or TNF- 
α. Of all the predictors, only daytime sleepiness (ESS) was a significant predictor of IL-6 
concentrations. The cubic regression line in this model had two “bends” and explained 
11% of the variance. It is well established that daytime sleepiness associated with sleep 
disorders like sleep apnea and narcolepsy is associated with higher levels of IL-6, but the 
link has not yet been made in BCS.  
No relationships were found between IL-6 and loneliness which is inconsistent 
with the research from Hughes et al. (2014), who reported that loneliness predicted IL-6 
concentrations in BCS using a standard linear regression (b = −.009, t(87) = −2.12,  p = 
.037,  R2 change = .02).  This discrepancy could be explained by their large sample 
(N=164; Hughes et al., 2014). Our findings are consistent with Muscatell et al. (2016) 
that reported no significant relationships between loneliness and IL-6 (r = -.37, p = .18, 
n=15). No significant predictors were found using the curvilinear (cubic) simple 
regression models with TNF- α as the dependent variable.  
AIM 2: TO ASSESS THE IMPACT OF INFLAMMATORY MARKERS (IL-6, TNF-Α, IL-6* 
TNF-Α) ON COGNITIVE FUNCTION (COGNITIVE PERFORMANCE, PERCEIVED COGNITIVE 
FUNCTIONING) AFTER CONTROLLING FOR SELECTED INDIVIDUAL FACTORS. 
The findings related to this aim are contrary to the growing body of research 
supporting linear relationships between cytokines and cognitive function in BCS who 
have undergone chemotherapy (Ganz et al., 2013; Janelsins et al., 2012; Kesler et al., 
2013; Patel et al., 2015; Muscatell et al., 2016). It was determined that the assumption of 
linearity was violated between cytokine concentrations and cognitive measures in the 
preliminary analyses; therefore, curvilinear (cubic) simple regression models were used 
to determine the variance in cognitive outcomes that was explained by the cytokines. The 
PI found no reports in the literature of curvilinear modeling between these variables in 
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BCS populations. These findings provide unique knowledge about the complex 
relationships that exist between IL-6, TNF-α and cognitive measures in BCS. Only one 
significant cubic predictor was identified in all of these regression models. TNF-α 
significantly explained 2.7% variance in delayed memory performance (HVLT-D). These 
findings are inconsistent with a recent study by Lyon et al. (2016) that described linear 
relationships between cytokines and cognitive performance across time starting before 
chemotherapy and continuing two years after chemotherapy ended. These researchers 
report that the relationships between cytokine concentrations and cognitive measures 
varied across time, suggesting that the relationships between IL-6, TNF-α, and cognitive 
performance could be curvilinear when evaluated cross-sectionally in a group of BCS 
from six months to 10 years following chemotherapy (Lyon et al., 2016).  
AIM 3: TO EXPLORE DIRECT AND INDIRECT EFFECTS (THROUGH INFLAMMATORY 
MEDIATORS IL-6 AND TNF-Α) OF PSYCHOSOCIAL (STRESS, SOCIAL ISOLATION) AND 
BEHAVIORAL (PHYSICAL ACTIVITY, SLEEP QUALITY) FACTORS ON COGNITIVE FUNCTION 
(MEMORY, ATTENTION, PROCESSING SPEED, EXECUTIVE FUNCTION PERFORMANCE, 
PERCEIVED COGNITIVE FUNCTION) AFTER CONTROLLING FOR SELECTED INDIVIDUAL 
FACTORS.  
The findings related to this aim indicated that perceived cognitive function is not 
only explained by emotional distress (Asher, 2011; Poppelreuter et al., 2004; Pullens, De 
Vries, & Roukema, 2010) and fatigue (Bower & Lamkin, 2013; Cheung et al., 2013; 
Hodgson et al., 2013; Hutchinson, et al., 2012), but that stress, loneliness, and sleep 
quality can also influence perceived cognitive functioning in BCS. The analyses for aim 3 
focused on exploring the direct effects of psychosocial and behavioral predictors on 
cognitive function because the relationships between the majority of the predictors and 
cognitive outcomes were linear. The findings from the hierarchical regression analyses 
suggest that anxiety (PROMIS Anxiety) and fatigue (PROMIS Fatigue) but not 
  
 




depressive symptoms (PROMIS Depression), are related to perceived cognitive function 
(FACT-Cog).  These findings support those reported by Li et al. (2015) that hyper-
arousal and fatigue, together explained 26% of the variance in perceived cognitive 
impairments in BCS. The findings are consistent with the literature linking self-report 
emotional and psychosocial measures with self-report measures of cognitive function in 
BCS (Cheung et al., 2015; Janelsins et al., 2016; Myers et al., 2015; Myers et al., 2017). 
Controlling for age and years of education, daytime sleepiness (ESS), perceived 
sleep quality (PSQI), and minutes of physical inactivity (IPAQ Min Sit) significantly 
explained 9.1% of the variance in delayed verbal memory performance (HVLT-D). It 
appears that perceived sleep quality (PSQI scores) accounted for the majority of this 
variance explained. Links have been made between objectively measured sleep in older 
adults but not between perceived sleep quality (PSQI scores) and HVLT scores (Cavuoto, 
2016), suggesting that objectively and subjectively measures sleep quality are measuring 
different aspects of sleep quality. These findings support those by other researchers that 
describe inconsistent relationships between sleep parameters and cognitive outcomes 
(Brewster et al., 2015). When controlling for age, use of a sleep aid (PSQI Sleep aid 
Subscale) and minutes of physical activity (IPAQ Min Act) significantly explained 7.6% 
of the variance in the measure of executive functioning (Trails B scores) and it appears 
that minutes of physical activity (IPAQ Min Act) accounted for the majority of this 
explained variance. These results support the findings of other studies (Miki et al., 2014; 
Pradhan et al., 2014; Pradhan et al., 2016) and extend the findings of Crowgey et al. 
(2014) who reported significant relationships between self-reported exercise and verbal 
memory. Additionally, these study findings could be spurious due to multiple 
comparisons and uncorrected p values in the analyses. 
  
 





The findings from aims 1 and 2 suggested that the associations among the 
psychosocial, behavioral factors, and cytokines, and between the cytokines and cognitive 
outcomes were not linear, quadratic, or cubic. Therefore, non-parametric procedures were 
utilized to adequately describe the extant relationships among these variables in aim 4. 
Furthermore the results from aim 3 showed significant inter-correlations between the 
psychosocial variables, sleep quality, and perceived cognitive function, so the direct and 
indirect effects of psychosocial factors (stress, perceived social isolation, emotional 
distress, and fatigue) and sleep on perceived cognitive function were explored. Finally, 
research suggests that relationships between peripheral cytokines and behavioral factors 
may only emerge within populations in pathological states; therefore, the patterns of 
correlations between individual factors, predictor variables, and cytokines were explored 
in participants categorized as cognitively “impaired” and those categorized as 
“unimpaired” in aim 6. 
Aim 4: To describe the nature of the relationships between psychosocial and 
behavioral factors and cytokines, and between cytokines and cognitive outcomes. 
Loess modeling techniques were used to extend understanding of the complex 
relationships that exist between psychosocial, behavioral, and cognitive variables and IL-
6 and TNF-α. As part of the analyses for aims 1 and 2, cubic functions were used to fit 
the data with cytokines either as the predictor or the dependent variables.  These models 
fit the data better than linear and quadratic models, but the curvilinear regression analyses 
proved that they were still not “great models” to explain the true nature of the 
relationships. Loess modeling was used to explore the complexities of these relationships 
and illustrated many bends in the regression lines that changed and varied across levels of 
the predictor variables. Similarly, when the cognitive outcomes were regressed on the 
cytokine variables using Loess lines of best fit, these graphs showed linear relationships 
  
 




do exist between the variables but only at certain levels of cytokines. These relationships 
appear very steep and strong at certain levels of the cytokine variables. Only graphs 
between IL-6 and immediate verbal memory (HVLT-I) and TNF-α and executive 
functioning (Trails A and B) were essentially straight across all levels of the cytokines 
suggesting either too much “noise” error in the data collected, or no relationship exists 
between the variables. To the PI’s knowledge, this is the first study to analyze and report 
Loess regression plots describing the complex nature of relationships between cytokines 
and psychosocial, behavioral, and cognitive variables in BCS. 
Aim 5: To explore direct and indirect effects of psychosocial factors (stress, 
perceived social isolation, emotional distress, and fatigue), and sleep quality on perceived 
cognitive function. 
The results of the study support that feeling more stress, social isolation, and 
experiencing worse sleep quality may result in poorer perception of cognitive functioning 
in BCS and that these effects are likely mediated by feelings of anxiety and fatigue. 
Pearson’s correlation analyses showed moderate to large correlations between the 
psychosocial variables (PROMIS Scales, PSS, UCLA-R), sleep quality (PSQI) and 
perceived cognitive function (FACT-Cog). There were significant relationships between 
the psychosocial and sleep variables as well. Therefore, a two-step hierarchical regression 
analysis was run and the results of this analysis revealed that only anxiety (PROMIS 
Anxiety) and fatigue (PROMIS Fatigue) remained significant predictors of perceived 
cognitive function (FACT-Cog), but that perceived stress (PSS) approached significance. 
These results suggested that perceived stress (PSS), loneliness (UCLA-R), and sleep 
(PSQI) impact perceived cognitive function (FACT-Cog) through indirect pathways of 
anxiety (PROMIS Anxiety) and fatigue (PROMIS Fatigue); therefore, a mediation 
analysis was conducted using ordinary least squares to explore the pathway. The findings 
of the mediation analysis are consistent with those found in the literature linking 
  
 




psychosocial and emotional factors to perceived cognitive function and extend our 
knowledge of how these factors may impact perceived cognitive function. Specifically, 1) 
perceived stress (PSS) may impact perceived cognitive function (FACT-Cog) both 
directly and indirectly through perceived anxiety and feelings of fatigue (PROMIS 
Scales); 2) loneliness (UCLA-R) may only indirectly effect perceived cognitive function 
(FACT-Cog) through anxiety and fatigue (PROMIS Scales), and 3) sleep quality (PSQI) 
may only indirectly effect perceived cognitive function (FACT-Cog) through anxiety and 
fatigue (PROMIS Scales). There is scant research on the nuances of how emotional 
distress, stress, loneliness, and sleep quality are related to perceived cognitive function. 
Our findings are consistent with Reid-Arndt (2011) who reported that helplessness 
mediates the relationship between self-reported stress and cognitive functioning (p<.01) 
in BCS.  
Aim 6: To explore patterns of relationships between cytokines (IL-6, TNF- α) and 
cognitive measures (FACT-Cog, HVLT-I, HVLT-D, COWAT, Trails A, Trails B) in BCS 
classified with “mild cognitive impairment” and those classified as “unimpaired”. 
The range for healthy levels of cytokines is very narrow, so it is possible that the 
relationships between cytokines and cognitive function are only detectable when 
cytokines are outside of this window, in pathological states (i.e. cognitively impaired 
individuals), and the range is wider. Similar patterns of relationships have been reported 
in the field of persistent fatigue in BCS— significant relationships between peripheral 
cytokines and behavioral factors in fatigued BCS but not in non-fatigued survivors 
(Bower & Lamkin, 2013). To explore whether patterns of correlations differed by 
cognitive impairment status, the sample was divided into impaired (n=13, -1.5 SD below 
the mean on at least one NP test) and unimpaired individuals (n=53).  
The patterns of correlations were in fact different between groups. In the impaired 
group, significant large negative relationships were observed between perceived 
  
 




cognitive function (FACT-Cog) and both IL-6 and the interaction between IL-6 and TNF-
α, and in the unimpaired group, a moderate positive relationship was observed between 
TNF-α and perceived cognitive function (FACT-Cog). In the impaired group moderate 
positive relationships were observed between the measures of attention and executive 
function performance (Trails A and B) and the interaction of IL-6 and TNF-α and 
between just the Trails B scores and TNF-α. No significant relationships were found 
between the cytokines and NP test scores in the unimpaired group.  
These findings suggest that there may be significant linear relationships between 
perceived cognitive function (FACT-Cog), executive functioning performance (Trails A 
and B), and the cytokines (IL-6 and TNF-α) in those BCS who have mild cognitive 
impairment. More specifically, as levels of IL-6 increase, perceived cognitive functioning 
(FACT-Cog) worsens; as levels of TNF-α increase, executive functioning worsens (Trails 
B); and that the interaction between IL-6 and TNF-α (but not individual concentrations of 
either cytokine) is related to attention (Trails A). Interestingly, the only significant 
relationship found in the unimpaired group was a moderate positive relationship between 
perceived cognitive function (FACT-Cog) and TNF-α, which was in the opposite 
direction of the relationships in the impaired group.  
Differing patterns of correlations were also observed in the impaired and 
unimpaired groups between the cytokines (IL-6, TNF-α) and individual and predictor 
variables (age, education, months since chemotherapy, BMI, PROMIS Scales, PSS, 
UCLA-R, PSQI, ESS, IPAQ). A significant positive relationship was found between BMI 
and IL-6 and the interaction term in the impaired group, suggesting that as BMI increases 
so does IL-6 in this group. The opposite pattern was observed in the unimpaired group 
suggesting that as BMI decreases in the unimpaired group, IL-6 levels increase. For the 
predictor variables, a large positive relationship was observed between daytime 
sleepiness (ESS) and IL-6 and the interaction term suggesting that as daytime sleepiness 
  
 




worsens, IL-6 levels increase in the impaired group. Again, the opposite pattern was 
observed in the unimpaired group suggesting that as daytime sleepiness worsens, IL-6 
levels decrease.  
Taken together, these exploratory findings suggest that the patterns of 
relationships between cytokines, daytime sleepiness, BMI, perceived cognitive function, 
and executive functioning are different for those BCS with cognitive impairments than 
for those BCS without cognitive impairments. These exploratory correlation analyses in 
the impaired and unimpaired groups help explain the curvilinear relationships found in 
the Loess regression modeling. Importantly, the sample of impaired BCS was very small, 
requiring non-parametric correlation analyses (n=13) and the findings need to be 
replicated in a larger sample of BCS with “mild cognitive impairment” in order to draw 
conclusions. Additionally, the p values in these analyses were not adjusted for multiple 
comparisons, therefore, type I error was inflated and it is possible that the significant 
correlations are due to chance.  
CONCEPTUAL MODEL 
The biobehavioral model (Kang et al., 2010), used in this study provided a useful 
conceptual approach to understanding how psychosocial, behavioral, and biological 
factors are related to and influence CRCI in BCS following chemotherapy. In the present 
study, it was theorized that psychosocial, behavioral, and biological factors would 
influence CRCI through direct and indirect pathways. Kang et al. (2010) explain that 
these pathways are complex, and may be bi-directional. Using this conceptual model shed 
light on how psychosocial predictors impact perceived cognitive function but not 
cognitive performance.  
Considering inflammation was a central factor in the conceptual model, and that 
the pro-inflammatory cytokines chosen to test in this model did not explain variability in 
BCS’ cognitive function, it calls to question whether the model should be refined. 
  
 




Perceived stress, emotional distress, fatigue, loneliness, and sleep quality did in fact 
predict perceived cognitive function, and it is possible that other biological measures of 
inflammation might explain how the modifiable factors in this study influence CRCI 
(Wang et al., 2015; Wardill et al., 2016). In this study, cognitive function was 
operationalized in two ways— perceived cognitive functioning and neuropsychological 
performance. This model proved useful in understanding the nuances of perceived 
cognitive function but not cognitive performance. This supports the notion that 
perception and performance are different phenomena and that different mechanisms may 
be responsible for the development and persistence of each. 
In future studies, the model could be refined in a way to better operationalize the 
“biological factor” of inflammatory dysregulation.  The decision to use these two pro-
inflammatory cytokines, IL-6 and TNF-α, was based on the most recent findings at the 
time of the study inception and design (Ganz et al., 2013, Pomykala et al., 2013, Kesler et 
al., 2013, Cheung et al., 2014, Janelsins et al., 2012). In the last three years, the science 
has evolved, and supports the likelihood that other cytokines play a role in the 
dysregulation (Lyon et al., 2016; Wang et al., 2015; Wardill et al., 2016) and that 
peripheral cytokine data is in general is “noisy” and unreliable (Creswell et al., 2012). 
Although IL-6 has been discussed as a “prototypical pro-inflammatory” cytokine in BCS 
research, Lyon et al. (2016) suggest that other cytokines “may be key to understanding 
the neuro-inflammatory connection in BCS”, such as IL-17 or IL-10 that correlated with 
several cognitive domains at various times in the treatment and recovery trajectory in 
their study (p 79). It is possible that cytokines are not the ideal measure for 
“inflammatory dysregulation” and more stable biomarkers such as genomic markers of 
inflammatory up-regulation, such as NF-kB, should be used to capture the phenomena. 
Another group of researchers recently reported that the SNP, IL1R1rs2287047, was 
significant predictor of perceived cognitive function in BCS (Myers et al., 2017). 
  
 





There were limitations to this study. First, the findings can only be generalized to 
women with a history of non-metastatic, non-inflammatory breast cancer who received 
chemotherapy as part of their treatment regimen.  Even though efforts were made to 
recruit a diverse sample for the study, the majority of the sample was White, well 
educated and financially stable; therefore, the external validity is limited 
demographically. Second, as in all studies, the measures in this study were subject to bias 
and error. The majority of the instruments in this study were self-report and that data 
could have been influenced by recall bias (participants may have difficulty remembering 
or inaccurately report data). The neurocognitive tests used in this study could have been 
impacted by ceiling effects, regression to the mean, random measurement error, and 
human error in testing and interpretation, calling into question their validity and 
reliability (Andreotti et al., 2016). Furthermore, only four neuropsychological tests were 
administered, limiting the assessment of “cognitive performance”. The study did not have 
either a non-chemotherapy or non-breast cancer comparison group, which limits the 
interpretations of the findings. The study was limited by sampling bias because only 
motivated women willing to travel for the study were included, the findings cannot 
generalize to women who could not attend or did not have the resources to participate. 
Finally, this study was cross-sectional; therefore, causality cannot be assumed. 
The biomarkers chosen for this study may not have adequately captured the 
phenomena of inflammatory dysregulation related to CRCI in BCS. Many factors could 
have increased the “noise” of this data including difficulty obtaining blood samples (i.e. 
breast cancer survivors are typically limited to blood draws in one arm secondary to 
lymph node removal, “chemo-veins”), damage to the samples during processing, 
potential damage to materials used for blood sampling, human error in running ELISA 
analysis, and cytometry machine error.  The cytokine panel could either be expanded to 
  
 




include many circulating cytokines or replaced by a genetic marker of pro-inflammatory 
expression. The surveys could be administered during the in-person appointments to limit 
the number of “life events” that could occur between the survey and the other data 
collected. Also, a biomarker obtained from saliva measurement might be better choice 
since saliva samples are easier to collect, and could be collected from participants living 
in other parts of the country through the mail. A clinical marker of peripheral 
inflammation such as C-reactive protein could be included since this measure is already 
monitored regularly in oncology settings.  
The following methodological changes could be made to address these 
limitations. To address the limitations in measurement, a different measure of physical 
activity could be used such as the global physical activity questionnaire (Hartman et al., 
2015) or accelerometers (Marinac et al., 2016). The cognitive test battery could be 
modified to use the Rey Auditory Verbal Learning Test (RAVLT; Schmidt, 2012) instead 
of the HVLT-R and the Comprehensive Trail Making Test (CTMT; Moses, 2004) instead 
of the Trails A & B, both of which require more cognitive demands and would likely 
result in a greater range and variability in performance. Alternatively, neuroimaging 
could be used in place of NP testing to quantify cognitive performance. Since different 
patterns of correlations were seen in those BCS who were classified with mild cognitive 
impairment than those classified as unimpaired, a larger and more homogenous group of 
impaired BCS should be recruited to further evaluate these relationships. This could be 
accomplished by adding a NP test to the prescreening tool. A larger more homogenous 
sample of BCS who have mild cognitive impairment would allow for a better a more 
comprehensive understanding of the relationships among the predictor variables, 
cytokines, and cognitive outcomes in this population. 
  
 




IMPLICATIONS FOR CLINICAL PRACTICE, FUTURE RESEARCH, AND PUBLIC POLICY  
Clinical Practice 
Some BCS perceive cognitive dysfunction for up to 10 years following the end of 
their chemotherapy.  Even though in this study the majority of the survivors’ cognitive 
performance on NP tests fell into the average to above average range, approximately 20% 
were classified with “mild cognitive impairment” on at least one NP test. The study 
findings suggest that this group as a whole still perceive problems with their cognitive 
functioning when asked about their day to day lives, and that these perceptions are 
unrelated to their performance on NP tests. Healthcare providers are in a position to 
support BCS after treatment is over. Providers must acknowledge survivors’ concerns 
and assess cognitive functioning throughout the cancer trajectory. It is essential that 
providers acknowledge that cancer-related cognitive changes may be influenced by many 
factors that extend far beyond receiving chemotherapy. The findings from this study 
highlight the importance of assessing and managing emotional distress, psychosocial 
needs, and sleep quality throughout survivorship. Patient reported outcomes are gaining 
traction in both clinical and research settings.  The PROMIS scales are available free of 
cost and provide psychometrically sound tools for clinicians and researchers to use to 
measure symptoms such as anxiety, depression, fatigue, perceived cognitive impairments, 
and sleep quality. Most of the scales are eight items or less and are easy to administer and 
score (http://www.healthmeasures.net/resource-center/nih-toolbox-ipad-app). 
Treatment history alone did not explain variations in cognitive functioning in this 
group of women, suggesting that other factors besides treatment may be influencing 
cognitive functioning. Healthcare providers must look beyond cancer treatments and 
consider lifestyle modifications when assessing and managing cognitive dysfunction in 
survivors including improving sleep quality, managing stress, increasing physical 
activity. When providers are considering recommendations for patients reporting 
  
 




cognitive problems, it is important to consider that psychosocial interventions may be 
beneficial for improving perceived cognitive functioning in addition to those targeted at 
increasing physical activity or teaching compensatory strategies. If time is a limited 
resource for a particular patient, suggesting stress management and relaxation therapies 
might be the best choice for patients complaining of CRCI, based on the findings from 
this study. Mind-body therapies may be appropriate interventions for survivors 
experiencing emotional distress, stress, or cognitive dysfunction especially if 
inflammatory mechanisms are playing a role in symptomology. Recent research suggests 
that mind-body therapies may improve regulation of inflammatory pathways in the body 
(Morgan et al. 2014; Bower & Irwin, 2016). Bower et al. (2015) conducted a pilot study 
with premenopausal BCS utilizing a mindfulness intervention and reported significant 
reductions in perceived stress, pro-inflammatory gene expression, and inflammatory 
signaling.  
Future Research 
The findings from this study prompt further inquiry in the field of CRCI. 
Directions for future research include: 
1. The study findings support that more stress, social isolation, and sleep quality 
impact perceived cognitive functioning in BCS. Importantly, the constructs of stress and 
social isolation are very complex and a more in depth evaluation of the concepts within 
each of these constructs is needed. For example, when considering stress, one should also 
consider the concept of “coping”.  Researchers have started to look at the impact of stress 
and coping in BCS (Reid-Arndt & Cox, 2012) and have started to theorize the role of 
self-regulatory capacity in regards to stress in BCS (Arndt et al., 2014). Reid-Arndt & 
Cox (2012) reported that passive coping styles mediated the negative effects of perceived 
stress on cognitive functioning in their sample.  Their sample was small (N=36) and more 
research is needed to replicate these findings in other samples and to understand how 
  
 




emotional factors fit into the model of stress, coping, and perceived cognitive 
functioning.  
Similarly, loneliness should not be considered in conceptual isolation. Other 
concepts such as social support, social environments (Cacioppo & Hawkley, 2009), and 
personality traits should be considered. Weiss (1973) theorized that the experience of 
loneliness involves both social and emotional components. The results from this study 
support Weiss’ theory in that loneliness impacted cognitive function indirectly through 
emotional feelings of anxiety and fatigue. Hawkley and Cacioppo (2010) proposed a 
Loneliness Model that explains how loneliness can impact cognitive functioning starting 
with feelings of being unsafe that result in a hyper-vigilance and subsequently result in 
cognitive biases that lead to negative social experiences. This model has yet to be applied 
to the study of CRCI in BCS and could be useful in future studies aimed to better 
understand the mechanisms of loneliness and cognitive function in BCS.  
2. The results from this study suggest that the NP tests recommended to use in this 
population may not be sensitive enough to detect the cognitive dysfunctions that BCS 
experience (Wefel & Vardy, 2011). Considering that only 20% of the participants 
exhibited mild cognitive impairment (-1.5 SD or more below the age and education 
adjusted mean scores) on one or more of the cognitive tests, calls to question whether the 
NP tests recommended by the ICCTF in 2011 to evaluate BCS’ cognitive performance 
are sufficient measures for quantification of CRCI (Wefel & Vardy, 2011). Perhaps other 
NP tests would be more sensitive to the cognitive deficits in this population such as the 
Comprehensive Trail Making Test (CTMT; Moses, 2004) and the Rey Auditory Verbal 
Learning Test (RAVLT; Schmidt, 2012).   The Trails A and Trails B that were used in 
this study are part of the CTMT but the CTMT has three additional tests that are more 
complex and require more executive resources including executive attention and control 
and working memory. The HVLT-R used in this study is similar to the RAVLT, but the 
  
 




RAVLT is more complex as there are 16 words rather than 12 to recall over multiple 
trials, challenging short and long-term memory more than the HVLT-R. Research also 
supports that brain imaging data is more sensitive to structural and functional changes 
reported by BCS, and is more often associated with perceived functioning (Kesler et al., 
2017, Muscatell et al., 2016); therefore, neuroimaging may be a preferred way of 
objectively quantifying CRCI in BCS. 
3. The follow up analyses looking at the correlations separately in the impaired 
group of BCS and those that were unimpaired indicated that the relationships between 
cytokines and cognitive measures are very different. Future research should evaluate the 
variables in this study using the biobehavioral model (Kang et al., 2010) in sample of 
BCS with more serious cognitive impairment to better understand how these variables are 
related to and interact to affect cognitive performance in BCS. 
4. There is a need to better understand the impact of hormonal therapies on 
cognitive function in survivors following chemotherapy because the majority of survivors 
will be on these treatments for 5-10 years. A link has already been made between 
tamoxifen use and worse cognitive functioning in BCS (Janelsins et al., 2012; Jim et al., 
2012; Schilder et al., 2009), but how hormonal therapies interfere with the 
neuroendocrine systems in BCS is poorly understood at this time. Most survivors will go 
on and off various endocrine treatments throughout the survivorship phase and it is likely 
that these personalized treatment regimens interfere with cognitive functioning, but we do 
not know exactly how at this time.  Fortunately, a research group out of the Netherlands 
is starting to address these research questions (Zwart et al., 2015). 
5. The vast majority of CRCI research has been conducted with BCS, including 
the present study.  Research needs to expand to include the experiences of persons with 
other types of cancer. Evidence supports cognitive changes in testicular, colon, and 
prostate cancer survivors but little research has been done in these areas (Gunlusoy et al., 
  
 




2017; Harrington et al., 2010; Stouten-Kemperman, 2015). A recent review of CRCI in 
hematological cancers concluded that, “The limited CRCI literature in hematological 
malignancy survivors is currently dominated by studies of childhood acute lymphoblastic 
leukemia survivors” (Williams et al., 2015, pp. 843), so work in the area of adult 
hematological survivors is also needed. 
Additionally, there is a need to expand the age criteria of studies of CRCI to 
include older survivors who are typically excluded from studies, despite the fact that 
breast cancer is more prevalent in older women. Very few studies have focused on CRCI 
in older survivors (Loh et al., 2016; Mandelblatt et al., 2013; Mandelblatt et al., 2015) 
highlighting the need to study this phenomenon in women over age 65. Similarly, women 
with metastatic breast cancer are often excluded from CRCI related studies.  Now that 
women with stage IV breast cancer are living longer with their disease, a better 
understanding of their cognitive functioning throughout their treatment is essential. 
6. Since the Loess Regression plots illustrated that the relationships between 
cytokines and cognitive measures in this study were complex, a multivariate non-linear, 
analysis of the data using Random Forest Regression (Breiman, 2001) should be 
conducted to understand the best model to fit the data and to determine an algorithm to 
predict cognitive function with the psychosocial and inflammatory factors. Random 
Forest Regression is a non-parametric type of machine learning that analyzes all possible 
interactions that could occur between the predictor variables and the dependent variable 
utilizing bootstrapping sampling of training sets. Predictor variables are chosen based on 
prior knowledge from the literature and thus allow for hypothesis testing. Random Forest 
Regression is robust to “model over fitting”, and an appropriate choice when the sample 
size is small or there are a large number of predictors (Breiman, 2001). 
7. Another consideration for future research is that the FACT-Cog is a 37-item 
questionnaire and two shorter surveys have been developed directly from this measure 
  
 




and are available in the NIH PROMIS toolbox. The PROMIS Cognitive Abilities, and 
PROMIS Cognitive Impairments Scales are both eight items long and are 
psychometrically sound. Using shorter scales could decrease study burden on 
participants, especially those who are cognitively fatigued, anxious, or feeling depressed 
(http://www.healthmeasures.net/resource-center/nih-toolbox-ipad-app). 
8.  Considering the relationships found between sleep quality (PSQI) and daytime 
sleepiness (ESS) and both inflammation and cognitive functioning, a secondary analysis 
of the data focusing on sleep as the primary variable is warranted. Historically, people 
who score greater than five on the PSQI have been classified as “poor sleepers”. 
Therefore, analyses could be conducted to explore group differences in cytokine 
concentrations and cognitive outcomes between poor sleepers and good sleepers. 
Public Policy 
Approximately 3.1 million women have survived breast cancer in the United 
States (DeSantis et al., 2014). CRCI is a devastating and pervasive problem within the 
BCS community. CRCI can lead to poor quality of life and difficulty functioning day to 
day. If policy makers prioritize improving the cognitive functioning of these women, it 
may lead to more independence and better quality of life. Funds for research must be 
allocated to focus on both the mechanisms behind this treatment-related burden and on 
effective treatments to mitigate CRCI. Additionally, adequate cognitive assessment and 
management need to be included in oncology standards of care. Nurses, physicians, and 
other providers need to be educated on the cognitive effects of cancer and cancer 
treatment and interventions to mitigate these symptoms. Insurance coverage is needed for 
adequate cognitive assessment (fMRI or NP Battery) for survivors who require 
comprehensive assessments. Health insurance should cover or subsidize the cost for 
interventions to improve emotional and cognitive functioning throughout and following 
cancer treatment. Fortunately, in 2009 the American’s with Disabilities Act (ADA) was 
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amended to include and cover individuals who experience disabilities as a result of their 
cancer and prohibits discrimination of these individuals 
(https://www.eeoc.gov/laws/types/cancer.cfm). Policy makers need to ensure that the 
ADA is enforced and that those who are substantially limited in a major life activity 
either physically or cognitively, as a result of their cancer are adequately covered by the 
ADA.  
CHAPTER SUMMARY 
The purpose of this study was to identify modifiable psychosocial and behavioral 
factors that may contribute to cognitive function both directly and indirectly through 
inflammatory mediators in BCS six months to 10 years after chemotherapy. Contrary to 
expectations, IL-6 and TNF-α levels were unrelated to the modifiable predictor variables 
and did not predict either perceived cognitive functioning or cognitive performance in 
this sample as a whole. However, some correlations did emerge when the sample was 
divided into those BCS classified with “mild cognitive impairment” and those without 
impairment between IL-6, the interaction of IL-6 and TNF-α and perceived cognitive 
function (FACT-Cog); and between TNF-α, the interaction of IL-6 and TNF-α and 
executive functioning (measured by Trails A and B). The subsample of participants with 
impairments was very small (n=13) making it difficult to draw conclusions; so, these 
relationships need to be evaluated in a larger, more homogeneous sample of BCS 
experiencing cognitive impairment.   
The state of the science in this field has evolved since the inception of this study 
and genetic biomarkers of pro-inflammatory dysregulation may be more stable and 
predictive of cognitive function. The findings from this study suggest that perceived 
stress and loneliness contribute to perceived cognitive functioning in breast cancer 
survivors but that elevated IL-6 and TNF-α do not mediate these effects. These findings 
may be reflective of methodological problems discussed above in the “Limitations” 
  
 




section, or they may reflect the complex nature of relationships involving cytokines. 
Additional non-parametric analyses in this study illustrated that the cytokines were 
related to the predictor variables but that the relationships varied in direction and 
magnitude across levels of the predictor variables. Similarly, cognitive outcomes were 
related to the cytokines, but these relationships varied in direction and magnitude across 
levels of the cytokines. In three cases, the graphs suggested that no relationships existed 
between factors: 1) IL-6 and HVLT-I; 2) TNF- α and Trails A, and 3) TNF- α and Trails 
B. 
When evaluating the direct effects of the predictor variables on cognitive 
function, two patterns emerged from the data. Psychosocial variables (perceived stress, 
loneliness, anxiety, and fatigue) and sleep quality predicted perceived cognitive function, 
and behavioral factors (physical activity, sleep quality) predicted verbal memory and 
executive functioning performance. The effects of psychosocial variables on perceived 
cognitive function were examined further. Effects of feeling more stress, social isolation, 
and experiencing worse sleep quality on cognitive functioning were mediated by feelings 
of anxiety and fatigue. 
CONCLUSION 
Cognitive dysfunction following breast cancer treatment is a serious and 
pervasive problem (Janelsins et al., 2017; Janelsins et al., 2014; Wefel & Schagen, 2012; 
Jim et al., 2012). The underlying mechanisms of CRCI remain unclear, but there is 
consensus within the scientific community that the causes are multifactorial (Ahles et al., 
2012; Argyriou et al., 2011; Jim et al., 2012). The findings from this study further support 
this notion. This study provides a unique contribution to the literature by illustrating the 
non-linear relationships between the selected psychosocial and behavioral variables and 
cytokines, and between the cytokines and the cognitive measures. The findings from this 
study also have clinical implications. Healthcare providers must acknowledge survivors’ 
  
 




concerns and assess cognitive functioning throughout the cancer trajectory. It is essential 
that providers recognize that these cognitive concerns may be influenced by many factors 
that extend far beyond the receipt of chemotherapy. This study provided new knowledge 
on inflammation and cognitive function six months to 10 years after breast cancer 
chemotherapy using a biobehavioral model to simultaneously evaluate modifiable 
psychosocial and behavioral factors that contribute to cognitive function in BCS.  
Findings from this study provide initial evidence for needed future prospective and 
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